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Summary 
Background 
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide causing in 
only Europe 3.9 million deaths corresponding the 45% of total deaths [1]. In particular, among CVD, 
the congenital heart disease (CHD) is one of the most serious heart defect with an incidence of 8 per 
1,000 live births [2]. 
Purpose  
In recent years, the role of imaging techniques in the diagnosis and follow-up of these patients has 
become increasingly important due to their progressive technological advancement. This doctoral 
thesis shows the results that we achieved in the use of cardiac computed tomography (CCT) and 
cardiac magnetic resonance (CMR) examination in patients with CHD. 
Section I – Cardiac computed tomography in CHD patients 
In this chapter, we propose a study showing the possibility to obtain an impressively low ionizing dose 
reduction in pediatric CHD patients. Indeed, because the CCT can give valuable anatomic information 
on CHD in children but implies radiation exposure in subjects who are more radiosensitive than adult 
patients and that have a longer lifetime to develop stochastic effects from radiation, is very important 
to perform high-quality but low-dose examinations in this kind of patients. Thus, we evaluated a total 
of 100 pediatric CCT performed using 80, 100, or 120 kVp, showing that a high-quality pediatric CT 
can be performed using a 64-slice scanner, with a radiation effective dose close to 2 mSv in about 50% 
of the cases [3]. 
Section II – Heart and great vessels CMR evaluation  
In this section, are shown four studies focused on the use of CMR as a non-invasive imaging tool for 
the morpho-functional evaluation of heart and great vessels in patients with CHD. Concerning the 
study of heart dysfunction we published one paper on patients with non-obstructive hypertrophic 
cardiomyopathy (HCM) [4] and another one on patients with functional univentricular heart (FUH) 
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[5]; while regarding the study of great vessels we focused on the evaluation of the aortic strain [6] and 
flow measurement [7] in patients with different CVD, including CHD. 
The 2% HCM patients have a left ventricle wall thickness that reaches 13-15 mm, overlapped 
with those measured in mild forms of HCM. This overlap makes clinically relevant to differentiate 
athlete’s heart from mild forms of non-obstructive HCM. Thus, we decide to assess the left ventricle 
wall thickness and the myocardial metabolism of HCM patients compared to competitive athletes 
(CAs) using the magnetic resonance spectroscopy (MRS). We demonstrated that at the 1H-MRS there 
is a significant increase in myocardial lipids in HCM patients compared to competitive athletes, 
leading to the fact that it may be used as an additional final phase of a CMR protocol including 
standard morphologic and functional imaging in the differential diagnosis between HCM and athlete’s 
heart [4]. 
Starting from the results of an our previous study [8] showing that the inclusion of the hypoplastic 
chamber during the segmentation of cine images of FC patients may result in a less accurate 
measurement of the ejection fraction, we decided to validated a blood-threshold (BT) segmentation 
method for CMR cine images in FUH patients. Thus, we successfully validated in a pool of 44 FUH 
patients the use of a BT technique for the segmentation of cine images observing that a high intra- and 
inter-reader reproducibility for the assessment of ventricular stroke volume (SV) and an excellent 
agreement with aortic flow values used as a benchmark. [5]. 
Arterial stiffness is one of the earliest manifestations of adverse structural and functional changes 
within the vessel wall. When the aorta is considered, stiffness is a main determinant of age-related 
systolic and pulse pressure increase, a major predictor of stroke and myocardial infarction, and has 
been associated with heart failure [9]. Previous authors showed that ascending aortic strain (AAS) 
measured at CMR is markedly decreased before the fifth decade of life and that can be considered as 
an early manifestation of vascular aging [10]. Our aim was to evaluate the AAS in 1,027 consecutive 
patients with different types of CVD who underwent CMR , showing that differences in age, gender, 
and cardiovascular disease independently affect ascending aorta strain; in particular the lower 
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ascending aorta strain observed in tetralogy of Fallot (ToF) fosters its assessment during follow-up in 
adulthood  [6]. 
Blood flow measurements are based on the segmentation of a vessel contour that may be 
performed manually or, more typically, semi-automatically, with the use of computer software likely 
impacting on measurement reproducibility. Reader experience may play a role as well. Thus, we 
aimed to estimate the intra- and inter-reader reproducibility of blood flow CMR measurements 
through the ascending aorta and main pulmonary artery in 50 patients affected with CHD or with 
aortic and/or pulmonary valve disease; also investigating the impact on reproducibility of the reader’s 
experience with CMR. Our results showed a good-to-excellent reproducibility for all variables except 
the backward flow of the ascending aorta, with a limited impact of operator’s training [7]. 
 
Section III – To share or not to share our trial data?  
In clinical research, spontaneous data sharing is not yet as common as it is in other fields such as 
genetics, astronomy or physics [11]. However, the concept of data sharing has been suggested for 
many reasons, including the patient-centred nature of medical research and healthcare and the 
expectation that knowledge from existing data should be maximized to benefit all stakeholders. 
Although a transition to data sharing is a process that will take time and planning, those who adopt the 
principles and practices of open science will likely benefit from it [12, 13]. In addition, the emergence 
of data sharing as a potential requirement by some agencies and journals warrants attention by the 
imaging community. Indeed, from July 1st, 2018 the International Committee of Medical Journal 
Editors (ICMJE) will require a data sharing statement as a condition of consideration for publication 
of clinical trials [14]. 
Thus, considering the amount of results that we collected in these three years of my PhD 
program, we asked ourselves about the potential advantages and disadvantages in sharing our source 
data with the scientific world. Our conclusions, enclosed in a paper published this year on European 
Radiology [15], have been discussed in this section. 
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Conclusions 
Both imaging modalities have limitations and advantages. CMR can evaluate heart function and vessel 
flow but require a long acquisition time and in same patients a long sedation time. CCT has a very 
high spatial resolution and short acquisition time but implies ionizing radiation exposure. 
This PhD thesis confirms the crucial role of CMR in functional analysis and the relevant 
possibilities of x-ray dose reduction in CCT, leading the foundations for future studies on the 
application of imaging techniques in the diagnosis and prognosis of CVD.  
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High-quality low-dose cardiovascular computed tomography 
(CCT) in pediatric patients using a 64-slice scanner 
Introduction 
In the setting of CHD, noninvasive imaging techniques such as echocardiography, CMR, and CCT 
play a crucial role in the visualization of cardiovascular structures [16]. 
Echocardiography, being a ubiquitous and radiation free technique, represents the ﬁrst approach 
for patients having or suspected to have CHD, but it has limitations in deﬁning complex anatomy and 
reliable imaging of coronary arteries, especially in older children who have a poor acoustic window 
[16, 17]. CMR is considered the standard of reference for evaluation of ventricular volumes and valve 
regurgitation but it still usually requires relatively long imaging times and sedation or anesthesia in 
children aged<8 years as well as in developmentally delayed patients of all ages [18–20]. CCT and 
invasive angiography expose patients to ionization radiation, with potentially more dangerous eﬀects 
in younger patients. A previous study demonstrated that the radiation exposure from diagnostic 
catheterization is substantially higher than that from CCT in a pediatric population [16]. 
In recent years, CCT technology has advanced rapidly. It now provides improved spatial and 
temporal resolution. Electrocardiographically (ECG)-gated coronary CCT can now be routinely 
obtained in pediatric patients with a radiation dose as low as 1.2 mSv using dual-source CCT 
technology [21]. Unfortunately, these scanners are still available in few centers. On the other hand, in 
order to reduce radiation exposure keeping a good image quality, radiologists can apply tailored 
protocols for CCT in pediatric patients even using 64slice scanners which are currently a kind of 
‘‘standard’’ technology in radiology department. 
Thus, our aim was to estimate radiation dose and image quality in pediatric CCT using a 64-slice 
scanner. 
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Material and methods 
Patient population 
Ethics Committee approval was obtained for this retrospective study. A total of 100 CCT exams of 
patients aged <18 years, performed between January 2010 and December 2016 at our Institution, were 
retrospectively evaluated. Disease distribution in the study population is summarized in Table 1. 
Table 1: disease distribution in the study population 
 
Image acquisition 
At our department, all CCT studies, including those performed in pediatric patients, are performed 
under the direct responsibility of a cardiovascular radiologist. To minimize technical errors, 
technicians are carefully instructed by the radiologist on a case-by-case basis. 
The CCT examinations were performed on a 64-slice computed tomography (CT) scanner 
(Somatom 64, Siemens Healthcare, Erlangen, Germany). Patients aged less than 3 years needed 
sedation. The administration of sedative drugs happened shortly before the CT exam. The 
anesthesiologist monitored the patient conditions during the procedure and evaluated the patient status 
after the exam. Midazolam was administered intravenously (dose of 0.1–1.1mg/kg), orally (dose of 
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0.5–0.6mg/ kg), or intramuscularly (only in one patient, dose of 0.2mg/kg). The administration route 
of ketamine was intravenous (dose of 0.9–1.9mg/kg) or intramuscular (dose of 3.3–5.4mg/kg). 
Propofol was intravenously administered at a dose of 0.5–2.4mg/kg. The variability of the 
administered doses depended on age, comorbidities, and known drug response of the patient. 
A tailored CCT protocol was performed according to the clinical question. In the majority of 
patients (n=80), the unenhanced scan was waived to reduce the radiation dose. A bolus of contrast 
material of 5–60mL (Iopamiro 370, Bracco Imaging S.p.A., Milan, Italy) followed by saline solution 
in the range of 10–60mL was intravenously injected by means of a power injector (Empower CTA, 
EZEM, Westbury, NY, USA) at a ﬂow rate of 1.5–3.0mL/s according to the patient’s characteristics 
and the clinical question. 
When investigating cardiac anatomy or coronary arteries, a test-bolus technique was used. A time 
Attenuation curve was obtained by measuring the enhancement within a region of interest (ROI) 
positioned in an ascending aorta or in the pulmonary trunk according to the clinical question. The 
contrast arrival time was determined from the time to peak enhancement and was used to estimate the 
scan delay for a full-bolus diagnostic CCT [22]. 
To acquire an angiogram, we used the bolus tracking technique, based on real-time monitoring of 
the main bolus during injection to acquire a series of dynamic low-dose monitoring scans at the level 
of the vessel of interest. The trigger threshold inside the ROI was set at 100 HU above the baseline. 
The delay between each monitoring scan acquisition was 1.25s. As soon as the threshold was reached, 
the table moved to the cranial start position. During this interval the contrast material concentration 
increased to the desired level of enhancement [23]. 
The CCT were either performed without ECG synchronization or using a prospective or a 
retrospective ECG-gating depending on the patient’s heart rate and rhythm and on whether an 
evaluation of myocardial function was indicated [24]. Tube voltage was set at 80, 100, or 120kVp; 
tube current was set between 36 and 100mAs, according to body size. The gantry rotation time was 
0.33s; pitch was 0.2–0.5. The reconstruction parameters were set as follows: section 
thickness=0.75mm; reconstruction interval=0.45mm; matrix size=512–512; and ﬁeld of view=250mm. 
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Two-dimensional images were then transferred to a workstation (Multimodality, Siemens Healthcare, 
Erlangen, Germany) for obtaining oﬀ-line three-dimensional reconstructions. 
Radiation exposure 
The dose length product (DLP) was retrieved for each patient. The eﬀective dose (ED) in mSv was 
calculated as DLP*k. The conversion factor for the chest, k (measured in mSv/mGy/cm), varied with 
age and was estimated from the International Commission on Radiological Protection publication 103 
recommendation [25, 26]. The ED was then evaluated for four patient age groups (newborns<1 year, 
1–5 years, 6–10 years, and 11–17 years), and according the tube voltage used (kVp). 
Image quality assessment  
Signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) were calculated for each scan using the 
following formulas: SNR=HUleft ventricle/SDair; CNR= [(HUleft ventricle – HUmyocardium)/SDair]. Assessment of 
subjective image quality was independently performed by two observers with eight and four years of 
experience in cardiovascular imaging. Image analysis was performed individually and image series 
were evaluated in a random order. Scans were classiﬁed using a three-level scale (3=very good; 
2=good; and 1=poor). The two readers agreed on the following criteria: 
- images were judged as very good when all structures were well visualized without 
artifacts; 
- images were judged as good when almost all structures were well visualized even 
though some artifacts were visible; 
- images were judged as poor when the vascular structures were not well visualized 
due to the presence of large artifacts. 
Statistical analysis  
Statistical analyses were performed using statistical software (SPSS for Windows v.21.0, SPSS Inc., 
Chicago, IL). Parametric variables were expressed as mean and standard deviation (SD), whereas non-
parametric variables were expressed as median and interquartile ranges (IQR). Overall comparisons 
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among groups were performed using the Kruskal–Wallis test; the paired post-hoc analysis of the two 
groups was performed using the Mann–Whitney U test. A P value<0.05 was considered as signiﬁcant. 
The inter-observer agreement about the image quality qualitative assessment was evaluated using 
the Cohen k, with the following interpretation of the k values: <0.20=slight agreement; 0.21–0.40=fair 
agreement; 0.41–0.60=moderate agreement; 0.61–0.80=substantial agreement; 0.81–1.0=almost 
perfect agreement [27]. 
Results 
Study population 
The study population included 100 patients (63 boys, 37 girls), aged 6.9±5.4 years (mean±SD). The 
most common primary indications for CCT were complex CHD (n=34), pulmonary arteries 
abnormalities (n=22), and coronary arteries abnormalities (n=24). A detailed list of indications is 
provided in Table 1. 
Radiation exposure 
The overall median ED was 1.3 mSv (IQR=0.8–2.7mSv). Concerning the subgroup analysis, the 
median ED was 1.0 mSv (IQR= 0.6–1.4mSv) for exams performed at 80 kVp, 1.9 mSv (1.1–3.5mSv) 
for exams performed at 100 kVp, and 5.1mSv (3.6–6.0) for exams performed at 120 kVp (P <0.001). 
Post-hoc analysis is reported in Table 2. 
Table 2: effective dose by tube voltage 
 
Examples of CCT images obtained at 80, 100, and 120kVp are shown in Figs. 1–4. Comparing 
not ECG-triggered, prospectively ECGtriggered, and retrospectively ECG-gated examinations, median 
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ED were 1.1 (0.6–3.1) mSv, 1.3 (1.0– 1.8) mSv and 1.7 (1.3–3.5) mSv, respectively (P <0.036). Post-
hoc analysis is reported in Table 3. 
Table 3: effective dose for not ECG-synchronized examinations, 
prospectively ECG-triggered examinations, and retrospectively 
ECG-gated examinations 
 
Data of effective dose are medians and interquartile ranges in parentheses. The 
Kruskal–Wallis test was used for the overall comparison while the Mann–Whitney 
U test was used for the post-hoc analysis. 
 
Finally, a signiﬁcantly diﬀerent ED was also found among the age groups (P <0.001). Post-hoc 
analysis is reported in Table 4. 
Table 4: effective dose by patient age 
 
Data of effective dose are medians and interquartile ranges in parentheses. 
The Kruskal–Wallis test was used for the overall comparison while the 
Mann–Whitney U test was used for the post-hoc analysis. 
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Figure 1: Cardiac CT of a one-month-old new born with a double outlet right ventricle 
 
Prospectively ECG-triggered scan for the definition of coronary and intra-cardiac anatomy was performed. Effective dose 
was 0.3 mSv using 80 kVp. On the left panel, the abnormal origin of left main coronary artery is shown. On the right panel, a 
3D reconstruction of great vessels anatomy is shown (double outlet right ventricle) 
 
Figure 2:  Cardiac CT of a two-year-old with tetralogy of Fallot with sub-pulmonary stenosis 
surgically treated 
 
Retrospectively ECG-triggered scan for the definition of coronary and intra-cardiac anatomy was performed before a new 
surgical procedure. Effective dose was 1.1 mSv using 80 kVp. Anomalous left coronary origin from right sinus passed 
anterior of right ventricle outflow tract is shown (arrows). 
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Figure 3: cardiac CT of an eight-year-old girl with tetralogy of Fallot treated with a pulmonary 
conduit 
 
An angiographic not ECG-triggered scan was performed for evaluating pulmonary stents. Effective dose was 1.1 mSv using 
100 kVp. On the left panel, a thrombosis of the pulmonary conduit due to endocarditis is shown. On the right panel, a 3D 
reconstruction of pulmonary conduit and pulmonary arteries is shown. 
 
Figure 4: cardiac CT of a 14-year-old girl with tetralogy of Fallot and pulmonary stenosis. 
 
An angiographic not ECG-triggered scan was performed to evaluate pulmonary stents. The effective dose was 2 mSv using 
120kVp. On the left panel, a maximum intensity projection of both stents is shown. On the right panel, a 3D reconstruction of 
pulmonary arteries is shown. 
  
22 
 
Image quality 
Overall, the image quality was judged by the ﬁrst reader (most expert) to be very good in 56 
examinations (56%), good in 39 (39%), and poor in ﬁve (5%). The agreement between the two readers 
was almost perfect (k=0.880). A non-signiﬁcant diﬀerence in terms of subjective image quality was 
found, both overall and among the three groups of kilovoltage used (P =0.296). In terms of objective 
image quality, the SNR was 30.6 (IQR=23.4–33.6), 29.4 (IQR=23.7–34.8), and 24.7 (IQR=19.4–
34.3), at 120, 100, and 80 kVp, respectively (P =0.486). The median CNR was 21.0 (IQR=14.8–24.4), 
19.1 (IQR=15.6–23.9), and 25.3 (IQR=19.4–33.4), at 120, 100 and 80 kVp, respectively (P =0.336). 
There were not signiﬁcant diﬀerences according to SNR and CNR in the diﬀerent age-group patients. 
In particular, the median of SNR was 30.5 (IQR=22.5– 36.6), 25.2 (IQR=15.1–30.9), 24.9 (IQR=20.6–
41.1), and 24.4 (IQR=20.7–30.9) in newborn, 1–5, 6–10, and 11–17 age groups, respectively (P 
=0.227). The mean CNR was 19.4 (IQR=24.8–23.5), 20.1 (IQR=10.8–20.9), 23.3 (IQR=13.7–41.1), 
and 18.4 (IQR=10.7–20.8) in newborn, 1–5, 6–10, and 11–17 age groups, respectively (P =0.101). 
Discussion 
In this study, we assessed radiation exposure and image quality of 64-slice CCT in a consecutive 
series of 100 pediatric patients. Using a tailored dose-saving protocol with careful radiologist’s 
supervision of technical performance, the overall median ED was limited to 1.3 mSv, including both 
prospective and retrospective ECG-triggering. Image quality was very good or good in 95/100 
patients. Of note, the inter-observer reproducibility for the qualitative evaluation of image quality was 
almost perfect. 
Our results can be favorably compared with those obtained by other authors. Tsai et al. [28] 
described an average ED for pediatric CCT of 2.6, 2.1, and 2.0 mSv for 16-, 64-, and 128-slice CCT, 
respectively, using a prospectively triggered acquisition. Conversely, the dose estimated in other 
studies was 6.8 mSv [25] or 12 mSv [29] using a 64-slice scan with retrospective ECG-gating. 
In recent years, the advent of new generation scanners implied a drastic decrease in radiation 
exposure, also in the pediatric setting. The study published by Han et al. [20] analyzed a cohort of 70 
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pediatric patients and found an average ED of 1.7 mSv for retrospectively ECG-gated CCT and 0.9 
mSv for prospectively ECG-triggered CCT. These ﬁndings highlighted the increasing role of CCT in 
the pediatric setting, in particular as a tool that allows to avoid diagnostic angiography or to limit or 
overcoming the diagnostic phase of interventional angiography. In fact, Lee et al. [30] demonstrated 
that in a population of 14 neonates with complex CHD referred for diagnostic cardiac catheterization 
after initial assessment with echocardiography and CCT, none of them required additional diagnostic 
imaging. This is a goal in terms of reduction of radiation dose considering the 13.4 mSv that are 
required on average for a diagnostic catheterization [16]. 
Our study showed that using a ‘‘standard’’ 64-slice scanner high-quality images can be obtained 
with a relatively low radiation exposure, fulﬁlling the diagnostic aim of the examination. This is an 
important clinical ﬁnding considering that 64-slice CT units remain the most available type of CT 
scanner in the majority of radiology departments [31–33]. 
Rapid technological development resulted in accelerated technical and functional obsolescence of 
imaging equipment, creating a need for renewal [34]. A dramatic change in this scenario, in the 
current era of ‘‘spending review’’ by public health systems, is not expected. 
Thus, implementing CCT dose-saving protocols on 64-slice scanners should be considered as 
mandatory, especially in the pediatric population. Importantly, since no diﬀerences were found in 
terms of SNR and CNR among the diﬀerent tube voltages used (120, 100, or 80 kVp), our experience 
suggests that an 80-kVp protocol could be adequate to image most pediatric patients. 
The results in terms of CNR deserve a particular comment. Although the diﬀerence among the 
groups was not statistically signiﬁcant, probably due to the small sample size combined with data 
distribution, a higher CNR at the lowest tube voltage (80 kVp) was observed (median 25.3 vs. 21.0 for 
120kVp and 19.1 for 100kVp). This possible increase in CNR could be explained with the higher 
contrast eﬀect of the iodinated contrast material at lower voltages [35]. Notably, the agreement in 
image quality evaluation between the two observers was not conditioned by the voltage used. 
The approach here presented (tailored protocols under strict control by the cardiovascular 
radiologist) could be generally applied also to late-generation CT scanners, allowing for a lower and 
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lower dose exposure, in particular in the pediatric population. All these results are inverting the 
traditional way of thinking about the comparison between CCT and CMR in pediatric patients. Most 
probably, CMR will no longer be an easy winner because of being radiation-free. As radiation doses 
go lower and lower, towards 0.1–0.2 mSv, examination time and need for sedation, spatial resolution 
as well as image quality related to movement artifacts can play in favor of CCT. In addition, when 
considering the probability of multiple CMR examinations, the potential gadolinium accumulation in 
the brain should be taken into account [35]. 
The results of this study should be interpreted in view of its limitations. First, we should consider 
the retrospective study design. However, we included the whole consecutive series of pediatric 
patients who underwent CCT at our institution in the study period (starting from the installation of the 
64-slice unit). Thus, the study reports what happened in real clinical life. Second, the number of 
patients is rather small as CMR is still preferred in the evaluation of CHD patients. 
In conclusion, CCT is a valuable imaging modality when evaluating pediatric patients with a 
large spectrum of known or suspected cardiovascular abnormalities. Using dose-saving techniques, 
CCT protocols tailored to the pediatric population allowed for performing high-quality CCT in 
children with a relatively low radiation exposure also using a ‘‘standard’’ 64-slices scanner.  
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1H and 31P myocardial magnetic resonance spectroscopy in non-
obstructive hypertrophic cardiomyopathy patients and competitive 
athletes 
Introduction 
HCM is the most common genetic cardiac disease with a prevalence of 0.2% [36]. In half the cases, 
the transmission is autosomal dominant with incomplete penetration [37, 38]. The most common 
mutations involve sarcomere proteins, particularly C-binding myosin protein, the heavy beta-myosin 
chain and troponin T [39]. This disease is characterized by hypertrophy of the left ventricle, mostly 
asymmetric, and is usually located at the basal portion of the septum [40]. Diastolic dysfunction and 
outflow tract obstruction of the left ventricle may be present, causing major clinical manifestations 
such as angina, dyspnea, dizziness and syncope [41, 42]. In approximately 30% of HCM patients, 
ventricular hypertrophy is moderate without obstruction of the outflow tract of the left ventricle, both 
at rest and under stress and, therefore, the disease is silent [43]. In this form, the clinical onset can be 
the sudden death induced by rhythm disorders. Indeed, HCM was reported to be responsible for 35% 
of sudden deaths in young athletes [44, 45]. 
Competitive athletes with intense and regular training exercise usually develop cardiovascular 
changes leading to a reversible para physiological myocardial hypertrophy known as athlete’s heart. 
This condition shows symmetrical and homogeneous hypertrophy, with variations in the wall 
thickness smaller than 2 mm [46]. In 2% of such athletes, the left ventricle wall thickness reaches 13–
15 mm [47], with a distribution partially overlapped with those measured in mild forms of HCM, 
especially mutations of troponin T [48]. Thus, it is clinically relevant to differentiate between athlete’s 
heart and mild forms of non-obstructive HCM. 
MRS is a non-invasive diagnostic technique allowing for the in vivo evaluation of myocardial 
metabolism [49, 50] by measuring the signal intensity of 31P or 1H. In particular, with 31P-MRS, the 
ratio between phosphocreatine (PCr) and γ-adenosine triphosphate (γATP) may be measured, 
representing an index of the myocardial energy reserve [38, 51–53]. On the other side, 1H-MRS allows 
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for estimating the total creatine (Cr) (sum of PCr and Cr) [54, 55], which is associated with 
myocardial contractility [56, 57]; moreover, myocardial lipids may be measured using 1H-MRS [58, 
59]. 
The aim of this study was to evaluate the left ventricle function in patients affected by HCM 
compared with that of competitive athletes and to assess the myocardial metabolism using 31P-MRS 
and 1H-MRS in the two populations. 
 
Materials and methods 
Study design and inclusion criteria  
This prospective cross-sectional study was approved by the local ethics committee and each subject 
signed a written informed consent. Inclusion criteria were as follows: patients aged 18 years or more 
with a known diagnosis of non-obstructive HCM, defined as asymmetric hypertrophy of the left 
ventricle, with the typical patchy pattern with local distribution of late gadolinium enhancement [47, 
48]; competitive athletes aged 18 years or more, in good health, without any reported cardiovascular 
symptoms and with intense exercise training in the month prior to the enrollment, quantified in at least 
10h per week. Exclusion criteria were contraindications to magnetic resonance such as 
pacemakers/defibrillators, intracranial ferromagnetic vascular clips, intraocular metal fragments, or 
severe claustrophobia. 
Magnetic resonance imaging  
Each enrolled subject underwent a 1.5-T magnetic resonance (Magnetom Sonata Maestro Class, 
Siemens Medical Solutions, Erlangen, Germany), including a morphologic and functional imaging 
study, with the patient in the supine position. 
The imaging protocol included balanced steady-state free precession sequences (true fast imaging 
with steady-state free precession, true-FISP) using a four-channel surface phased-array coil in the 
short axis plane covering the entire heart. Technical parameters were as follows: ECG-gating; TR/TE 
4.0/1.5 ms; flip angle 80°; slice thickness 8 mm; temporal resolution 45 ms; field of view 300 × 400 
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mm2; matrix 119 × 256; 30 phases in breath-hold at end expiration. The kinetic study was processed 
by manual segmentation using Syngo Argus software (version VE32B, Siemens Medical Solutions, 
Erlangen, Germany) by a radiologist with a 7-year experience in CMR imaging. 
For each subject, the following imaging-derived variables were measured for the left ventricle: 
end diastolic thickness of the septum; end diastolic thickness of the posterior wall; mass index (i.e., 
normalized to the body surface area); end diastolic volume index (EDVI); end systolic volume index 
(ESVI); ejection fraction (EF); stroke volume; and ventricular end diastolic diameter. We have also 
calculated an asymmetry index, defined as the left ventricle septal-to-posterior wall thickness ratio. 
1H MRS 
After morphologic and functional imaging, hydrogen containing metabolites were measured in a 
single voxel of 10 × 20 × 40 mm3 within the interventricular septum. A point-resolved spectroscopy 
sequence (ECG synchronization; diaphragm navigator; acquisition in the end systolic phase; TR/TE 
2000/90 ms; flip angle 90°; number of excitations 150; suppression of the water signal; supine 
position) was performed using the same four-channel surface phased-array coil used for imaging. 
A physicist with 8-year experience in MRS processed all spectra using the jMRUI software that 
implements the AMARES (Advanced Method for Accurate, Robust, and Efficient Spectral) algorithm 
quantitation [60]. Preprocessing steps were: apodization (3 Hz), manual or automatic phase correction 
and subtraction of the baseline with the polynomial method. The area of the two peaks attributable to 
Cr (3.0 and 3.9 ppm) and the that of the two peaks attributable to lipids (0.9 and 1.3 ppm) were 
measured and corrected for decay using T2 values published in the literature [61, 62]. The total Cr as 
well as the total fat was obtained summing up the two relevant components. Data were presented as 
arbitrary units (au). 
31P MRS 
Myocardial phosphates were measured through 31P-MRS using a dedicated surface coil tuned for 31P 
and with the patient in the prone position. On the basis of repeated low-resolution scout images, we 
placed a grid of volumes of interest so as to guarantee at least one voxel within the anterior ventricular 
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junction, trying to minimize contamination by ventricular blood. Then, we acquired a multivoxel 
chemical shift imaging sequence for a single slice (nuclear Overhauser enhancement technique; ECG 
synchronization for acquisition in the end diastolic phase; repetition time/echo time (TR/ TE) = 
800/2.3 ms; flip angle 90°; grid size 8 × 8×60 mm3; field of view 300 × 300 mm2; free breathing). 
Pre-processing included: exponential filter, zero-filling from 1024 to 2048 points, Fourier 
transform, frequency and phase correction and subtraction of the baseline with the polynomial method. 
All spectra were processed by the same physicist using Spectroscopy-Argus software (version VE32B, 
Siemens Medical Solutions, Erlangen, Germany). The area under the peak of the following 
metabolites was measured: PCr at 0 ppm; phosphomonoester (PME) at 5.4 and 6.3 ppm; inorganic 
phosphate (Pi) at 3.7 and 5.2 ppm; phosphodiester (PDE) at 2–3 ppm; γATP at 16.3 ppm. Moreover, 
we identified the 2,3-diphosphoglycerate (DPG), contained in red blood cells, at about 5.5 ppm, used 
to correct data for the blood contamination. To this end, we subtracted 11% and 19% of 2,3-DPG from 
γATP and PDE, respectively, as already described [63]. The signals of γATP, PCr, PDE and Pi were 
corrected for decay using T2 values published in the literature [64]. Finally, we calculated the 
following ratios: PCr/γATP; PDE/γATP; 2,3-DPG/γATP; PME/PCr; and Pi/PCr [64]. Data were 
reported in au. 
Statistical analysis  
Statistical analysis was performed using non-parametric methods, more appropriate for small samples 
[65]. Differences between the two groups of subjects were evaluated with the Mann–Whitney U test or 
the χ2 test, while bivariate correlations were estimated using the Spearman correlation coefficient. 
Statistical analysis was performed using SPSS v.17.0 (IBM SPSS Inc., Chicago, IL, USA). 
Continuous variables were reported as median and IQR and P values <0.050 were considered 
statistically significant. 
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Results 
Population characteristics  
A total of 22 subjects were enrolled, whose characteristics are reported in Table 5. There were 7 HCM 
patients and 15 competitive athletes. In particular, athletes were nine bikers and six professional 
volleyball players with a median weekly training of 10h (IQR 10–14h). The median body mass index 
(BMI) in HCM patients (25 kg/m2; IQR 24–29 kg/m2) was higher (P = 0.041) than that of athletes (22 
kg/m2; IQR 20–23 kg/m2). Moreover, HCM patients were older than athletes [56 years (IQR 45–62 
years) versus 41 years (IQR 35–42 years), P = 0.009]. 
The mean total duration of magnetic resonance (MR) examinations was approximately 40 min: 
20 min for imaging, 5 min for 1H-MRS, and 15 min for 31P-MRS. Processing required 5 min. 
Table 5: distribution of demographics of the study 
population 
 
HCM hypertrophic cardiomyopathy 
* χ2 test. $ Mann–Whitney U test 
a Data are presented as median and interquartile range in brackets 
Morphology and function  
The distribution and comparison of morphologic and functional characteristics of the left ventricle in 
the two groups are shown in Table 6. Of note, HCM patients showed a lower stroke volume than 
athletes [74 ml (IQR 72–86 ml) versus 111 ml (IQR 102–142 ml), P = 0.008], but an equivalent 
ejection fraction [68% (IQR 55–73%) versus 68% (IQR 65–69%), P = 1.000]. Moreover, HCM 
patients showed a much larger asymmetry index than athletes [2.0 (IQR 1.6–2.3) versus 1.1 (IQR 1.0–
1.3), P =0.022]. Figure 5 shows examples of an athlete and a HCM patient. 
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Table 6: functional and morphologic variables of the left ventricle in 
the two groups 
 
Data are presented as medians and interquartile range in brackets 
HCM hypertrophic cardiomyopathy. * Mann–Whitney U test 
 
Figure 5: Cardiac magnetic resonance images in diastolic phase of a mid-ventricular short axis 
section of an athlete (a) and a hypertrophic cardiomyopathy patient (b). Note that the septal 
thickness of the patient is greater than that of the athlete 
 
1H‑MRS 
The 1H-MRS spectrum of one athlete had too low signal to-noise ratio that prevented its analysis. The 
distribution of the variables measured using 1H-MRS in the two groups and their comparison are 
shown in Table 7. Importantly, the lipid resonance at 1.3 ppm greatly differed between patients and 
athletes with a much higher content in HCM patients [554 au (IQR 121–2377 au)] than in competitive 
athletes [0 au (IQR 0–67 au)] (P = 0.020); similarly for the total lipid content [763 au (IQR 155–1994 
au) versus 35 au (IQR 0–183 au), P = 0.046]. Figure 6 shows an example of a hydrogen spectrum of a 
competitive athlete and a HCM patient. 
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Table 7: distribution and comparison of metabolites measured 
by 
1
H-MRS in the two groups of subjects 
 
HCM hypertrophic cardiomyopathy. *Mann–Whitney U test. a Data are 
presented as median and interquartile range in brackets 
 
Figure 6: example of a hydrogen spectrum obtained 
 
Hydrogen spectrum obtained in an athlete (a) and a hypertrophic cardiomyopathy patient (b). Note that the lipid peak is 
higher in the patient than in the athlete. 
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31P MRS 
Data from 31P-MRS were not available for two HCM patients due to examination interruption for 
claustrophobia (in one case) or to low signal-to-noise ratio probably related to patient movement (in 
the other case). The distribution of the phosphate content in the two groups and their comparison are 
shown in Table 8. 
 
No differences between patients and athletes were noted in terms of PCr [22 au (IQR 9–25 au) 
versus 29 au (IQR 20–36 au), P =0.168] and PCr/γATP [4 (IQR 2–5) versus 5 (IQR 4–6), P =0.230]. 
Vice versa, a significant difference between patients and athletes was noted in terms of 2,3-DPG/γATP 
[0.2 (IQR 0.0–0.2) versus 0.5 (IQR 0.3–0.7), P =0.008].  Figure 7 shows examples of 31P-MRS spectra 
of an athlete and a HCM patient. 
Table 8: distribution and comparison of phosphate 
content between the two groups of subjects 
 
HCM, hypertrophic cardiomyopathy; PCr, phosphocreatine; 
γATP, γ-adenosine triphosphate; PDE, phosphodiester; PME, 
phosphomonoester; Pi, inorganic phosphate; 2,3-DPG, 2,3-
diphosphoglycerate; * Mann–Whitney U test a Data are 
presented as median and interquartile range in brackets. The 
content of metabolites is presented in arbitrary units 
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Figure 7: examples of 
31
P-MRS spectra 
 
31P-MRS spectra in an athlete (a) and a hypertrophic cardiomyopathy patient (b). PCr, 
phosphocreatine; ATP, adenosine triphosphate; PDE, phosphodiester; Pi, inorganic phosphate; PME, 
phosphomonoester. Note that PCr/gamma-ATP ratio is reduced in the HCM patient 
 
Bivariate correlation analysis 
As reported in Tables 2, 3, and 4, the variables found to be significantly different in the two groups at 
bivariate analysis were: age, BMI, stroke volume, EDVI, left ventricular mass index, interventricular 
septal thickness, asymmetry index, 2,3-DPG/γATP, lipids at 1.3 ppm and total lipids. BMI did not 
correlate with either lipid resonances at 1.3 ppm (r = 0.318, P = 0.184) or total lipids (r = 0.421, P = 
0.065). 
 
Discussion 
The main finding of this study is that 1H-MRS, performed in only 5 min after a standard C MR 
examination, enabled detecting increased intramyocardial lipids in HCM patients in comparison with 
competitive athletes. These results are somewhat new and may open a perspective for future studies 
aimed at using  
1H-MRS in the differential diagnosis between HCM and athlete’s heart. This study adds a new 
potential biomarker to the well-known differences in the left ventricle remodeling and function. 
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Causes for the accumulation of intramyocardial lipids in early stages of HCM need to be clarified 
and a thorough explanation is currently not available. Nonetheless, we can hypothesize that the 
combined effect of lipid deposition superimposed on fibrosis might help to identify individuals at 
higher risk of arrhythmias. One study showed that increased myocardial triglycerides in healthy 
subject are positively correlated to the cardiac volumes [66]. However, to our knowledge, pathologic 
studies demonstrated only fibrosis infiltration and not fat infiltration in HCM patients [67, 68]. Only 
patients affected with generalized lipodystrophy were proven to present with left ventricle hypertrophy 
associated with myocardial steatosis [69]. Other authors showed that overweight and obese women 
show increase of myocardial triglyceride associated with reduction in cardiopulmonary fitness [70]. 
Similar results were obtained in patients affected by type-2 diabetes [71, 72]. 
In our study, the phosphate metabolism of athlete’s heart was preserved and the PCr/γATP ratio 
was in the range of normal values [49], as expected [73]. In advanced HCM, this ratio is known to be 
reduced resulting in heart failure [42]. The 31P-MRS analysis also showed a significant difference 
between the two groups in terms of 2,3-DPG/ γATP, with a lower value in HCM patients than in 
athletes. Considering that γATP alone was not significantly different in the two groups, an increase of 
2,3-DPG may explain the difference in 2,3-DPG/γATP. The reason for this phenomenon could lay in 
the contamination of the blood pool in the voxel in subjects with a small septum. The variation of 
PME/PCr and Pi/PCr between the two groups was not significant, in line with the literature [64]. 
Notably, a not significant difference was observed in terms of PCr/γATP, as an indicator of energy 
metabolism. This may be due to the normal value of septal thickness in our athlete’s population, 
without any overt athlete’s heart condition. 
As a potential clinical application of our study, we highlight that while 1H-MRS required only 
five additional minutes, the 31P-MRS protocol required the extraction of the patient from the magnet, 
the change of the coil and a new patient positioning in an uncomfortable prone position. This means 
that the clinical feasibility of cardiac 1H-MRS is much higher than that of cardiac 31P-MRS. Moreover, 
31P-MRS is no longer available commercially for 1.5-T MR units. It is offered only for 3-T units, 
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whose results for cardiac imaging were reported to be not clearly better than those obtained with 1.5-T 
units in terms of image quality [74]. 
Morphologic and functional imaging data, EDVI and stroke volume, were significantly lower in 
HCM patients than in athletes, confirming the typical geometric pattern of the disease on one side and 
the heart adaptation to the intense sport activity on the other, as already reported [41]. A significant 
increase in left ventricle mass and septal thickness was found in HCM patients compared to athletes, 
as expected [41]. Interestingly, indexes of systolic function were not significantly different in the two 
groups, a finding that appears consistent with a relatively early stage of nonobstructive HCM patients. 
This study has limitations. First, the number of subjects studied was small and bikers and volley 
players are different in terms of exercise (low static moderate dynamic for volley; high static and 
dynamic for cycling), leading to potential differences in cardiac metabolic activity. However, 
subgroup analysis was not possible due to the lack of statistical power. Second, the higher BMI and 
age in HCM patients may represent a source of bias, so that we cannot exclude that they can explain 
the difference in lipid content; however, bivariate correlation analysis between lipids and BMI did not 
show any significant correlation. Third, we did not calculate the concentrations of metabolites using 
internal or external references. However, the area under the peak as we used in this work can be 
considered a valid quantitative approach, utilized in cardiac [63, 75] and non-cardiac studies [76]. 
Fourth, due to the enrollment criteria, we were not able to test for differences among various 
underlying etiologies of HCM or specific HCM gene mutations. Fifth, ethical issues prevented from 
performing late gadolinium enhancement in athletes. 
In conclusion, we found a significant increase in myocardial lipids in HCM patients compared to 
competitive athletes at 1H-MRS. Myocardial 1H-MRS may be an additional final phase of a CMR 
protocol including standard morphologic and functional imaging in the differential diagnosis between 
HCM and athlete’s heart. Prospective larger studies are needed to confirm this preliminary 
unexplained, but intriguing observation. 
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Blood-threshold CMR volume analysis of functional univentricular 
heart 
Introduction 
The definition of univentricular heart has evolved from a narrow anatomical focus to a comprehensive 
view of heterogeneous conditions that ultimately result in a FUH [1–3]. A total cavo-pulmonary 
connection or Fontan circulation (FC) is the surgical approach of FUH [1, 4–6]. Constant advances in 
cardiac magnetic resonance CMR techniques and equipment in the last decade now grant adequate 
anatomical detail in addition to the accurate and not operator-dependent functional assessment of 
ventricular chambers (main and accessory), cardiac valves, and intra- or extracardiac shunts and 
conduits. Furthermore, the functional evaluation of FC performed by CMR does not require the use of 
intravenous contrast material. The possibility of using non-contrast radiation-free CMR restricts the 
use of computed tomography in circumstances that require a detailed anatomical assessment [7–10]. In 
addition, contrast-enhanced CMR could allow the detection of the myocardial fibrotic evolution, an 
evaluation still not clinically feasible with computed tomography [11]. Non-invasive imaging 
techniques play a major role in the follow-up of patients with FC. In particular, CMR is emerging as 
the leading modality for pre-/post-surgical assessment of congenital heart disease CHD as well as for 
early diagnosis of cardiac and systemic complications, clarifying cardiovascular anatomy and 
physiology [7, 12–15]. Several studies have progressively asserted the correlation between the 
prognosis of patients with FC and their ventricular size and function calculated with analysis and 
segmentation of CMR images, showing it to be equally or more accurate than echocardiographic 
assessment and distinctly more reproducible [8, 16, 17]. In literature, there is limited experience 
regarding the volume analysis of FC patients. A study [18] showed that the inclusion of the 
hypoplastic chamber during the segmentation of cine images of FC patients has no effect on the 
quantification of cardiac volumes, but may result in a less accurate measurement of the ejection 
fraction. 
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The aim of our study is to validate the BT segmentation algorithm in CMR cine images for the 
evaluation of cardiac function in patients with FUH. 
Materials and methods 
Study population 
The ethics committee approval was obtained for this retrospective study (Ethics Committee of the 
University Hospital San Raffaele; protocol code UH_01; approved on July 14th, 2016). A total of 70 
CMR examinations of patients with FUC performed at our institution between March 2008 and March 
2015 were initially considered. The inclusion criteria for the re-assessment of the images were: (1) 
complete acquisition of cardiac volume with cine images; (2) acquisition of through-plane images of 
flow in the ascending aorta; and (3) the absence of atrial–ventricular valve insufficiency. Therefore, 15 
examinations were excluded, and a total of 55 examinations, belonging to 44 patients (7 patients were 
scanned 2 times and 2 patients 3 times), were included. In case of repeated examinations on the same 
patient, the time interval was at least 12 months. The 44 patients included 30 males and 14 females, 
with a mean age and its corresponding SD at the first examination of 25 ± 8 years (mean ± SD). The 
youngest patient was 7-year-old at the time of examination, and the oldest patient was 41-year-old. 
Image acquisition 
All CMR examinations were performed with a 1.5-T unit (Magnetom Sonata Maestro Class or 
Magnetom Aera, Siemens Medical Solutions) with 40- or 45-mT/m gradient power, respectively, 
using a 4- or 18-channel surface phased-array coil placed over the thorax and with the patient in a 
supine position. The image acquisition was gated to the ECG signal to produce a cine sequence 
throughout the systole and diastole and to avoid cardiac artifacts. Each CMR study included a 
complete set of short-axis (from base to apex) cine images, using an ECG-triggered steady-state free 
precession pulse sequence acquired with the following technical parameters: TR/TE = 4.0/1.5 ms; flip 
angle 80°; slice thickness 8 mm; time resolution 45 ms; mean acquisition time 14 ± 4 s (mean ± SD); 
number of phases 30. Phase contrast (PC) through-plane sequences were used for blood flow 
quantification [19]. Images perpendicular to the ascending aorta were obtained (1 cm distal to the 
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sinotubular junction). A breath-hold turbo spoiled gradient echo sequence (fast low-angle shot) was 
performed for phase velocity mapping with the following technical parameters: TR/TE 4.0/3.2 ms; 
slice thickness 5 mm; velocity encoding (VENC) from 150 ms to 350 ms; time resolution 41 ms; mean 
acquisition time 15 ± 4 s. Initially, we acquired the PC sequence with a VENC of 150 ms. In the 
presence of aliasing, we modified the VENC adding 50 ms for each new sequence, step by step up to 
the complete disappearance of the aliasing artifact. The PC through-plane sequences produced two sets 
of images: the magnitude image and the phase-velocity map, the former to provide details on the 
anatomy and identify the boundaries of the vessel and the latter for blood flow estimation [20]. 
 
Image assessment  
Two independent radiologists, R1 and R2, with comparable experience (about 4 years) performed the 
segmentation of cardiac and flow images using MEDIS QMass 7.6 and QFlow 5.6 (Medis Medical 
Imaging Systems, Leiden, The Netherlands) [21, 22]. For the segmentation of cardiac images, in each 
session both readers independently manually traced the epicardial contour of the FUH both in the end-
diastolic and end-systolic phases. Thus, the blood-threshold technique (Mass-K mode) was applied 
using a 50% BT and the EDVI, ESVI, SV, EF, and cardiac mass values were calculated in a totally 
automated way. For the segmentation of flow images of the ascending aorta, in each session each 
one of the two readers positioned a region of interest on the vessel boundary of a selected slice. 
Subsequently, each reader propagated the segmentation through the remaining slices, the software 
proposed an automated adjustment, and the reader was allowed to manually correct the adjusted 
contours. For each session, forward flow and backward flow measurements were obtained. 
 
Statistical analysis  
Data were reported as mean ± SD or median and IQR according to normal distribution or non-normal 
distribution, respectively. The Wilcoxon test and Spearman correlation were used to compare and 
correlate the median value of SV and aortic forward flow, respectively. The Bland–Altman method 
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was used to estimate the intra- and inter-reader reproducibility. The intra-reader reproducibility was 
performed only for R1 with at least a 10-day interval between the two sessions. The coefficient of 
repeatability (CoR) was calculated as 1.96 × SD of differences of the two datasets. Reproducibility 
was reported as complement to 100% of the ratio between the CoR and the mean. Bias (mean of the 
differences of the two datasets) and 95% limits of agreement (bias ± 2 SD) were plotted as well. 
 
Results 
The image analysis was feasible in all patients and no artifacts prevented readers from performing the 
segmentation. Fifty-five examinations were analyzed. No clinically relevant aortic regurgitation was 
found. The median value of the SV and aortic forward flow were 57.7 ml (IQR 47.9–75.6 ml) and 
57.4 ml (IQR 48.9–80.4 ml), respectively. We found no significant difference (P = 0.123), but a 
significant correlation (r = 0.789, P < 0.001) between mean SV and aortic forward flow. All ventricle 
and aortic functional parameters are shown in Table 9. 
Table 9: ventricle and aortic functional parameters 
 
Data reported as median (interquartile interval) EDVI, end-diastolic 
volume index; ESVI, end-systolic volume index; SV, stroke volume; 
EF, ejection fraction. 
 
The bias between the SV values measured by R1 was 0.12 ml, accompanied by a CoR of 8.1 ml, 
corresponding to an intra-reader reproducibility of 86%. The bias was − 0.1 ml, accompanied by a 
CoR of 2 ml corresponding to a reproducibility of 96%. The inter-reader analysis of SV showed a CoR 
of 8.63 ml over a bias of − 1.9 ml, corresponding to an inter-reader reproducibility of 85%. The same 
data for the aortic forward flow were 2.12 ml over a mean difference of 0.24 ml, corresponding to an 
inter-reader reproducibility of 96%. Bland–Altman plots for intra- and inter-reader reproducibility are 
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shown in Figs. 8a, b and 9a, b, respectively. An example of segmentation of cine CMR images with 
the BT technique is shown in Fig. 10. 
 
Figure 8: Bland-Altman plots of intra-reader reproducibility 
 
Bland–Altman plot for intra-reader reproducibility of stroke volume measurement (a); 
Bland–Altman plot for aortic forward flow measurement (b). 
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Figure 9: Bland-Altman plots of inter-reader reproducibility 
 
Bland–Altman plot for inter-reader reproducibility of stroke volume measurement (a); 
Bland–Altman plot for aortic forward flow measurement (b). 
 
Discussion 
In CMR, ventricular volume and function assessment is achieved through the segmentation of cine 
images. This post-processing technique, initially exclusively manually performed by trained readers, 
implies the recognition of the difference between the blood pool in the ventricular cavity, of other 
anatomical structures normally in the ventricular chamber such as trabeculae and papillary muscles 
(TPM) as well as of the ventricular walls. Manual tracing of contours for the ventricular walls and 
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TPM by an experienced reader still constitutes the most widely validated and employed approach. 
However, in the last decade, several studies have validated techniques that, while less time-efficient 
than a fully automated solution, have tried to address the numerous limitations of the fully automated 
approach and provided a solid method, well-balanced in terms of cost-effectiveness analysis, to obtain 
a proper estimate of the ventricular volume and mass with minimal manual input [22–25]. One of 
these limitations is the unreliable allocation of TPM to the myocardial mass or to the blood pool. TPM 
allocation was shown to substantially influence the accuracy of ventricular volume and mass 
assessment. In some recent automatic software, there is the possibility to exclude TPM from the blood 
pool [26–28]. However, in particular conditions such as FUH, the delineation of hyper trabeculations 
remains difficult. 
A BT technique such as the Mass-K Mode algorithm can serve as a time-saving and accurate 
solution to this clinical issue. In this technique, after the reader has manually traced only the epicardial 
contours on the end-systolic and end-diastolic phases of the cine images, the software calculates a 
blood percentage for each pixel inside the contoured area, considering the different signal intensity of 
the blood and myocardium. After visual inspection, the reader can freely alter, in any slice and phase, 
the default BT value of signal intensity discrimination. Moreover, semi-automated detection of the 
epicardial margin can be used, requiring only small manual adjustments on good quality images, 
further curtailing the time required for the post-processing stage [29]. 
The Mass-K Mode algorithm has been validated for clinical routine application, showing both 
accurate and reproducible evaluation of ventricular mass and volume and reduced time of analysis, by 
Jaspers et al. [29] on phantoms and on 12 patients with normal cardiac anatomy and function and more 
recently by Varga-Szemes et al. [25] on 137 patients with a broad range of cardiac diseases not 
including CHD. 
The results of our study validate the use of this BT technique in patients with an abnormal cardiac 
anatomy, such as the one that is found in patients with FC. In the absence of other reference tools to 
validate ventricular volume assessments, we choose to use aortic flow measurements as an 
independent benchmark for SV, since previous studies showed it to be a solid and reproducible 
44 
 
standard. Of note, we found no significant difference and a significant correlation between the two 
values [30–32]. 
Figure 10: example of segmentation of short-axis cine images with blood-threshold 
technique 
 
a, c, e Short-axis slices of cine images from base to apex without the blood-threshold mode. 
b, d, f The same images after manual epicardial volume analysis with blood-threshold mode activation. 
 
In addition, a greater level of automation and a lesser need of manual adjustments granted by the 
use of the BT technique and the semi-automated recognition of epicardial contours and aortic walls 
account for the excellent inter- and intra-reader reproducibility of both SV and aortic flow volume (85 
and 96%, respectively). 
Our study has limitations. First, it is a retrospective study on a relatively small number of subjects 
and it is based on a single-center historical series of FC patients; however, FUV patients are a very 
small population and usually referred to a single center. Second, it is possible that, due to the 
retrospective design of our study, even small differences in the acquisition parameters, reasonably 
likely to happen in the absence of a standardized CMR acquisition protocol, may have negatively 
influenced the quality of cine images and therefore the performance of the BT technique. Third, the 
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study lacks an independent reference standard, though the aortic flow analysis may be considered 
substantially independent of the cardiac cine study. Fourth, both readers were equally experienced 
(about 4 years); further studies are required to investigate reproducibility between readers with 
different levels of experience. 
Finally, we should consider the possibility of obtaining the same volume analysis with different 
software; this new function could be integrated in future software to be used in FUH patients. To 
summarize, we successfully validated the use of a BT technique for the segmentation of cine images in 
patients with FC. We observed a high intra- and inter-reader reproducibility for the assessment of 
ventricular SV and excellent agreement with aortic flow values used as a benchmark. 
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Strain of ascending aorta on cardiac magnetic resonance in 1027 
patients: Relation with age, gender, and cardiovascular disease 
Introduction 
Arterial stiﬀness is one of the earliest manifestations of adverse structural and functional changes 
within the vessel wall. When the aorta is considered, stiﬀness is a main determinant of age-related 
systolic and pulse pressure increase, a major predictor of stroke and myocardial infarction, and has 
been associated with heart failure [9, 77, 78]. Pulse wave velocity measured by applanation tonometry 
is a well-known functional method to non-invasively quantify aortic stiﬀness providing an average 
measure of stiﬀness over a certain vessel length. Conversely, strain, compliance, and distensibility are 
local markers of arterial elasticity, which can be measured using MR imaging, allowing the detection 
of more subtle changes in regional stiﬀness [79]. 
The use of MR imaging has several advantages over ultrasound imaging including three-
dimensional visualization that allows to place the imaging plane perpendicular to the vessel with a 
high reproducibility. Thus, aortic distensibility can be measured as a change in two dimensional vessel 
perimeter or area instead of one-dimensional vessel diameter [79]. Previous authors showed that AAS 
measured with cardiac CMR is markedly decreased before the ﬁfth decade of life and that can be 
considered as an early manifestation of vascular aging [10]. AAS was also shown to be independently 
correlated with coronary atherosclerosis and coronary calcium content [80] as well as to be an 
independent predictor of progression toward hypertension in non-hypertensive subjects [81]. 
Our aim was to evaluate the AAS in a large consecutive series of patients who underwent CMR, 
comparing age classes, gender, and diﬀerent types of CVD, also including subjects with normal CMR 
examinations. 
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Materials and methods 
Study design and population  
The local Ethics Committee approved this retrospective study (Ethics Committee of the University 
Hospital San Raffaele; protocol code AS01; approved on April 7th, 2016) and informed consent was 
waived. Patients were selected from a database of CMR studies performed between September 2008 
and August 2014 at the Radiology unit of the IRCCS Policlinico San Donato, San Donato Milanese, 
Italy. CMR examinations with an image quality that impairs AAS evaluation were excluded from 
analysis. Moreover, in the case of multiple CMR examinations in the same patient, only the ﬁrst one 
was included. 
 
Image acquisition 
We retrospectively selected images acquired with two diﬀerent 1.5 T machines. Magnetom Sonata 
Maestro Class (Siemens, Erlangen, Germany), was used to perform the studies from September 2008 
to March 2014 (n =1294); subsequent studies (n= 69) were performed using Magnetom Aera 
(Siemens, Erlangen, Germany). Retrospectively ECG-gated breath-hold two-dimensional phase-
contrast gradient recalled echo sequences with a through-plane velocity encoding gradient ranging 
from 150 to 350 cm/s were performed on a transverse plane above the aortic bulb. Sequence 
parameters were as follows: repetition time 49.75 ms, echo time 3.1 ms, ﬂip angle 30° for Magnetom 
Sonata; 37.12 ms, 2.47 ms, 20° for Magnetom Aera. Parallel imaging with acceleration factor 2 and 
retrospective ECG-gating with 30 phases per cycle (with repetition time dependent on the R-R 
interval) were set on both machines. 
 
Image analysis 
Image post-processing was performed using Argus Flow software (Syngo Argus Flow, version 4.02, 
Siemens, Erlangen, Germany). Magnitude images were used to semi-automatically segment aortic 
contours in each cardiac phase. During the segmentation process, an expert cardiac radiologist with 2–
7 years of experience in CMR selected the frame with the optimal contrast between aortic lumen and 
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aortic wall. Then, the operator traced in the same frame the aortic contour, which was automatically 
propagated in all frames of the cardiac cycle and manually corrected when necessary. 
The AAS was calculated as deﬁned by Redheuil et al. [5], namely: 
𝐴𝐴𝑆 =
𝐴𝑚𝑎𝑥 − 𝐴𝑚𝑖𝑛
𝐴𝑚𝑖𝑛
 
where Amax and Amin represent respectively the maximum and minimum aortic cross-sectional area 
measured during a single cardiac cycle. 
 
Statistical analysis  
The Shapiro-Wilk test was employed to assess normality of data distribution. Due to non-normal data 
distribution, descriptive statistics are provided as median and corresponding IQR values. To evaluate 
the inﬂuence of age, gender, and CVD on the AAS values, we performed a three-way ANOVA test. 
The log-transformation of the data was obtained to reach the condition of normal distribution needed 
to perform the tree-way ANOVA. Age was categorized into 7 age bins (0–9, 10–19, 20–29, 30–39, 
40–49, 50–59 and ≥60 years). Moreover, post-hoc tests for CVD and age bin factors were performed. 
After this global analysis, the statistical diﬀerences in AAS values were analyzed in the larger 
subgroups, namely: subjects with normal CMR (i.e. unremarkable examination in subjects examined 
to exclude cardiac abnormalities), patients with ToF, and patients with ischemic heart disease (IHD). 
Taking into account only these types of CVD, the evaluation of AAS changes over all the selected age 
bins was not possible, due to the diﬀerent age distribution of subjects aﬀected by congenital (ToF) and 
age-related (IHD) CVD. Therefore, statistical inference on AAS trends over age was evaluated 
comparing ToF and IHD subjects only with normal CMR subjects. To this aim, the Mann-Whitney U 
tests was used for each age bin. On the other hand, to evaluate the inﬂuence of gender and CVD on 
AAS values, a two-way ANOVA was performed. Also, in this case, log-transformation of the data was 
obtained to perform multivariate analysis. Finally, age was considered as a continuous variable and 
correlation between age and AAS values was estimated using Spearman correlation coeﬃcient. 
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Statistical signiﬁcance level was set to P < 0.050 and the analysis was performed using SPSS (IBM 
Corporation, New York, NY, United States). 
 
Results 
A total of 1363 CMRs were retrieved; among them, 42 examinations were excluded due to an 
insuﬃcient image quality. Moreover, in order to create homogenous CVD categories, we excluded 
disease subgroups composed of less than 10 subjects. For this reason, other 294 cases were excluded 
from the analyzed sample. 
The ﬁnal number of analyzed patients was 1027. Among them, 726 were men (median age 37 
years, IQR18–60) and 301 were women (median age 34 years, IQR 16–54), with borderline 
signiﬁcance between genders (P = 0.051). Fig. 11 shows age distribution between genders. 
Figure 11:  age distribution in the analysed sample 
 
Histograms representing age distribution among diﬀerent genders in the 1027 analyzed patients. 
 
Taking into account all the analyzed subjects, the median AAS value was 0.25 (IQR 0.17–0.38). 
Shapiro Wilks test showed that AAS data were not normally distributed (P < 0.001) The AAS resulted 
inversely correlated with age (ρ= −0.51, P < 0.001). Moreover, women showed a signiﬁcantly (P = 
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0.006) higher AAS (median 0.28, IQR 0.20–0.41) compared to men (median 0.24, IQR 0.16–0.36). 
The results of the three-way ANOVA are shown in Table 10. 
Table 10: output of ANOVA analysis 
 
Output of the three-way ANOVA analysis that takes into account the eﬀect of age, 
gender and cardiovascular disease on ascending aortic strain values. Data shows that all 
the three variables (age, gender and CVD) are independently associated to AAS. 
Statistically signiﬁcant p-values are highlighted in bold. 
CVD: cardiovascular disease; df: degrees of freedom. 
Post-hoc analysis showed signiﬁcant diﬀerences in AAS among all the age bins except for those 
between 30 and 49 years of age. Fig. 12 shows the AAS trend over decades of age, while results of 
post-hoc test for diﬀerent CVD type sand their corresponding descriptive statistics are presented in 
Table 11. 
Figure 12: ascending aortic strain over age 
 
Ascending aortic strain (AAS) values over decades of age in the analyzed 
sample of 1027 consecutive subjects. For each age subgroup the number of 
included subjects is reported between brackets 
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Of the total of 1027 cases, the major subgroups were represented by 192 subjects with normal 
CMR (128 men, 64 women; median age 36 years, IQR 18–51), 166 patients aﬀected with IHD (132 
men, 34 women, median age 64 years, IQR 58–71), and 92 patients aﬀected with ToF (57 men, 35 
women; median age 25 years, IQR 14–40). In all the three subgroups, there was no signiﬁcant 
diﬀerence in terms of age between men and women (normal CMR, P =0.997; IHD, P = 0.658, ToF: P 
= 0.361). 
Table 11: post hoc tests performed on diﬀerent cardiovascular 
disease subgroups 
 
In this table are shown only post hoc tests performed between subjects with normal 
cardiac magnetic resonance and patients with diﬀerent diseases. Statistically 
signiﬁcant p-values are highlighted in bold. 
CMR: cardiac magnetic resonance; CVD: cardiovascular disease. 
 
Multivariate analysis performed on the subsample composed by these three major subgroups 
showed signiﬁcant diﬀerences in AAS values between genders (P = 0.002) and among CVD 
subgroups (P < 0.001), without interaction between CVD subgroups and genders (P =0.119). In 
general, median AAS values were higher in women than in men, as can be seen in the boxplot 
represented in Fig. 13. However, post-hoc analysis showed a signiﬁcant diﬀerence in AAS between 
men and women only for ToF patients (P = 0.008). Moreover, men with ToF showed a signiﬁcantly 
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lower AAS when compared with men with normal CMR (P =0.005). In the other two subgroups, this 
diﬀerence appeared to be not signiﬁcant within the analyzed sample. No signiﬁcant diﬀerence was 
found between genders in subjects with normal CMR (P = 0.728). In IHD patients, AAS was 
signiﬁcantly lower compared to that of normal CMR subjects (men: P < 0.001, women: P =0.016), 
without signiﬁcant diﬀerence between genders (P =0.732). In subjects with normal CMR, the analysis 
of AAS trend over age showed an inverse correlation with age both in men (ρ= −0.53, P < 0.001) and 
women (ρ= −0.54, P < 0.001); AAS decreased with age also in IHD patients (ρ= −0.16, P =0.039), 
this correlation remaining signiﬁcant in women (ρ= −0.40, P = 0.021) but not in men (ρ= −0.11, P 
=0.224). Evaluating AAS over decades of age, men with IHD had an AAS signiﬁcantly lower than 
that of normal CMR subjects only between 50 and 59 years of age (P = 0.019). No signiﬁcant 
diﬀerences were found between women aﬀected with IHD and women with normal CMR for all age 
bins. 
Figure 13: subgroup analysis 
 
Three boxplots that represents ascending aortic strain values in normal cardiac magnetic resonance (CMR) subjects, 
patients with tetralogy of Fallot (ToF) and ischemic heart disease (IHD), subdivided by gender 
 
Also, in ToF patients the AAS decreased with age, signiﬁcantly in men (ρ= −0.66, P < 0.001), 
not signiﬁcantly in women (ρ= −0.28, P = 0.106). Moreover, men aﬀected with ToF belonging to the 
20–49 age range had AAS values signiﬁcantly lower than men with normal CMR (20–29 years, P = 
0.002; 30–39 years, P = 0.011; 40–49 years, P < 0.001); after 50 years of age, this diﬀerence was not 
signiﬁcant. On the other hand, women aﬀected by ToF did not show signiﬁcantly lower AAS values 
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for all the age bins when compared to normal CMR women. Fig. 14 shows the age-related changes of 
AAS over decades of age for all the above-mentioned subgroups. 
Figure 14: ascending aortic strain over age in subgroup analysis 
 
Ascending aortic strain (AAS) values over decades of age in subjects with normal cardiac magnetic resonance 
(CMR), patients with tetralogy of Fallot (ToF) and ischemic heart disease (IHD), divided by gender. Statistically 
signiﬁcant comparisons are marked with a star (*). 
 
Discussion 
In this study, AAS values were analyzed in a large consecutive series of patients with different types 
of CVD and in subjects with normal (unremarkable) CMR. This study proved that difference in age, 
gender, and CVD independently affect the AAS. 
Age distribution of the analyzed sample was characterized by two peaks, the ﬁrst at age 15 and 
the second at age 60, as visible in Fig. 11, reﬂecting the high number of patients with congenital and 
age-related heart diseases in our series. This was conﬁrmed by the fact that, among the analyzed 
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CVDs, the most frequent were IHD and ToF, which represent two diﬀerent pathophysiological 
processes both aﬀecting AAS: age-related factors and congenital/developmental factors, respectively. 
Gender diﬀerence in AAS in the whole patient dataset was likely due to a diﬀerent proportion 
between males and females in some CVD subgroups, since subjects with normal (unremarkable) CMR 
showed no signiﬁcant gender diﬀerence in term of AAS. Gender-related diﬀerences appeared not to be 
inﬂuenced by age or CVD, although in patients with ToF there was a gender-related diﬀerence in 
AAS, in line with a previous study where diﬀerences in functional cardiovascular parameters between 
male and female patients with ToF was found [82]. Furthermore, other studies demonstrated a gender-
related difference in arterial aging and stiffening process, suggesting that hormonal and other gender-
speciﬁc factors can modulate the aging process [83]. 
Vascular changes with age are well-known. The progressive decrease in AAS during life reﬂects 
physiological and pathological modiﬁcations of mechanical, histological, and functional properties of 
the aortic wall. Moreover, diﬀerences in cardiac function and pulse wave reﬂection by medium and 
small arteries contribute to AAS. Animal studies indicated that age-related changes in aortic stiﬀness 
and strain may not entirely due to pathologic causes such as atherosclerosis and diabetes but also to 
physiological aging [9]. However, we found that patients with IHD have a signiﬁcantly lower AAS 
compared to normal (unremarkable) CMR subjects between 50 and 59 years of age, highlighting the 
association between coronary artery disease and reduction in aortic elasticity. 
Multivariate analysis showed the presence of signiﬁcant differences in AAS among patient with 
diﬀerent age, genders, and cardiovascular conditions. Moreover, these results show that the interaction 
among these parameters does not impact on AAS. In patients with certain diseases such as IHD, a 
decrease or increase in AAS is more easily explainable on the basis of diﬀerent age, morpho-
functional or pathophysiologic characteristics. On the other hand, in patients with other diseases such 
as ToF, the results are less obvious. 
Patients with IHD showed a reduced AAS compared to normal CMR subjects between 50 and 59 
years of age; this diﬀerence is reduced for subjects over 60 years of age, being not signiﬁcant. This 
result may be due to a combination of factors: increased aortic stiﬀness determined by atherosclerosis 
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(more pronounced in patients with IHD) and reduced cardiac output, implying a decreased stretching 
of the ascending aorta. This value may however underestimate the real diﬀerence because subjects 
with normal CMR were not really healthy controls but patients with unremarkable CMR who may 
have had one or more CVD risk factors that could have contributed to a decrease in AAS. 
AAS was signiﬁcantly lower in patients with ToF than in patients with normal CMR, especially 
in males in the 3rd and 4th decade of life. This result is probably due at least in part to an intrinsic 
morpho-functional defect in ToF, described by other authors as a fragmentation of elastic ﬁbres in 
aortic medial wall [84–89]. A similar study by Christensen et al. [89] highlighted the relationship 
between age at repair of ToF and AAS. One of the most though-provoking results was the poor 
correlation between AAS and PWV, highlighting the need for a local assessment of the aortic elastic 
properties. Our results were slightly different, the AAS being higher in the present study, probably due 
to the age diﬀerence in the study population or the timing of the ToF repair, with comparable 
correlations between AAS and ascending aortic cross-sectional area. The gender difference could 
reﬂect diﬀerences in biventricular volumes and function, as well as diﬀerences in timing and type of 
ToF treatment. Nonetheless, we could hypothesize that there is also a gender-related factor that aﬀects 
AAS in ToF patients. AAS was also lower in patients affected by TGA and in those patients that 
underwent Fontan and Ross procedures, in accordance with previously reported ﬁndings [88, 90–92]. 
These results reaﬃrm the importance of including aortic morphological and functional evaluation in 
the follow-up of patients with congenital heart diseases. 
Aortic strain reﬂects vascular compliance in large vessels and is lower in older patients. We did 
not ﬁnd a signiﬁcant diﬀerence in subjects over 60 regardless of the pre-existing diseases, probably 
because of the prevailing aging process [93]. Another possible explanation is that older subjects with a 
normal (unremarkable) CMR could have been exposed to the same risk factors and have ongoing 
pathophysiological processes similar to those affecting patients with IHD, making them less suitable 
for a direct comparison. On the other hand, differences in AAS in young patients with congenital heart 
disease could reﬂect a precocious arterial stiﬀening [10]. 
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This study also showed that aortic strain can be easily and rapidly obtained using phase-contrast 
sequences usually performed for ﬂow analysis; its evaluation and monitoring could be beneﬁcial in 
detecting aortic stiffening. Moreover, it may be used for non-invasive follow-up evaluations of aortic 
condition in CVD patients. 
This study is aﬀected by several limitations mainly due to its retrospective design. Firstly, we 
should consider that prospective studies included blood pressure data measured after the sequence [88] 
since it is somewhat diﬃcult to measure blood pressure during the acquisition of a CMR sequence. We 
could not include this parameter in our analysis. However, brachial blood pressure measurements 
could lead to an overestimation of central blood pressure and biased aortic distensibility. Secondly, we 
did not use a standardized plane placement on the ascending aorta. The sequences were not purposely 
acquired to measure aortic cross-sectional area but they were placed by the same operator above the 
aortic root to evaluate ascending aortic ﬂow. For this reason the systolic motion of the ascending aorta 
due to myocardial contraction was not accounted for, similarly to another study [89]. Our technique, 
being simple and not relying on peak ﬂow to choose the timing for plane placement in order to assess 
minimum and maximum area, is surely less accurate than the one used by Grotenhuis et al. [94]. 
Finally, we lack really healthy control subjects. Since the diﬀerences in terms of AAS were signiﬁcant 
when comparing age matched subgroups of patients with normal (unremarkable) CMR and with CVD, 
we are conﬁdent that there was a signiﬁcant reduction in AAS in at least two of the major subgroups 
of patients compared to what we expect in normal subjects of similar age. 
In conclusion, we found that AAS is independently affected by differences in age, gender, and 
cardiovascular condition. In particular, this tendency was evident in patients with ToF and IHD, where 
the aging process seems to prevail on pre-existent diﬀerences in terms of AAS in subjects over 60. Our 
results highlight the possibility to use AAS for a non-invasive assessment of the aortic status in CVD 
patients. Nevertheless, further investigations on elderly patients and, in particular, in adults with 
congenital heart disease are advised. 
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Intra- and inter-reader reproducibility of blood flow measurements 
on the ascending aorta and pulmonary artery using cardiac 
magnetic resonance 
Introduction 
In the past years, cardiovascular magnetic resonance CMR has emerged as an alternative non-invasive 
imaging technique for the evaluation of patients with cardiovascular disease, providing an accurate 
anatomic and functional characterization of the heart and great vessels as well as the possibility to 
investigate nearly the whole spectrum of cardiac disease [95]. Especially for patients affected with 
congenital heart disease, CMR plays an important role in the quantification of blood flow and 
evaluation of valve stenosis/insufficiency using PC through-plane sequences [19, 96–103]. The PC 
sequences were validated in phantom and in vivo studies and have proven to be a reliable tool for the 
quantitative and qualitative analysis of blood flow and tissue motion. 
Despite its importance for the assessment of disease progression, few data are available about the 
reproducibility of CMR in the measurement of blood flow in patients with valve stenosis and/or 
insufficiency [96, 104–106]. Moreover, segmentation methods were validated indirectly, through the 
ability to provide accurate flow measurement [104, 107] or pulse wave velocity [107, 108] or directly 
in terms of operator variability [104, 105] or agreement with manual tracing [108]. 
Blood flow measurements are based on the segmentation of a vessel contour that may be 
performed manually or, more typically, semi-automatically, with the use of computer software likely 
impacting on measurement reproducibility. Reader experience may play a role as well. 
Thus, the aim of our study was to estimate the intra- and inter-reader reproducibility of blood 
flow CMR measurements through the ascending aorta and main pulmonary artery in patients affected 
with congenital heart disease or with aortic and/or pulmonary valve disease. The impact on 
reproducibility of the reader’s experience with CMR was also investigated. 
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Materials and methods 
Study design and population  
The ethics committee approval was obtained for this retrospective study. A total of 50 consecutive 
patients affected with a congenital heart disease or with aortic and/or pulmonary valve disease were 
reviewed. They all underwent CMR at our institution between November 2012 and May 2013. Of 50 
patients, 35 were males and 15 females, with a mean age of 27 ± 13 years (mean ± standard deviation). 
The disease spectrum is shown in Table 12. The majority of patients (n = 28, 56%) had a Tetralogy of 
Fallot. 
Table 12: disease spectrum in 50 studied patients 
 
ToF: tetralogy of Fallot; VSD: ventricular septal defect. 
 
Images acquisition  
All CMR examinations were performed with a 1.5-T unit with 40-mT/m gradient power (Magnetom 
Sonata Maestro Class, Siemens Medical Solution, Erlangen, Germany), using a four-channel surface 
phased-array coil placed over the thorax and with the patient in supine position. 
A CMR study included a complete set of short-axis (from base to apex) and long-axis (2-, 3- and 
4-chamber views) cine images, using an ECG-triggered breath-hold steady-state free precession 
sequence acquired with the following technical parameters: TR/TE 4.0/1.5 ms; flip angle 80°; slice 
thickness 7 mm; time resolution 45 ms; mean acquisition time 14 ± 4 s. 
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The PC through-plane sequences were used for blood flow quantification. Images perpendicular 
to the vessel of interest were obtained. A breath-hold turbo spoiled gradient echo sequence (fast low-
angle shot) was performed for phase-velocity mapping with the following technical parameters: 
TR/TE 4.0/3.2 ms; slice thickness 5 mm; VENC from 150 cm/s to 350 cm/s; time resolution 41 ms; 
mean acquisition time 15 ± 4 s. For each patient, we initially acquired the PC sequence with a VENC 
of 150 cm/s: in the presence of aliasing, we increased the VENC adding 50 cm/s for each new 
sequence, step-by-step up to the complete disappearance of the aliasing artifact. 
 
Images analysis 
Flow measurements were performed right above the aortic or pulmonary valve in patients with 
surgical or percutaneous valve replacement. In patients without valve replacement, measurements 
were performed below, at the level and above the native valve. The PC sequences produced two sets 
of images: the gradient echo image and the phase velocity map (Fig. 15). The magnitude image depicts 
the anatomy and allows to identify the vessel boundaries, while the phase velocity map corresponds to 
blood velocity [96]. 
Figure 15: example of pulmonary artery segmentation 
 
The image represents the pulmonary artery segmentation showing the gradient echo image, with 
a region of interest right after the valve, and the phase velocity map with the same ROI 
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Two independent readers (R1 and R2) performed measurements twice, with at least a 10-day 
interval between the two sessions, for a total of four sessions. These readers had different educational 
background and different level of training in CMR segmentation. While R1 was a radiology resident 
with 4 months of full-immersion training (under the supervision of a radiologist with a 5-year 
experience in CMR), R2 was a technician student with 2 weeks of training (under the supervision of 
the same experienced radiologist). 
Both readers used the Argus software on a remote workstation (Leonardo, Siemens Medical 
Solution, Erlangen, Germany). For each patient, the reader positioned a region of interest on the vessel 
boundary of a selected slice and propagated the segmentation through the remaining slices. Then, the 
software proposed an automated adjustment and the reader was allowed to manually correct the 
adjusted contours (hence semi-automated method). Blood peak velocity, forward and backward flows 
were obtained. An example of flow analysis is shown in Fig. 15. 
Intra- and inter-reader reproducibility was estimated using the Bland–Altman method; for the 
inter-reader reproducibility the first measurement of both readers was used. The CoR was calculated 
as 1.96 × standard deviation of differences of the two compared datasets. Reproducibility was reported 
as complement to 100% of the ratio between the CoR and the mean. Bland–Altman graphs were 
plotted as well, showing bias (mean of the differences of the two compared datasets), and 95% limits 
of agreement (bias ± CoR). 
 
Results  
Of 50 analyzed patients, 46 (92%) had a pulmonary disease, two (4%) ventricular septal defect, one 
(2%) aortic insufficiency, and one (2%) truncus arteriosus. Further details are reported in Table 13. 
Image analysis was feasible in all patients and no malformations or artifacts prevented from a 
correct segmentation. The PC sequence showed no artifacts in patients with a surgical or percutaneous 
valve replacement. The time needed for measurement was about 5 min per patient, without substantial 
difference between the two readers. 
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The mean blood peak velocity of the aortic flow measured by R1 was 103 cm/s, accompanied by 
a CoR of 1 cm/s, corresponding to an intra-reader reproducibility of 99%; the same data for R2 were 
103 cm/s, 9 cm/s, and 92%. The mean blood peak velocity of the pulmonary flow measured by R1 was 
180 cm/s, accompanied by a CoR of 1 cm/s, corresponding to an intra-reader reproducibility of 99%; 
the same data for R2 were 181 cm/s, 3 cm/s, and 98%. Further details are reported in Table 2 for R1 
and in Table 3 for R2, while Bland–Altman plots for R1 only are shown in Fig. 16.  
Table 13: first reader intra-reader reproducibility 
 
Figure 16: Bland-Altman plot for intra-reader reproducibility 
 
Bland–Altman plots for intra-reader reproducibility analysis of the first reader: a and b peak 
velocity, c and d forward flow and e and f backward flow of the aorta (left column) and 
pulmonary artery (right column). 
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The inter-reader reproducibility analysis of the aortic flow peak velocity showed a CoR of 10 
cm/s, over a mean of 103 cm/s, corresponding to an inter-reader reproducibility of 91%; the same data 
for the pulmonary flow were 7 cm/s, 180 cm/s, and 96%. Further details regarding the inter-reader 
reproducibility are reported in Table 14, while Bland–Altman plots are shown in Fig. 17. 
Table 14: inter-reader reproducibility results 
 
Figure 17: Bland-Altman plot for inter-reader reproducibility 
 
Bland–Altman plots for inter-reader reproducibility analysis: a and b peak velocity, c and d forward flow 
and e and f backward flow of the aorta (left column) and pulmonary artery (right column). 
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Discussion  
Cardiac magnetic resonance has emerged as a reliable imaging technique for assessing heart valve 
disease, quantify its severity, and to evaluate its effect on the heart morphology and function [19, 95, 
96, 98]. It is used for evaluating cardiomyopathy-related valve dysfunction since more than two 
decades [109]. Patient management using CMR includes follow-up for treatment effect monitoring or 
disease progression [110, 111]. 
Reproducibility means the ability of a reader to provide the same values when repeating the 
measurement, a number of times. If two or more readers are involved in the patient management, they 
need to provide as similar as possible results when analyzing a given CMR examination. When a 
follow-up measurement is performed on a patient, the clinician needs to identify a true change that can 
be ascribed to treatment effect or worsening of disease, rather than to measurement errors [112]. In 
this scenario, the readers’ experience may play a role and skilled operators may be necessary. 
In this study, we obtained a good-to-excellent intrareader reproducibility of CMR in flow 
measurement for all variables under consideration, except for the backward flow of the ascending 
aorta. Indeed, intra-reader reproducibility was higher than 90% for the trained reader (R1) and higher 
than 86% for the lower trained reader (R2). Such a good result may be due thanks to the semi-
automated method used for segmentation that is not difficult to be used also by less experienced 
readers [101]. This means that a reader’s learning curve should be short and that the segmentation of 
vessel boundaries through a semi-automated method may also be performed by not highly specialized 
personnel. Probably, if we had used a manual method of segmentation we could have found a lower 
reproducibility for the untrained reader. However, although of a small magnitude, data suggest an 
additional reproducibility of R1 over R2, likely due to the different educational background and the 
different level of training [101]. 
Inter-reader reproducibility, even if reaching a maximum of 96% for the blood peak velocity of 
the pulmonary artery, decreased to 75 and 82% for the forward and backward flow of the pulmonary 
artery, respectively, being lower than that observed in previous studies. Van Der Geest et al. compared 
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an automated contour detection algorithm for analysis of the ascending aorta flow with a fully manual 
segmentation, showing intra- and inter-reader variability lower than 2% for both manual and 
automated methods [104]. Conversely, Herment et al. demonstrated a higher inter-reader variability 
for manual tracing than for automated segmentation using PC CMR images in healthy volunteers and 
in patients with a dilated aorta [105]. 
The backward flow of the ascending aorta deserves some considerations. In fact, a low to very 
low reproducibility for this variable was obtained, being lower than 50% for the intra-reader analysis 
and equal to 20% for the inter-reader analysis. This is only an apparently negative result being mainly 
related to the low magnitude of the ascending aorta backward flow, even in patients with aortic 
insufficiency. Reproducibility being given as percentage of the mean, even subtle measurement 
variations due to small differences in segmentation may have a strong negative impact on 
reproducibility. 
The major limitation of this study is that results are related to the particular 1.5-T unit used for 
imaging patients and to the sequences and technical parameters used, also including the use of breath-
hold or respiratory gating for avoiding artifacts from respiratory movements. However, 1.5-T magnets 
are mostly used for cardiac imaging and our imaging protocol is quite generally accepted. Thus, our 
results should be generalizable. Another limitation may be the study population that included patients 
affected with different cardiovascular diseases (even if the majority of patients had a Tetralogy of 
Fallot) who had a pathology of the aortic and/or pulmonary valve. However, we wanted to estimate the 
intra- and inter-reader reproducibility in a heterogeneous population for a higher generalizability. 
Probably, limiting to a more homogeneous population could demonstrate an even higher 
reproducibility. 
In conclusion, this study showed a good-to-excellent intra- and inter-reader reproducibility of 
blood flow measurements in patients with congenital heart disease using CMR and a semi-automated 
method of segmentation, with a limited impact of the operator’s training. 
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To share or not to share? Expected pros and cons of data sharing in 
radiological research 
Introduction  
In clinical research, spontaneous data sharing is not yet as common as it is in other fields such as 
genetics, astronomy or physics [11]. However, the concept of data sharing has been suggested for 
many reasons, including the patient-centered nature of medical research and healthcare and the 
expectation that knowledge from existing data should be maximized to benefit all stakeholders. 
Although a transition to data sharing is a process that will take time and planning, those who 
adopt the principles and practices of open science will likely benefit from it [12, 13]. In addition, the 
emergence of data sharing as a potential requirement by some agencies and journals warrants attention 
by the imaging community. Indeed, from July 1st, 2018 the ICMJE will require a data sharing 
statement as a condition of consideration for publication of clinical trials [14]. In this article, we 
discuss potential advantages and disadvantages of data sharing. 
From open-access to data sharing 
A trend towards larger accessibility to scientific medical knowledge is already visible in the 
progressive tendency of medical journals in ensuring the open-access option, in which the authors or 
their institutions pay an article-level fee to guarantee the immediate free availability of their papers 
[113]. 
In Table 15 we report the policies of all the 18 general imaging journals on access and data 
sharing [114–125]. This was derived from the current Thomson Reuters list – Radiology, Nuclear 
Medicine, and Medical Imaging. For comparison, the 17 most-impacted general medicine journals 
were selected from the current Thomson Reuters list – Medicine, General and Internal [126–143]. 
Among the 18 imaging journals, four are open access, 12 offer open access as an option (Radiology 
provides free access 12 months after publication), and two do not offer an open-access option. Among 
the 17 medical journals, six are open access (The Medical Journal of Australia only for research 
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articles and case reports), eight offer open access as an option (Journal of the American Medical 
Association [JAMA] provides free access 6 months after publication), two do not offer an open access 
option, and one (The New England Journal of Medicine [NEJM]) provides free access to research 
articles 6 months after publication. Thus, the open access option is currently widely adopted by both 
general imaging journals (11/18) and general medicine journals (8/17). 
Table 15: policies on access and data repository or sharing by major general imaging 
journals and major general medicine journals 
 
Note: Imaging journals were selected for being general (not subspecialty) journals from the Thomson Reuters 
list – Radiology, Nuclear Medicine, and Medical Imaging (n=18). For comparison, the general medicine 
journals from the first quartile were selected from the Thomson Reuterslist – Medicine, General and Internal 
(n=17). 
1Most journals offer free accessibility for selected articles. 
2Despite individual journals do not mention any policy on data sharing, some publishers (e.g. Elsevier) have 
their own general rules to which refer to. Moreover, when data sharing is encouraged, authors are informed to 
be prepared to provide original study data if requested by the editors. 
3Publishes only invited reviews.  
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The practice of data sharing entails much more than open access. It is the regulated availability of 
the original participant-by-participant data obtained during a study, which may include data not yet 
analyzed. Among the 18 general imaging journals, data sharing is not even mentioned by 12 journals, 
encouraged by three, mandatory only upon request in two, and requested by one. Among the 17 
general medicine journals, it is not mentioned by seven journals, encouraged by six, requested by three 
(NEJM only for data obtained by microarray), and considered mandatory only up on request by one 
(Table1). In practice, data repository or sharing is currently not mentioned in the instructions for 
authors of the majority of general imaging journals (14/18) and major general medicine journals 
(10/17). Despite individual journals do not mention any policy on data sharing, some publishers such 
as Elsevier have their own general suggestions, which refer to Open Access [118], even though not 
immediately visible to the authors when they submit a manuscript. When data sharing is encouraged, 
authors are informed they should be prepared to provide original study data if requested by the editors.  
In recent years, several funding bodies declared the necessity for data sharing. In 2015, the U.S. 
National Institutes of Health (NIH) expressed its intention to request making the digital data from 
NIH-funded studies publicly available [144]. Regulatory agencies, specifically the European 
Medicines Agency, have requested greater data sharing by companies manufacturing drugs and 
clinical devices. Influential organizations such as the World Health Organization and the U.S. National 
Academy of Medicine published reports asking for responsible sharing of data from clinical trials 
[145]. Also, several foundations, for instance the Alfred P. Sloan Foundation [146], the Bill and 
Melinda Gates Foundation [147], the Ford Foundation [148], the Gordon and Betty Moore Foundation 
[149], and the National Science Foundation [150], require data sharing and data management plans for 
all research grant proposals. 
The pharmaceutical industry also plays a role in promoting data sharing. The Yale University 
Open Data Access (YODA) project [151] performs independent scientific review of investigators’ 
requests for pharmaceutical and medical data from clinical trials on devices marketed by Johnson & 
Johnson, including both full clinical study reports and participant level data. Notably, the YODA 
project has obtained permission to make independent decisions about the release of Johnson & 
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Johnson’s clinical trial data. This project establishes a process in which requests are judged fairly and 
decisions are made by an independent academic partner, a model that could be applied to other fields 
of medicine [151]. 
Another example is the Academic Research Organization Consortium for Continuing Evaluation 
of Scientific Studies – Cardiovascular (ACCESS CV) [152]. They propose a secure method for 
sharing patient-sensitive data that combines the protection of patients’ identity with the legitimate 
desire of the scientific community for data access and the viewpoint of the researchers who created the 
database. This approach consists of the following steps: (1) After publication of the primary results of 
a trial, researchers interested in the study data may send a request to the trial's publication committee; 
(2) Twenty-four months after the publication of the primary study, requests should be considered by a 
review group composed of members of ACCESS CV not involved in the trial, the trial principal 
investigator, a trial statistician, and a member of the data and safety monitoring board. This committee 
evaluates all proposals to approve those that are feasible, hypothesis-based, non-duplicative, and 
guided by investigators with technical capability and a plan for publication. The period of 24 months 
is chosen to secure the database and to allow the original investigators to perform their own 
preplanned secondary analyses; (3) All requests and subsequent decisions will be posted on an 
ACCESS CV Web portal, ideally within 60 days [152]. 
In the field of radiology, data sharing also means accessibility to medical images. Indeed, 
“Images are more than pictures, they are data” [153]. This implies access to the images produced in a 
given study for additional reading, interpretation, and extraction. To this end, several image 
repositories were created. An example is the XNAT Central [154, 155], a publicly accessible data 
repository based on the XNAT open-source platform which hosts a wide variety of research imaging 
datasets, especially from neuroimaging, but also from oncology, orthopedics and cardiology. Other 
examples are The Cancer Imaging Archive [156] and the Lung Image Database Consortium [157]. 
Such repositories may be very helpful in several fields, especially for image biomarker 
development, radionics and machine learning, each field demanding different approaches. Moreover, 
the integration, standardization and analysis of these data poses a big challenge, the solution to which 
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may be addressed using cognitive computing. An example of cognitive computing is the system 
developed by IBM named Watson (IBM Watson Health Imaging, Armonk, NY, USA). It strives to 
organize available information and present it in a contextually relevant, probability-driven manner to 
assist healthcare professionals in an objective manner, whether at a reading workstation or at the point-
of-care [158]. An important change is underway. To make datasets from medical research publicly 
available in a timely fashion requires regulations that maximize the benefits and minimize the risks 
[159, 160]. Indeed, data sharing provides a potential for stimulating new ideas, avoiding duplication of 
trials, and enhance transparency [144, 161–164] as well as increasing collaboration and 
interdisciplinary research [11, 165, 166]. However, at the same time, sharing clinical data presents 
some risks, burdens and challenges such as the need to preserve the privacy of patients, to defend the 
legitimate economic interests of the sponsors, and to guard against invalid secondary analyses 
potentially undermining trust in clinical trials or otherwise harming public health [144, 145, 160, 167]. 
Potential benefits of data sharing  
These can be subdivided into: (i) verification and advancement in knowledge; (ii) reduced cost and 
time for clinical research; and (iii) clinical improvement (Fig. 18). 
Figure 18: expected pros and cons of data sharing. IPD 
individual patient data meta-analyses 
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Verification and advancement in knowledge  
The first potential implication of data-sharing is the verification by independent authors of the results 
presented in a given publication. When data are shared, they may be used by other researcher stopper 
form alternative or supplementary analyses. This ‘second-hand’ analysis may show results in support 
of the initial findings or could reveal errors or inconsistencies in the original research or could identify 
issues needing extended analysis. 
In other cases, data sharing can allow elucidation of new results. New findings can be disclosed 
starting from hypotheses not considered by the original study team. New insights can be presented 
from existing data but not yet analyzed in the original publication(s). Also, investigators may be 
interested in performing the analysis of datasets coming from various sources to enhance precision, i.e. 
to perform reproducibility analyses across different databases, regarding established theories or new 
hypotheses. In fact, reproducibility analysis is crucial for emergent topics in radiology such as 
standardization of imaging biomarkers, especially from magnetic resonance imaging [168]. The 
availability of databases from different studies could allow for this gap to be filled and could help in 
translating new imaging biomarkers into clinical practice [169]. In this regard, reproducibility analysis 
could become one of the main advantages of data sharing. 
The introduction of registries of patients affected with a defined disease could be considered a 
primitive form of data sharing [170, 171], important not only for widespread diseases, such as cancers, 
but especially for rare diseases. 
Another approach of spontaneous data sharing is that underlying individual patient data meta-
analyses [172]. Authors of an individual patient data meta-analysis typically contact the authors of 
each eligible study asking to share their data, with the aim of creating a new unique individual-patient 
database. Of note, the power of the individual-patient data approach is higher than that of conventional 
(study-level) meta-analyses, which rely on complex statistical methods [173]. For instance, in a study 
published by Marinovich et al. [174] on the agreement between MRI and pathological breast tumor 
size after treatment, a total of 24 studies (1,228 patients) were eligible for inclusion, but only eight of 
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these contributed to the individual-patient data analysis for a total of 300 patients. Had regulated data 
sharing been in place, that individual patient data meta-analysis would have included a much richer 
dataset. Moreover, data sharing could boost a wider adoption of health technology assessment. Indeed, 
in the context of a new product evaluation, data sharing may be useful in the validation level, requiring 
a high number of data/images, rather than at the initial development level. 
Another potential advantage of data sharing is to reduce the publication of false studies, 
especially when the data are intentionally falsified. Recently, 64 articles were retracted from ten 
Springer journals after editorial checks found fake email addresses, and subsequent internal 
investigations uncovered fabricated peer-review reports [175]. This retraction came only a few months 
after BioMed Central had retracted 43 articles for the same reason; however, this phenomenon 
involved most major publishers such as also SAGE, Elsevier, Informa, and Lippincott Williams & 
Wilkins [176]. Data sharing might discourage data creation and manipulation, potentially more 
detectable in a complete database than in reported results. 
Reduced cost and time for clinical research 
Data sharing could potentially lead to an optimization of time and costs of clinical research by 
preventing the duplication of trials [177, 178]. For example, costs for the stipulation of insurances for 
patients’ coverage, the purchase of materials or the salaries of the staff responsible for data collection 
can be avoided. In addition, using an existing shared database, the new results could be obtained many 
years prior to those derived from a new clinical study. 
Clinical improvement 
An effect in terms of clearer evidence on the safety and effectiveness of diagnostic procedures and 
therapies, improving public healthcare [179–181], may be considered the final aim of data sharing. To 
avoid the loss of findings contained in the original dataset and not used for the primary publication(s) 
could play a role in this direction [160]. Institutions sharing their data could obtain a more 
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comprehensive picture about the benefits and risks of a medical decision. However, a real clinical 
improvement from data sharing is a hypothesis that still needs to be demonstrated. 
Potential drawbacks from data sharing  
The sharing of clinical databases raises several concerns (see Fig. 18). One of the reasons not to share 
data is that researchers are evaluated competitively, based on the quality and number of articles 
published during their career, so they may worry that other people will use their data and efforts to 
produce new publications. The potential for secondary analyses contradicting initially reported results 
may be deterrent. Authors may not be willing to share data that had cost them great effort and 
resources. However, reciprocally, they would also directly benefit from using someone else’s data. 
Bierer et al. [182] recently suggested formalizing ‘data authorship’ as an incentive to data 
sharing: “as a matter of fairness and as a matter of providing an incentive for data sharing, the persons 
who initially gathered the data should receive appropriate and standardized credit that can be used for 
academic advancement, for grant applications, and in broader situations”. 
Another concern is the potential for fault in the patient identity protection caused by the 
transmission of sensitive information. Data must be de-identified: de-identification, not simply 
anonymization, consists of transforming a dataset so that the back identification of individuals 
becomes impossible or extremely difficult. Different regulations may require different degrees of de-
identification, particularly in the absence of informed consents specifying the possibility of data 
sharing. De-identification can be achieved with different types of data transformations that must 
ensure patient privacy without affecting data quality [183]. However, the de-identified data do not 
eliminate all risks of re-identification. Moreover, the reduction of this risk to zero may destroy or 
significantly impair the utility of the data for subsequent analysis or verification. For these reasons, the 
stipulation of Data Use Agreements (DUAs) is considered a useful strategy and best practice for 
increasing the benefits and mitigating the risks of clinical data sharing [184]. Specifically, DUAs 
address important issues such as limitations on date usage, obligations to data safeguard, liability for 
harm arising from data usage and publication, and privacy rights that are associated with transfer of 
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confidential or protected data. In contrast, the U.S. Office for Human Research Protections stated that 
there is no need for separate consent from trial participants for the sharing of de-identified data [14]. 
A limitation to the adoption of data sharing can originate from technical barriers. The image 
conformity is influenced by vendor, modality, and acquisition parameters on the one hand; and by 
image post-processing manufacturer, reconstruction parameters, and software versions, on the other 
hand. An example is represented by the use in magnetic resonance of arbitrary units that clearly 
depend on the specific vendor and model, making a between-study comparison impossible. Away to 
overcome this limitation could be a drastic standardization, with manufacturers defining new shared 
standards. 
Another intrinsic barrier to data sharing could be the poor documentation of datasets, especially if 
not documented in English. Moreover, important information about methodology might not be 
contained immediately in the database or immediately retrievable. All these issues should be 
considered when planning for potential data sharing of research. 
To share or not to share? 
In conclusion, in a world that moves towards greater transparency and privacy protection, data sharing 
stands between these two competing interests. Not all concerns on data sharing have already been 
solved and many questions remain to be addressed: Who is the rightful owner of the data? What is the 
role of individual patients and advocacy groups in decision making about sharing of data and images? 
Should Ethics Committees change their approach for study approval? And how? What is the exact role 
of institutions, especially public ones, that funded the original study? Should patient advocacy groups 
and funding organizations be involved in decision making about data sharing? These issues must be 
regulated. 
Despite all the above-described issues relating to data sharing, a transition to a more open medical 
science has begun. If benefits of data sharing will be more and more perceived as prevailing over 
harms therefrom, this option will win. Researchers and institutions who first seize this opportunity will 
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be on the wave-front of an innovation likely to be in favor of patients and public health. Radiologists 
should be kept informed of this emerging issue. It is time to share! 
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Conclusions 
Imaging techniques play a main role in heart impairment diagnosis, etiological evaluation and 
treatment guidance; in particular CCT and CMR could provide additional information, especially in 
selected populations. This thesis reviewed potential future applications of imaging modalities for the 
study of CHD to improve the management of these patients. 
We contributed to show the possibility to obtain an impressively low ionizing dose reduction in 
CHD patients using a dedicate acquisition protocol on a standard 64-slice CT scanners. This really 
open a new windows of opportunities for using CCT in CHD, especially when CMR requires long 
sedation times and a high spatial resolution is considered useful for treatment planning [3]. 
On the other hand, CMR holds a pivotal role when functional and flow imaging is required. 
Firstly, we showed the role of MRS in evaluating the heart dysfunction on patients with HCM 
demonstrating that 1H-MRS may be used as an additional final phase of CMR protocol in the 
differential diagnosis between HMC and athlete's heart [4]. 
Secondly, we successfully validated the use of a BT technique for the segmentation of cine 
images in patients with FC, also observing a high intra- and inter-reader reproducibility for the 
assessment of ventricular SV and excellent agreement with aortic flow values used as a benchmark 
[5]. 
Third, we highlighted the possibility to use AAS for a non-invasive assessment of the aortic status 
in CVD patients [6]. 
Last but not least, we showed a good-to-excellent intra- and inter-reader reproducibility of blood 
flow measurements in patients with congenital heart disease using CMR and a semi-automated method 
of segmentation, with a limited impact of the operator’s training [7]. 
In conclusion CCT and CMR are two fundamental imaging techniques to evaluate patients with 
complex CHD. In the last years, we are moving from a competition to cooperation between CCT and 
CMR. Both imaging modalities have limitations and advantages. CCT has a very high spatial 
resolution and short acquisition time but implies ionizing radiation exposure, while CMR can evaluate 
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heart function vessel flow but require a long acquisition time and in same patients a long sedation 
time.  On the one side, we confirming the crucial role of CMR when function analysis is required but 
also showed the relevant possibilities of x-ray dose reduction in CCT, also using standard 64-slice 
scanners in the study of CHD patients. 
To definitively confirm our results, more large and multi-centric studies will be necessary. In this 
sense, a wide and coordinated cooperation between the different research centers in sharing their data 
could lead to new and interesting results [15].  
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High-quality low-dose cardiovascular
computed tomography (CCT) in pediatric
patients using a 64-slice scanner
Paola Maria Cannao`1, Francesco Secchi1, Marco Alı`2,
Ida Daniela D’Angelo3, Marco Scarabello3, Giovanni Di Leo1
and Francesco Sardanelli1,4
Abstract
Background: Cardiovascular computed tomography (CCT) technology is rapidly advancing allowing to perform good quality
examinations with a radiation dose as low as 1.2 mSv. However, latest generation scanners are not available in all centers.
Purpose: To estimate radiation dose and image quality in pediatric CCT using a standard 64-slice scanner.
Material and Methods: A total of 100 patients aged 6.9 5.4 years (mean standard deviation) who underwent a 64-slice
CCT scan using 80, 100, or 120 kVp, were retrospectively evaluated. Radiation effective dose was calculated on the basis of the
dose length product. Two independent readers assessed the image quality through signal-to-noise ratio (SNR), contrast-to-
noise ratio (CNR), and a qualitative score (3¼ very good, 2¼ good, 1¼ poor). Non-parametric tests were used.
Results: Fifty-five exams were not electrocardiographically (ECG) triggered, 20 had a prospective ECG triggering, and
25 had retrospective ECG triggering. The median effective dose was 1.3 mSv (interquartile range [IQR]¼ 0.8–2.7 mSv).
Median SNR was 30.6 (IQR¼ 23.4–33.6) at 120 kVp, 29.4 (IQR¼ 23.7–34.8) at 100 kVp, and 24.7 (IQR¼ 19.4–34.3) at
80 kVp. Median CNR was 21.0 (IQR¼ 14.8–24.4), 19.1 (IQR¼ 15.6–23.9), and 25.3 (IQR¼ 19.4–33.4), respectively.
Image quality was very good, good, and poor in 56, 39, and 5 patients, respectively. No significant differences were found
among voltage groups for SNR (P¼ 0.486), CNR (P¼ 0.336), and subjective image quality (P¼ 0.296). The inter-observer
reproducibility was almost perfect (k¼ 0.880).
Conclusion: High-quality pediatric CCT can be performed using a 64-slice scanner, with a radiation effective dose close
to 2 mSv in about 50% of the cases.
Keywords
Cardiovascular computed tomography, pediatric computed tomography, congenital heart diseases, radiation dose,
64-slice CT, image quality
Date received: 9 August 2017; accepted: 16 December 2017
Introduction
In the setting of congenital heart diseases (CHD), non-
invasive imaging techniques such as echocardiography,
cardiac magnetic resonance (CMR), and cardiovascular
computed tomography (CCT) play a crucial role in the
visualization of cardiovascular structures (1).
Echocardiography, being a ubiquitous and radiation-
free technique, represents the ﬁrst approach for patients
having or suspected to have CHD, but it has limitations
in deﬁning complex anatomy and reliable imaging of cor-
onary arteries, especially in older children who have a
poor acoustic window (1,2). CMR is considered the stan-
dard of reference for evaluation of ventricular volumes
and valve regurgitation but it still usually requires rela-
tively long imaging times and sedation or anesthesia in
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children aged< 8 years as well as in developmentally
delayed patients of all ages (3–5). CCT and invasive angi-
ography expose patients to ionization radiation, with
potentially more dangerous eﬀects in younger patients.
A previous study demonstrated that the radiation expos-
ure from diagnostic catheterization is substantially higher
than that from CCT in a pediatric population (1).
In recent years, CCT technology has advanced rap-
idly. It now provides improved spatial and temporal
resolution. Electrocardiographically (ECG)-gated cor-
onary CCT can now be routinely obtained in pediatric
patients with a radiation dose as low as 1.2 mSv using
dual-source CCT technology (6). Unfortunately, these
scanners are still available in few centers. On the other
hand, in order to reduce radiation exposure keeping a
good image quality, radiologists can apply tailored
protocols for CCT in pediatric patients even using 64-
slice scanners which are currently a kind of ‘‘standard’’
technology in radiology department.
Thus, our aim was to estimate radiation dose and
image quality in pediatric CCT using a 64-slice scanner.
Material and Methods
Patient population
Ethics Committee approval was obtained for this retro-
spective study. A total of 100 CCT exams of patients
aged < 18 years, performed between January 2010 and
December 2016 at our Institution, were retrospectively
evaluated. Disease distribution in the study population
is summarized in Table 1.
Image acquisition
At our department, all CCT studies, including those
performed in pediatric patients, are performed under
the direct responsibility of a cardiovascular radiologist.
To minimize technical errors, technicians are care-
fully instructed by the radiologist on a case-by-case
basis.
The CCT examinations were performed on a 64-slice
CT scanner (Somatom 64, Siemens Healthcare,
Erlangen, Germany). Patients aged less than 3 years
needed sedation. The administration of sedative drugs
happened shortly before the CT exam. The anesthesi-
ologist monitored the patient conditions during the
procedure and evaluated the patient status after the
exam. Midazolam was administered intravenously
(dose of 0.1–1.1mg/kg), orally (dose of 0.5–0.6mg/
kg), or intramuscularly (only in one patient, dose of
0.2mg/kg). The administration route of ketamine was
intravenous (dose of 0.9–1.9mg/kg) or intramuscular
(dose of 3.3–5.4mg/kg). Propofol was intravenously
administered at a dose of 0.5–2.4mg/kg. The variability
of the administered doses depended on age, comorbid-
ities, and known drug response of the patient.
A tailored CCT protocol was performed according
to the clinical question. In the majority of patients
(n=80), the unenhanced scan was waived to reduce
the radiation dose. A bolus of contrast material of
5–60mL (Iopamiro 370, Bracco Imaging S.p.A.,
Milan, Italy) followed by saline solution in the range
of 10–60mL was intravenously injected by means of a
power injector (Empower CTA, EZEM, Westbury,
NY, USA) at a ﬂow rate of 1.5–3.0mL/s according to
the patient’s characteristics and the clinical question.
When investigating cardiac anatomy or coronary
arteries, a test-bolus technique was used. A time-
attenuation curve was obtained by measuring the
enhancement within a region of interest (ROI) pos-
itioned in a ascending aorta or in the pulmonary
trunk according to the clinical question. The contrast
arrival time was determined from the time to peak
enhancement and was used to estimate the scan delay
for a full-bolus diagnostic CCT (7).
To acquire an angiogram, we used the bolus tracking
technique, based on real-time monitoring of the main
bolus during injection to acquire a series of dynamic
low-dose monitoring scans at the level of the vessel of
interest. The trigger threshold inside the ROI was set at
100 HU above the baseline. The delay between each
monitoring scan acquisition was 1.25 s. As soon as the
threshold was reached, the table moved to the cranial
start position. During this interval the contrast material
concentration increased to the desired level of enhance-
ment (8).
Table 1. Disease distribution in the study population.
Disease Patients (n)
Known or suspected coronary abnormality
Anomalous origins 18
Coronary fistula 6
Complex congenital heart disease
Tetralogy of Fallot 20
Transposition of great arteries 10
Truncus arteriosus 4
Aortic disease
Stent evaluation in coarctation 18
Interrupted or hypoplastic arch 2
Pulmonary artery disease
Pulmonary artery stenosis with stent 11
Subvalvar pulmonary stenosis 3
Major aorto-pulmonary collateral arteries
in pulmonary atresia
3
Total 100
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The CCT were either performed without ECG syn-
chronization or using a prospective or a retrospective
ECG-gating depending on the patient’s heart rate and
rhythm and on whether an evaluation of myocardial
function was indicated (9). Tube voltage was set at
80, 100, or 120 kVp; tube current was set between 36
and 100mAs, according to body size. The gantry
rotation time was 0.33 s; pitch was 0.2–0.5. The recon-
struction parameters were set as follows: section thick-
ness¼ 0.75mm; reconstruction interval¼ 0.45mm;
matrix size¼ 512 512; and ﬁeld of view¼ 250mm.
Two-dimensional images were then transferred to a
workstation (Multimodality, Siemens Healthcare,
Erlangen, Germany) for obtaining oﬀ-line three-dimen-
sional reconstructions.
Radiation exposure
The dose length product (DLP) was retrieved for each
patient. The eﬀective dose (ED) in mSv was calculated as
DLP*k. The conversion factor for the chest, k (measured
in mSv/mGy/cm), varied with age and was estimated
from the International Commission on Radiological
Protection publication 103 recommendation (10,11).
The ED was then evaluated for four patient age
groups (newborns< 1 year, 1–5 years, 6–10 years, and
11–17 years), and according the tube voltage used (kVp).
Image quality assessment
Signal-to-noise ratio (SNR) and contrast-to-noise ratio
(CNR) were calculated for each scan using the follow-
ing formulas: SNR¼HUleft ventricle/SDair; CNR¼
[(HUleft ventricleHUmyocardium)/SDair].
Assessment of subjective image quality was independ-
ently performed by two observers with eight and four
years of experience in cardiovascular imaging. Image ana-
lysis was performed individually and image series were
evaluated in a random order. Scans were classiﬁed using
a three-level scale (3¼ very good; 2¼ good; and 1¼ poor).
The two readers agreed on the following criteria:
– images were judged as very good when all struc-
tures were well visualized without artifacts;
– images were judged as good when almost all struc-
tures were well visualized even though some arti-
facts were visible;
– images were judged as poor when the vascular
structures were not well visualized due to the pres-
ence of large artifacts.
Statistical analysis
Statistical analyses were performed using statistical
software (SPSS for Windows v.21.0, SPSS Inc.,
Chicago, IL). Parametric variables were expressed as
mean and standard deviation (SD), whereas non-para-
metric variables were expressed as median and inter-
quartile ranges (IQR). Overall comparisons among
groups were performed using the Kruskal–Wallis test;
the paired post-hoc analysis of the two groups was per-
formed using the Mann–Whitney U test. A P
value< 0.05 was considered as signiﬁcant.
The inter-observer agreement about the image
quality qualitative assessment was evaluated using the
Cohen k, with the following interpretation of the
k values: <0.20¼ slight agreement; 0.210.40¼
fair agreement; 0.410.60¼moderate agreement;
0.610.80¼ substantial agreement; 0.811.0¼ almost
perfect agreement (12).
Results
Study population
The study population included 100 patients (63 boys,
37 girls), aged 6.9 5.4 years (mean SD). The most
common primary indications for CCT were complex
CHD (n¼ 34), pulmonary arteries abnormalities
(n¼ 22), and coronary arteries abnormalities (n¼ 24).
A detailed list of indications is provided in Table 1.
Radiation exposure
The overall median ED was 1.3 mSv
(IQR¼ 0.8–2.7mSv). Concerning the subgroup ana-
lysis, the median ED was 1.0 mSv (IQR¼
0.6–1.4mSv) for exams performed at 80 kVp, 1.9 mSv
(1.1–3.5mSv) for exams performed at 100 kVp, and
5.1mSv (3.6–6.0) for exams performed at 120 kVp
(P< 0.001). Post-hoc analysis is reported in Table 2.
Examples of CCT images obtained at 80, 100, and
120 kVp are shown in Figs. 1–4.
Comparing not ECG-triggered, prospectively ECG-
triggered, and retrospectively ECG-gated examina-
tions, median ED were 1.1 (0.6–3.1) mSv, 1.3 (1.0–
1.8) mSv and 1.7 (1.3–3.5) mSv, respectively
(P< 0.036). Post-hoc analysis is reported in Table 3.
Finally, a signiﬁcantly diﬀerent ED was also found
among the age groups (P< 0.001). Post-hoc analysis is
reported in Table 4.
Image quality
Overall, the image quality was judged by the ﬁrst reader
(most expert) to be very good in 56 examinations (56%),
good in 39 (39%), and poor in ﬁve (5%). The agreement
between the two readers was almost perfect (k¼ 0.880).
A non-signiﬁcant diﬀerence in terms of subjective image
quality was found, both overall and among the three
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groups of kilovoltage used (p0.296). In terms of object-
ive image quality, the SNR was 30.6 (IQR¼ 23.4–33.6),
29.4 (IQR¼ 23.7–34.8), and 24.7 (IQR¼ 19.4–34.3), at
120, 100, and 80 kVp, respectively (P¼ 0.486). The
median CNR was 21.0 (IQR¼ 14.8–24.4), 19.1
(IQR¼ 15.6–23.9), and 25.3 (IQR¼ 19.4–33.4), at 120,
100 and 80 kVp, respectively (P¼ 0.336).
There were not signiﬁcant diﬀerences according to
SNR and CNR in the diﬀerent age-group patients. In
particular, the median of SNR was 30.5 (IQR¼ 22.5–
36.6), 25.2 (IQR¼ 15.1–30.9), 24.9 (IQR¼ 20.6–41.1),
and 24.4 (IQR¼ 20.7–30.9) in newborn, 1–5, 6–10, and
11–17 age groups, respectively (P¼ 0.227). The
Fig. 2. Cardiac CT of a two-year-old with tetralogy of Fallot with sub-pulmonary stenosis surgically treated. Retrospectively ECG-
triggered scan for the definition of coronary and intra-cardiac anatomy was performed before a new surgical procedure. Effective dose was
1.1 mSv using 80 kVp. Anomalous left coronary origin from right sinus passed anterior of right ventricle outflow tract is shown (arrows).
Fig. 1. Cardiac CT of a one-month-old newborn with a double outlet right ventricle. Prospectively ECG-triggered scan for the
definition of coronary and intra-cardiac anatomy was performed. Effective dose was 0.3 mSv using 80 kVp. On the left panel, the
abnormal origin of left main coronary artery is shown. On the right panel, a 3D reconstruction of great vessels anatomy is shown
(double outlet right ventricle).
Table 2. Effective dose by tube voltage.
Effective dose (mSv) P value
80 kVp (n¼ 49) 1.0 (0.6–1.4) <0.001
100 kVp (n¼ 35) 1.9 (1.1–3.5)
120 kVp (n¼ 16) 5.1 (3.6–6.0)
80 kVp vs. 100 kVp <0.001
80 kVp vs. 120 kVp <0.001
100 kVp vs. 120 kVp 0.003
Data of effective dose are medians and interquartile ranges in parenth-
eses. The Kruskal–Wallis test was used for the overall comparison while
the Mann–Whitney U test was used for the post-hoc analysis.
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mean CNR was 19.4 (IQR¼ 24.8–23.5), 20.1
(IQR¼ 10.8–20.9), 23.3 (IQR¼ 13.7–41.1), and 18.4
(IQR¼ 10.7–20.8) in newborn, 1–5, 6–10, and 11–17
age groups, respectively (P¼ 0.101).
Discussion
In this study, we assessed radiation exposure and image
quality of 64-slice CCT in a consecutive series of 100
pediatric patients. Using a tailored dose-saving proto-
col with careful radiologist’s supervision of technical
performance, the overall median ED was limited to
1.3 mSv, including both prospective and retrospective
ECG-triggering. Image quality was very good or good
in 95/100 patients. Of note, the inter-observer reprodu-
cibility for the qualitative evaluation of image quality
was almost perfect.
Our results can be favorably compared with those
obtained by other authors. Tsai et al. (13) described an
average ED for pediatric CCT of 2.6, 2.1, and 2.0 mSv
for 16-, 64-, and 128-slice CCT, respectively, using a
prospectively triggered acquisition. Conversely, the
dose estimated in other studies was 6.8 mSv (10) or
12 mSv (14) using a 64-slice scan with retrospective
ECG-gating.
In recent years, the advent of new generation scan-
ners implied a drastic decrease in radiation exposure,
also in the pediatric setting. The study published by
Han et al. (3) analyzed a cohort of 70 pediatric patients
and found an average ED of 1.7 mSv for retrospectively
ECG-gated CCT and 0.9 mSv for prospectively
ECG-triggered CCT. These ﬁndings highlighted the
increasing role of CCT in the pediatric setting, in par-
ticular as a tool that allows to avoid diagnostic
Fig. 3. Cardiac CT of an eight-year-old girl with tetralogy of Fallot treated with a pulmonary conduit. An angiographic not ECG-
triggered scan was performed for evaluating pulmonary stents. Effective dose was 1.1 mSv using 100 kVp. On the left panel, a
thrombosis of the pulmonary conduit due to endocarditis is shown. On the right panel, a 3D reconstruction of pulmonary conduit and
pulmonary arteries is shown.
Fig. 4. Cardiac CT of a 14-year-old girl with tetralogy of Fallot and pulmonary stenosis. An angiographic not ECG-triggered scan was
performed to evaluate pulmonary stents. The effective dose was 2 mSv using 120 kVp. On the left panel, a maximum intensity projection
of both stents is shown. On the right panel, a 3D reconstruction of pulmonary arteries is shown.
Cannao` et al. 1251
angiography or to limit or overcoming the diagnostic
phase of interventional angiography. In fact, Lee et al.
(15) demonstrated that in a population of 14 neonates
with complex CHD referred for diagnostic cardiac
catheterization after initial assessment with echocardi-
ography and CCT, none of them required additional
diagnostic imaging. This is a goal in terms of reduction
of radiation dose considering the 13.4 mSv that are
required on average for a diagnostic catheterization (1).
Our study showed that using a ‘‘standard’’ 64-slice
scanner high-quality images can be obtained with a
relatively low radiation exposure, fulﬁlling the diagnos-
tic aim of the examination. This is an important clinical
ﬁnding considering that 64-slice CT units remain the
most available type of CT scanner in the majority of
radiology departments (16–18).
Rapid technological development resulted in accel-
erated technical and functional obsolescence of imaging
equipments, creating a need for renewal (19). A dra-
matic change in this scenario, in the current era of
‘‘spending review’’ by public health systems, is not
expected.
Thus, implementing CCT dose-saving protocols on
64-slice scanners should be considered as mandatory,
especially in the pediatric population.
Importantly, since no diﬀerences were found in
terms of SNR and CNR among the diﬀerent tube volt-
ages used (120, 100, or 80 kVp), our experience suggests
that an 80-kVp protocol could be adequate to image
most pediatric patients.
The results in terms of CNR deserve a particular
comment. Although the diﬀerence among the groups
was not statistically signiﬁcant, probably due to the
small sample size combined with data distribution, a
higher CNR at the lowest tube voltage (80 kVp) was
observed (median 25.3 vs. 21.0 for 120 kVp and 19.1 for
100 kVp). This possible increase in CNR could be
explained with the higher contrast eﬀect of the iodi-
nated contrast material at lower voltages (20).
Notably, the agreement in image quality evaluation
between the two observers was not conditioned by the
voltage used.
The approach here presented (tailored protocols
under strict control by the cardiovascular radiologist)
could be generally applied also to late-generation CT
scanners, allowing for a lower and lower dose exposure,
in particular in the pediatric population. All these
results are inverting the traditional way of thinking
about the comparison between CCT and CMR in pedi-
atric patients. Most probably, CMR will no longer be
an easy winner because of being radiation-free. As
radiation doses go lower and lower, towards 0.1–0.2
mSv, examination time and need for sedation, spatial
resolution as well as image quality related to movement
artifacts can play in favor of CCT. In addition, when
considering the probability of multiple CMR examina-
tions, the potential gadolinium accumulation in the
brain should be taken into account (21).
The results of this study should be interpreted in
view of its limitations. First, we should consider the
retrospective study design. However, we included the
whole consecutive series of pediatric patients who
underwent CCT at our institution in the study period
(starting from the installation of the 64-slice unit).
Thus, the study reports what happened in real clinical
life. Second, the number of patients is rather small
Table 4. Effective dose by patient age.
Effective dose (mSv) P value
A
Newborn (n¼ 15) 1.0 (0.5–1.3) <0.001
B
1–5 years (n¼ 25) 0.8 (0.6–1.2)
C
6–10 years (n¼ 27) 1.6 (1.1–2.4)
D
11–17 years (n¼ 33) 3.4 (1.5–5.1)
A vs. B 0.639
A vs. C 0.038
A vs. D 0.020
B vs. C 0.003
B vs. D <0.001
C vs. D 0.081
Data of effective dose are medians and interquartile ranges in parenth-
eses. The Kruskal–Wallis test was used for the overall comparison while
the Mann–Whitney U test was used for the post-hoc analysis.
Table 3. Effective dose for not ECG-synchronized examin-
ations, prospectively ECG-triggered examinations, and retro-
spectively ECG-gated examinations.
Effective dose
(mSv) P value
A
Not ECG-synchronized (n¼ 55) 1.1 (0.6–3.1) 0.036
B
Prospective ECG-triggering (n¼ 25) 1.3 (1.0–1.8)
C
Retrospective ECG-gating (n¼ 20) 1.7 (1.3–3.5)
A vs. B 0.347
A vs. C 0.022
B vs. C 0.027
Data of effective dose are medians and interquartile ranges in parenth-
eses. The Kruskal–Wallis test was used for the overall comparison while
the Mann–Whitney U test was used for the post-hoc analysis.
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as CMR is still preferred in the evaluation of CHD
patients.
In conclusion, CCT is a valuable imaging modality
when evaluating pediatric patients with a large spec-
trum of known or suspected cardiovascular abnormal-
ities. Using dose-saving techniques, CCT protocols
tailored to the pediatric population allowed for per-
forming high-quality CCT in children with a relatively
low radiation exposure also using a ‘‘standard’’
64-slices scanner.
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volume index 95 (85–102) ml/m2, end systolic volume 
index 30 (28–32) ml/m2 and ejection fraction 68% (65–
69%); in HCM patients, 81 (76–111) g/m2 (P = 0.052), 18 
(15–21) mm (P = 0.003), 73 (58–76) ml/m2 (P = 0.029), 
20 (16–34) ml/m2 (P = 0.274) and 68% (55–73%) 
(P = 1.000), respectively. At 1H-MRS, total lipids were 35 
(0–183) arbitrary units (au) for CA and 763 (155–1994) 
au for HCM patients (P = 0.046). At 31P-MRS, PCr/γATP 
was 5 (4–6) au for CA and 4 (2–5) au for HCM patients 
(P = 0.230). Examination time was 20 min for imaging 
only, 5 min for 1H-MRS and 15 min for 31P-MRS.
Conclusions We observed a significant increase of myocar-
dial lipids, but a preserved PCr/γATP ratio in the metabo-
lism of HCM patients compared with competitive CAs.
Keywords Myocardial metabolism · Athlete’s heart · 
Hypertrophic cardiomyopathy · Magnetic resonance 
spectroscopy
Abstract 
Purpose The clinical differentiation between athlete’s heart 
and mild forms of non-obstructive hypertrophic cardiomy-
opathy (HCM) is crucial. We hypothesized that differences 
do exist between the myocardial metabolism of patients 
with non-obstructive HCM and competitive athletes (CAs). 
Our aim was to evaluate myocardial metabolism with 31P-
MRS and 1H-MRS in HCM patients and CAs.
Materials and methods After Ethics Committee approval, 
15 CAs and 7 HCM patients were prospectively enrolled. 
They underwent a 1.5-T cardiac MR including electrocar-
diographically triggered cine images, single-voxel 1H-MRS 
and multivoxel 31P-MRS. 1H-MRS was performed after 
imaging using standard coil with the patient in the supine 
position; thereafter, 31P-MRS was performed using a dedi-
cated coil, in the prone position. Data were reported as 
median and interquartile range. Mann–Whitney U test was 
used.
Results In CAs, left ventricular mass index was 72 (66–
83) g/m2, septal thickness 10 (10–11) mm, end diastolic 
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Introduction
Hypertrophic cardiomyopathy (HCM) is the most common 
genetic cardiac disease with a prevalence of 0.2% [1]. In 
half the cases, the transmission is autosomal dominant with 
incomplete penetration [2, 3]. The most common mutations 
involve sarcomere proteins, particularly C-binding myosin 
protein, the heavy beta-myosin chain and troponin T [4]. 
This disease is characterized by hypertrophy of the left 
ventricle, mostly asymmetric, and is usually located at the 
basal portion of the septum [5]. Diastolic dysfunction and 
outflow tract obstruction of the left ventricle may be pre-
sent, causing major clinical manifestations such as angina, 
dyspnea, dizziness and syncope [6, 7]. In approximately 
30% of HCM patients, ventricular hypertrophy is moder-
ate without obstruction of the outflow tract of the left ven-
tricle, both at rest and under stress and, therefore, the dis-
ease is silent [8]. In this form, the clinical onset can be the 
sudden death induced by rhythm disorders. Indeed, HCM 
was reported to be responsible for 35% of sudden deaths in 
young athletes [9, 10].
Competitive athletes with intense and regular training 
exercise usually develop cardiovascular changes leading 
to a reversible paraphysiological myocardial hypertrophy 
known as athlete’s heart. This condition shows symmetrical 
and homogeneous hypertrophy, with variations in the wall 
thickness smaller than 2 mm [11]. In 2% of such athletes, 
the left ventricle wall thickness reaches 13–15 mm [12], 
with a distribution partially overlapped with those meas-
ured in mild forms of HCM, especially mutations of tro-
ponin T [13]. Thus, it is clinically relevant to differentiate 
between athlete’s heart and mild forms of non-obstructive 
HCM.
Magnetic resonance spectroscopy (MRS) is a non-inva-
sive diagnostic technique allowing for the in vivo evalua-
tion of myocardial metabolism [14, 15] by measuring the 
signal intensity of 31P or 1H. In particular, with 31P-MRS, 
the ratio between phosphocreatine (PCr) and γ-adenosine 
triphosphate (γATP) may be measured, representing an 
index of the myocardial energy reserve [3, 16–18]. On the 
other side, 1H-MRS allows for estimating the total creatine 
(Cr) (sum of PCr and Cr) [19, 20], which is associated with 
myocardial contractility [21, 22]; moreover, myocardial 
lipids may be measured using 1H-MRS [23, 24].
The aim of this study was to evaluate the left ventri-
cle function in patients affected by HCM compared with 
that of competitive athletes and to assess the myocar-
dial metabolism using 31P-MRS and 1H-MRS in the two 
populations.
Materials and methods
Study design and inclusion criteria
This prospective cross-sectional study was approved by 
the local ethics committee and each subject signed a writ-
ten informed consent. Inclusion criteria were as follows: 
patients aged 18 years or more with a known diagnosis of 
non-obstructive HCM, defined as asymmetric hypertrophy 
of the left ventricle, with the typical patchy pattern with 
local distribution of late gadolinium enhancement [12, 
13]; competitive athletes aged 18 years or more, in good 
health, without any reported cardiovascular symptoms and 
with intense exercise training in the month prior to the 
enrollment, quantified in at least 10 h per week. Exclu-
sion criteria were contraindications to magnetic resonance 
such as pacemakers/defibrillators, intracranial ferromag-
netic vascular clips, intraocular metal fragments, or severe 
claustrophobia.
Magnetic resonance imaging
Each enrolled subject underwent a 1.5-T magnetic reso-
nance (Magnetom Sonata Maestro Class, Siemens Medical 
Solutions, Erlangen, Germany), including a morphologic 
and functional imaging study, with the patient in the supine 
position.
The imaging protocol included balanced steady-state 
free precession sequences (true fast imaging with steady-
state free precession, true-FISP) using a four-channel sur-
face phased-array coil in the short axis plane covering the 
entire heart. Technical parameters were as follows: electro-
cardiographic (ECG)-gating; TR/TE 4.0/1.5 ms; flip angle 
80°; slice thickness 8 mm; temporal resolution 45 ms; field 
of view 300 × 400 mm2; matrix 119 × 256; 30 phases in 
breath-hold at end expiration. The kinetic study was pro-
cessed by manual segmentation using Syngo Argus soft-
ware (version VE32B, Siemens Medical Solutions, Erlan-
gen, Germany) by a radiologist with a 7-year experience in 
cardiac MR imaging.
For each subject, the following imaging-derived vari-
ables were measured for the left ventricle: end diastolic 
thickness of the septum; end diastolic thickness of the pos-
terior wall; mass index (i.e., normalized to the body sur-
face area); end diastolic volume index (EDVI); end systolic 
volume index (ESVI); ejection fraction (EF); stroke vol-
ume; and ventricular end diastolic diameter. We have also 
calculated an asymmetry index, defined as the left ventricle 
septal-to-posterior wall thickness ratio.
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1H‑MRS
After morphologic and functional imaging, hydrogen-
containing metabolites were measured in a single voxel of 
10 × 20 × 40 mm3 within the interventricular septum. A 
point-resolved spectroscopy sequence (ECG synchroniza-
tion; diaphragm navigator; acquisition in the end systolic 
phase; TR/TE 2000/90 ms; flip angle 90°; number of exci-
tations 150; suppression of the water signal; supine posi-
tion) was performed using the same four-channel surface 
phased-array coil used for imaging.
A physicist with 8-year experience in MRS processed 
all spectra using the jMRUI software that implements 
the AMARES (Advanced Method for Accurate, Robust, 
and Efficient Spectral) algorithm quantitation [25]. Pre-
processing steps were: apodization (3 Hz), manual or 
automatic phase correction and subtraction of the base-
line with the polynomial method. The area of the two 
peaks attributable to Cr (3.0 and 3.9 ppm) and the that 
of the two peaks attributable to lipids (0.9 and 1.3 ppm) 
were measured and corrected for decay using T2 values 
published in the literature [26, 27]. The total Cr as well 
as the total fat was obtained summing up the two rele-
vant components. Data were presented as arbitrary units 
(au).
31P‑MRS
Myocardial phosphates were measured through 31P-MRS 
using a dedicated surface coil tuned for 31P and with the 
patient in the prone position. On the basis of repeated 
low-resolution scout images, we placed a grid of volumes 
of interest so as to guarantee at least one voxel within the 
anterior ventricular junction, trying to minimize contami-
nation by ventricular blood. Then, we acquired a multi-
voxel chemical shift imaging sequence for a single slice 
(nuclear Overhauser enhancement technique; ECG syn-
chronization for acquisition in the end diastolic phase; TR/
TE = 800/2.3 ms; flip angle 90°; grid size 8 × 8×60 mm3; 
field of view 300 × 300 mm2; free breathing).
Pre-processing included: exponential filter, zero-filling 
from 1024 to 2048 points, Fourier transform, frequency 
and phase correction and subtraction of the baseline with 
the polynomial method. All spectra were processed by the 
same physicist using Spectroscopy-Argus software (ver-
sion VE32B, Siemens Medical Solutions, Erlangen, Ger-
many). The area under the peak of the following metabo-
lites was measured: PCr at 0 ppm; phosphomonoester 
(PME) at 5.4 and 6.3 ppm; inorganic phosphate (Pi) at 3.7 
and 5.2 ppm; phosphodiester (PDE) at 2–3 ppm; γATP at 
16.3 ppm. Moreover, we identified the 2,3-diphosphoglyc-
erate (DPG), contained in red blood cells, at about 5.5 ppm, 
used to correct data for the blood contamination. To this 
end, we subtracted 11% and 19% of 2,3-DPG from γATP 
and PDE, respectively, as already described [28]. The sig-
nals of γATP, PCr, PDE and Pi were corrected for decay 
using T2 values published in the literature [29]. Finally, 
we calculated the following ratios: PCr/γATP; PDE/γATP; 
2,3-DPG/γATP; PME/PCr; and Pi/PCr [29]. Data were 
reported in au.
Statistical analysis
Statistical analysis was performed using non-parametric 
methods, more appropriate for small samples [30]. Differ-
ences between the two groups of subjects were evaluated 
with the Mann–Whitney U test or the χ2 test, while bivari-
ate correlations were estimated using the Spearman corre-
lation coefficient.
Statistical analysis was performed using SPSS v.17.0 
(IBM SPSS Inc., Chicago, IL, USA). Continuous variables 
were reported as median and interquartile range (IQR) and 
P values <0.050 were considered statistically significant.
Results
Population characteristics
A total of 22 subjects were enrolled, whose characteris-
tics are reported in Table 1. There were 7 HCM patients 
and 15 competitive athletes. In particular, athletes were 
nine bikers and six professional volleyball players with a 
median weekly training of 10 h (IQR 10–14 h). The median 
body mass index (BMI) in HCM patients (25 kg/m2; IQR 
24–29 kg/m2) was higher (P = 0.041) than that of athletes 
(22 kg/m2; IQR 20–23 kg/m2). Moreover, HCM patients 
were older than athletes [56 years (IQR 45–62 years) ver-
sus 41 years (IQR 35–42 years), P = 0.009].
The mean total duration of MR examinations was 
approximately 40 min: 20 min for imaging, 5 min for 
1H-MRS, and 15 min for 31P-MRS. Processing required 
5 min.
Table 1  Distribution of demographics of the study population
HCM hypertrophic cardiomyopathy
* χ2 test. $ Mann–Whitney U test
a Data are presented as median and interquartile range in brackets
Competitive athletes HCM patients P
N (male/female) 15 (11/4) 7 (6/1) 0.297*
Age (years)a 41 (35–42) 56 (45–62) 0.009$
Body mass index  
(kg/m2)a
22 (20–23) 25 (24–29) 0.041$
Weekly training (h)a 10 (10–14) – –
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Morphology and function
The distribution and comparison of morphologic and func-
tional characteristics of the left ventricle in the two groups 
are shown in Table 2. Of note, HCM patients showed a 
lower stroke volume than athletes [74 ml (IQR 72–86 ml) 
versus 111 ml (IQR 102–142 ml), P = 0.008], but an 
equivalent ejection fraction [68% (IQR 55–73%) versus 
68% (IQR 65–69%), P = 1.000]. Moreover, HCM patients 
showed a much larger asymmetry index than athletes [2.0 
(IQR 1.6–2.3) versus 1.1 (IQR 1.0–1.3), P = 0.022]. Fig-
ure 1 shows examples of an athlete and a HCM patient. 
1H‑MRS
The 1H-MRS spectrum of one athlete had too low signal-
to-noise ratio that prevented its analysis. The distribution of 
the variables measured using 1H-MRS in the two groups and 
their comparison are shown in Table 3. Importantly, the lipid 
resonance at 1.3 ppm greatly differed between patients and 
athletes with a much higher content in HCM patients [554 au 
(IQR 121–2377 au)] than in competitive athletes [0 au (IQR 
0–67 au)] (P = 0.020); similarly for the total lipid content 
[763 au (IQR 155–1994 au) versus 35 au (IQR 0–183 au), 
P = 0.046]. Figure 2 shows an example of a hydrogen spec-
trum of a competitive athlete and a HCM patient. 
Table 2  Functional and 
morphologic variables of the 
left ventricle in the two groups
Data are presented as medians and interquartile range in brackets
HCM hypertrophic cardiomyopathy
* Mann–Whitney U test
Competitive athletes HCM patients P*
End diastolic volume index (ml/m2) 95 (85–102) 73 (58–76) 0.029
End systolic volume index (ml/m2) 30 (28–32) 20 (16–34) 0.274
Stroke volume (ml) 111 (102–142) 74 (72–86) 0.008
Ejection fraction (%) 68 (65–69) 68 (55–73) 1.000
Left ventricle mass index (g/m2) 72 (66–83) 81 (76–111) 0.052
Interventricular septal thickness (mm) 10 (10–11) 18 (15–21) 0.003
Posterior wall thickness (mm) 8 (7–10) 9 (7–11) 0.520
Asymmetry index 1.1 (1.0–1.3) 2.0 (1.6–2.3) 0.022
Left ventricle diameter (mm) 55 (52–56) 50 (48–52) 0.258
Fig. 1  Cardiac magnetic 
resonance images in diastolic 
phase of a mid-ventricular short 
axis section of an athlete (a) 
and a hypertrophic cardiomyo-
pathy patient (b). Note that the 
septal thickness of the patient is 
greater than that of the athlete
Table 3  Distribution and comparison of metabolites measured by 
1H-MRS in the two groups of subjects
HCM hypertrophic cardiomyopathy
* Mann–Whitney U test
a Data are presented as median and interquartile range in brackets 
and measured in arbitrary units
Competitive athletesa HCM patientsa P*
Creatine at 3.0 ppm 19 (6–33) 0 (0–32) 0.799
Creatine at 3.9 ppm 55 (26–71) 43 (12–93) 0.799
Total creatine 58 (42–110) 95 (24–185) 0.447
Lipids at 0.9 ppm 0 (0–60) 125 (0–275) 0.397
Lipids at 1.3 ppm 0 (0–67) 554 (121–2377) 0.020
Total lipids 35 (0–183) 763 (155–1994) 0.046
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31P‑MRS
Data from 31P-MRS were not available for two HCM 
patients due to examination interruption for claustropho-
bia (in one case) or to low signal-to-noise ratio probably 
related to patient movement (in the other case). The distri-
bution of the phosphate content in the two groups and their 
comparison are shown in Table 4. No differences between 
patients and athletes were noted in terms of PCr [22 au 
(IQR 9–25 au) versus 29 au (IQR 20–36 au), P = 0.168] 
and PCr/γATP [4 (IQR 2–5) versus 5 (IQR 4–6), 
P = 0.230]. Vice versa, a significant difference between 
patients and athletes was noted in terms of 2,3-DPG/γATP 
[0.2 (IQR 0.0–0.2) versus 0.5 (IQR 0.3–0.7), P = 0.008]. 
Fig. 2  Example of a hydrogen spectrum obtained in an athlete (a) and a hypertrophic cardiomyopathy patient (b). Note that the lipid peak is 
higher in the patient than in the athlete
Author's personal copy
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Figure 3 shows examples of 31P-MRS spectra of an athlete 
and a HCM patient. 
Bivariate correlation analysis
As reported in Tables 2, 3, and 4, the variables found to be 
significantly different in the two groups at bivariate analy-
sis were: age, BMI, stroke volume, EDVI, left ventricular 
mass index, interventricular septal thickness, asymmetry 
index, 2,3-DPG/γATP, lipids at 1.3 ppm and total lipids. 
Body mass index did not correlate with either lipid reso-
nances at 1.3 ppm (r = 0.318, P = 0.184) or total lipids 
(r = 0.421, P = 0.065).
Discussion
The main finding of this study is that 1H-MRS, performed 
in only 5 min after a standard cardiac MR examination, 
enabled detecting increased intramyocardial lipids in HCM 
patients in comparison with competitive athletes. These 
results are somewhat new and may open a perspective for 
future studies aimed at using 1H-MRS in the differential 
diagnosis between HCM and athlete’s heart. This study 
adds a new potential biomarker to the well-known differ-
ences in the left ventricle remodeling and function.
Causes for the accumulation of intramyocardial lipids in 
early stages of HCM need to be clarified and a thorough 
explanation is currently not available. Nonetheless, we can 
hypothesize that the combined effect of lipid deposition 
superimposed on fibrosis might help to identify individu-
als at higher risk of arrhythmias. One study showed that 
increased myocardial triglycerides in healthy subject are 
positively correlated to the cardiac volumes [31]. However, 
to our knowledge, pathologic studies demonstrated only 
fibrosis infiltration and not fat infiltration in HCM patients 
[32, 33]. Only patients affected with generalized lipodys-
trophy were proven to present with left ventricle hyper-
trophy associated with myocardial steatosis [34]. Other 
authors showed that overweight and obese women show 
increase of myocardial triglyceride associated with reduc-
tion in cardiopulmonary fitness [35]. Similar results were 
obtained in patients affected by type-2 diabetes [36, 37].
In our study, the phosphate metabolism of athlete’s heart 
was preserved and the PCr/γATP ratio was in the range of 
normal values [14], as expected [38]. In advanced HCM, 
this ratio is known to be reduced resulting in heart fail-
ure [7]. The 31P-MRS analysis also showed a significant 
difference between the two groups in terms of 2,3-DPG/
γATP, with a lower value in HCM patients than in athletes. 
Table 4  Distribution and comparison of phosphate content between 
the two groups of subjects
HCM hypertrophic cardiomyopathy, PCr phopshocreatine, γATP 
γ-adenosine triphosphate, PDE phosphodiester, PME phosphomo-
noester, Pi inorganic phosphate, 2,3-DPG 2,3-diphosphoglycerate
* Mann–Whitney U test
a Data are presented as median and interquartile range in brackets. 
The content of metabolites is presented in arbitrary units
Competitive athletesa HCM patientsa P*
PCr 29 (20–36) 22 (9–25) 0.168
γATP 6 (4–6) 5 (5–6) 0.735
PCr/γATP 5 (4–6) 4 (2–5) 0.230
PDE 7 (4–9) 5 (5–10) 0.612
PME 0.2 (0.0–0.3) 0.4 (0.4–1.8) 0.081
Pi 0.4 (0.0–1.3) 0.4 (0.4–1.7) 0.395
Pi/PCr 0.03 (0.00–004) 0.02 (0.01–0.22) 0.445
PME/PCr 0.01 (0.00–0.01) 0.02 (0.01–0.20) 0.142
PDE/γATP 1.1 (0.6–1.8) 1.1 (0.8–1.7) 0.866
2,3-DPG/γATP 0.5 (0.3–0.7) 0.2 (0.0–0.2) 0.008
Fig. 3  Examples of 31P-MRS 
spectra in an athlete (a) and 
a hypertrophic cardiomyopathy 
patient (b). PCr phosphocre-
atine, ATP adenosine triphos-
phate, PDE phosphodiester, 
Pi inorganic phosphate, PME 
phosphomonoester. Note 
that PCr/gamma-ATP ratio is 
reduced in the HCM patient
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Considering that γATP alone was not significantly different 
in the two groups, an increase of 2,3-DPG may explain the 
difference in 2,3-DPG/γATP. The reason for this phenom-
enon could lay in the contamination of the blood pool in 
the voxel in subjects with a small septum. The variation of 
PME/PCr and Pi/PCr between the two groups was not sig-
nificant, in line with the literature [29]. Notably, a not sig-
nificant difference was observed in terms of PCr/γATP, as 
an indicator of energy metabolism. This may be due to the 
normal value of septal thickness in our athlete’s population, 
without any overt athlete’s heart condition.
As a potential clinical application of our study, we high-
light that while 1H-MRS required only five additional min-
utes, the 31P-MRS protocol required the extraction of the 
patient from the magnet, the change of the coil and a new 
patient positioning in an uncomfortable prone position. 
This means that the clinical feasibility of cardiac 1H-MRS 
is much higher than that of cardiac 31P-MRS. Moreover, 
31P-MRS is no longer available commercially for 1.5-T 
MR units. It is offered only for 3-T units, whose results for 
cardiac imaging were reported to be not clearly better than 
those obtained with 1.5-T units in terms of image quality 
[39].
Morphologic and functional imaging data, EDVI and 
stroke volume, were significantly lower in HCM patients 
than in athletes, confirming the typical geometric pat-
tern of the disease on one side and the heart adaptation to 
the intense sport activity on the other, as already reported 
[6]. A significant increase in left ventricle mass and septal 
thickness was found in HCM patients compared to athletes, 
as expected [6]. Interestingly, indexes of systolic function 
were not significantly different in the two groups, a finding 
that appears consistent with a relatively early stage of non-
obstructive HCM patients.
This study has limitations. First, the number of subjects 
studied was small and bikers and volley players are differ-
ent in terms of exercise (low static moderate dynamic for 
volley; high static and dynamic for cycling), leading to 
potential differences in cardiac metabolic activity. How-
ever, subgroup analysis was not possible due to the lack of 
statistical power. Second, the higher BMI and age in HCM 
patients may represent a source of bias, so that we cannot 
exclude that they can explain the difference in lipid con-
tent; however, bivariate correlation analysis between lipids 
and BMI did not show any significant correlation. Third, 
we did not calculate the concentrations of metabolites 
using internal or external references. However, the area 
under the peak as we used in this work can be considered a 
valid quantitative approach, utilized in cardiac [28, 40] and 
non-cardiac studies [41]. Fourth, due to the enrollment cri-
teria, we were not able to test for differences among vari-
ous underlying etiologies of HCM or specific HCM gene 
mutations. Fifth, ethical issues prevented from performing 
late gadolinium enhancement in athletes.
Conclusion
In conclusion, we found a significant increase in myo-
cardial lipids in HCM patients compared to competi-
tive athletes at 1H-MRS. Myocardial 1H-MRS may be an 
additional final phase of a cardiac MR protocol including 
standard morphologic and functional imaging in the differ-
ential diagnosis between HCM and athlete’s heart. Prospec-
tive larger studies are needed to confirm this preliminary 
unexplained, but intriguing observation.
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Abstract
Purpose To validate a blood-threshold (BT) segmentation software for cardiac magnetic resonance (CMR) cine images in 
patients with functional univentricular heart (FUH).
Materials and methods We evaluated retrospectively 44 FUH patients aged 25 ± 8 years (mean ± standard deviation). For 
each patient, the epicardial contour of the single ventricle was manually segmented on cine images by two readers and an 
automated BT algorithm was independently applied to calculate end-diastolic volume (EDV), end-systolic volume (ESV), 
stroke volume (SV), ejection fraction (EF), and cardiac mass (CM). Aortic flow analysis (AFA) was performed on through-
plane images to obtain forward volumes and used as a benchmark. Reproducibility was tested in a subgroup of 24 randomly 
selected patients. Wilcoxon, Spearman, and Bland–Altman statistics were used.
Results No significant difference was found between SV (median 57.7 ml; interquartile range 47.9–75.6) and aortic forward 
flow (57.4 ml; 48.9–80.4) (p = 0.123), with a high correlation (r = 0.789, p < 0.001). Intra-reader reproducibility was 86% 
for SV segmentation, and 96% for AFA. Inter-reader reproducibility was 85 and 96%, respectively.
Conclusion The BT segmentation provided an accurate and reproducible assessment of heart function in FUH patients.
Keywords Congenital heart disease · Univentricular heart · Cardiac magnetic resonance · Ventricular function · Image 
segmentation
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Introduction
The definition of univentricular heart has evolved from a 
narrow anatomical focus to a comprehensive view of het-
erogeneous conditions that ultimately result in a functional 
univentricular heart (FUH) [1–3].
A total cavo-pulmonary connection or Fontan circu-
lation (FC) is the surgical approach of FUH [1, 4–6]. 
Constant advances in cardiac magnetic resonance (CMR) 
techniques and equipment in the last decade now grant 
adequate anatomical detail in addition to the accurate and 
not operator-dependent functional assessment of ventricu-
lar chambers (main and accessory), cardiac valves, and 
intra- or extracardiac shunts and conduits. Furthermore, 
the functional evaluation of FC performed by CMR does 
not require the use of intravenous contrast material. The 
possibility of using non-contrast radiation-free CMR 
restricts the use of computed tomography in circumstances 
that require a detailed anatomical assessment [7–10]. In 
addition, contrast-enhanced CMR could allow the detec-
tion of the myocardial fibrotic evolution, an evaluation still 
not clinically feasible with computed tomography [11].
Non-invasive imaging techniques play a major role in 
the follow-up of patients with FC. In particular, CMR is 
emerging as the leading modality for pre-/post-surgical 
assessment of congenital heart disease (CHD) as well 
as for early diagnosis of cardiac and systemic complica-
tions, clarifying cardiovascular anatomy and physiology 
[7, 12–15]. Several studies have progressively asserted the 
correlation between the prognosis of patients with FC and 
their ventricular size and function calculated with analysis 
and segmentation of CMR images, showing it to be equally 
or more accurate than echocardiographic assessment and 
distinctly more reproducible [8, 16, 17].
In literature, there is limited experience regarding the 
volume analysis of FC patients. A study [18] showed that 
the inclusion of the hypoplastic chamber during the seg-
mentation of cine images of FC patients has no effect on 
the quantification of cardiac volumes, but may result in a 
less accurate measurement of the ejection fraction.
The aim of our study is to validate the blood-threshold 
(BT) segmentation algorithm in CMR cine images for the 
evaluation of cardiac function in patients with FUH.
Materials and methods
Study population
The ethics committee approval was obtained for this ret-
rospective study (Ethics Committee of the University 
Hospital San Raffaele; protocol code UH_01; approved 
on July 14th, 2016). A total of 70 CMR examinations of 
patients with FUC performed at our institution between 
March 2008 and March 2015 were initially considered. 
The inclusion criteria for the re-assessment of the images 
were: (1) complete acquisition of cardiac volume with cine 
images; (2) acquisition of through-plane images of flow in 
the ascending aorta; and (3) the absence of atrial–ventricu-
lar valve insufficiency. Therefore, 15 examinations were 
excluded, and a total of 55 examinations, belonging to 44 
patients (7 patients were scanned 2 times and 2 patients 3 
times), were included. In case of repeated examinations on 
the same patient, the time interval was at least 12 months.
The 44 patients included 30 males and 14 females, with 
a mean age and its corresponding standard deviation (SD) 
at the first examination of 25 ± 8 years (mean ± standard 
deviation, SD). The youngest patient was 7-year-old at the 
time of examination, and the oldest patient was 41-year-old.
Image acquisition
All CMR examinations were performed with a 1.5-T unit 
(Magnetom Sonata Maestro Class or Magnetom Aera, 
Siemens Medical Solutions) with 40- or 45-mT/m gradi-
ent power, respectively, using a 4- or 18-channel surface 
phased-array coil placed over the thorax and with the patient 
in a supine position. The image acquisition was gated to 
the electrocardiographic (ECG) signal to produce a cine 
sequence throughout the systole and diastole and to avoid 
cardiac artifacts.
Each CMR study included a complete set of short-axis 
(from base to apex) cine images, using an ECG-triggered 
steady-state free precession pulse sequence acquired with 
the following technical parameters: repetition time (TR)/
echo time (TE) = 4.0/1.5 ms; flip angle 80°; slice thickness 
8 mm; time resolution 45 ms; mean acquisition time 14 ± 4 s 
(mean ± SD); number of phases 30.
Phase contrast (PC) through-plane sequences were used 
for blood flow quantification [19]. Images perpendicular to 
the ascending aorta were obtained (1 cm distal to the sino-
tubular junction). A breath-hold turbo spoiled gradient echo 
sequence (fast low-angle shot) was performed for phase-
velocity mapping with the following technical parameters: 
TR/TE 4.0/3.2 ms; slice thickness 5 mm; velocity encoding 
(VENC) from 150 ms to 350 ms; time resolution 41 ms; 
mean acquisition time 15 ± 4 s. Initially, we acquired the 
PC sequence with a VENC of 150 ms. In the presence of 
aliasing, we modified the VENC adding 50 ms for each new 
sequence, step by step up to the complete disappearance 
of the aliasing artifact. The PC through-plane sequences 
produced two sets of images: the magnitude image and the 
phase-velocity map, the former to provide details on the 
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anatomy and identify the boundaries of the vessel and the 
latter for blood flow estimation [20].
Image assessment
Two independent radiologists, R1 and R2, with compara-
ble experience (about 4 years) performed the segmentation 
of cardiac and flow images using MEDIS QMass 7.6 and 
QFlow 5.6 (Medis Medical Imaging Systems, Leiden, The 
Netherlands) [21, 22].
For the segmentation of cardiac images, in each session 
both readers independently manually traced the epicardial 
contour of the FUH both in the end-diastolic and end-sys-
tolic phases. Thus, the blood-threshold technique (Mass-K 
mode) was applied using a 50% BT and the end-diastolic 
volume index (EDVI), end-systolic volume index (ESVI), 
stroke volume (SV), ejection fraction (EF), and cardiac mass 
values were calculated in a totally automated way.
For the segmentation of flow images of the ascending 
aorta, in each session each one of the two readers positioned 
a region of interest on the vessel boundary of a selected 
slice. Subsequently, each reader propagated the segmenta-
tion through the remaining slices, the software proposed an 
automated adjustment, and the reader was allowed to manu-
ally correct the adjusted contours. For each session, forward 
flow and backward flow measurements were obtained.
Statistical analysis
Data were reported as mean ± SD or median and interquar-
tile range (IQR) according to normal distribution or non-
normal distribution, respectively.
The Wilcoxon test and Spearman correlation were used 
to compare and correlate the median value of SV and aortic 
forward flow, respectively.
The Bland–Altman method was used to estimate the intra- 
and inter-reader reproducibility. The intra-reader reproduc-
ibility was performed only for R1 with at least a 10-day 
interval between the two sessions.
The coefficient of repeatability (CoR) was calculated as 
1.96 × SD of differences of the two datasets. Reproducibility 
was reported as complement to 100% of the ratio between 
the CoR and the mean. Bias (mean of the differences of the 
two datasets) and 95% limits of agreement (bias ± 2 SD) 
were plotted as well.
Results
The image analysis was feasible in all patients and no arti-
facts prevented readers from performing the segmentation. 
Fifty-five examinations were analyzed. No clinically relevant 
aortic regurgitation was found. The median value of the SV 
and aortic forward flow were 57.7 ml (IQR 47.9–75.6 ml) 
and 57.4 ml (IQR 48.9–80.4 ml), respectively. We found no 
significant difference (p = 0.123), but a significant correla-
tion (r = 0.789, p < 0.001) between mean SV and aortic 
forward flow. All ventricle and aortic functional parameters 
are shown in Table 1.
The bias between the SV values measured by R1 was 
0.12 ml, accompanied by a CoR of 8.1 ml, correspond-
ing to an intra-reader reproducibility of 86%. The bias was 
− 0.1 ml, accompanied by a CoR of 2 ml corresponding to 
a reproducibility of 96%.
The inter-reader analysis of SV showed a CoR of 8.63 ml 
over a bias of − 1.9 ml, corresponding to an inter-reader 
reproducibility of 85%. The same data for the aortic for-
ward flow were 2.12 ml over a mean difference of 0.24 ml, 
corresponding to an inter-reader reproducibility of 96%. 
Bland–Altman plots for intra- and inter-reader reproduc-
ibility are shown in Figs. 1a, b and 2a, b, respectively. 
An example of segmentation of cine CMR images with 
the BT technique is shown in Fig. 3.
Discussion
In CMR, ventricular volume and function assessment is 
achieved through the segmentation of cine images. This 
post-processing technique, initially exclusively manually 
performed by trained readers, implies the recognition of the 
difference between the blood pool in the ventricular cavity, 
of other anatomical structures normally in the ventricular 
chamber such as trabeculae and papillary muscles (TPM) as 
well as of the ventricular walls. Manual tracing of contours 
for the ventricular walls and TPM by an experienced reader 
still constitutes the most widely validated and employed 
approach. However, in the last decade, several studies have 
validated techniques that, while less time-efficient than a 
fully automated solution, have tried to address the numerous 
limitations of the fully automated approach and provided a 
solid method, well-balanced in terms of cost-effectiveness 
Table 1  Ventricle and aortic functional parameters
Data reported as median (interquartile interval)
EDVI  end-diastolic volume index, ESVI  end-systolic volume index, 
SV stroke volume, EF ejection fraction
EDVI (ml/m2) 63.7 (51.9–82.2)
ESVI (ml/m2) 26.8 (21.3–46.0)
SV (ml) 57.7 (47.9–75.6)
EF (%) 51.3 (43.4–60.0)
Mass index (g/m2) 89.2 (73.2–131.4)
Aortic forward flow (ml/heart beat) 57.4 (48.9–80.4)
Aortic backward flow (ml/heart beat) 1.9 (0.5–3.9)
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analysis, to obtain a proper estimate of the ventricular vol-
ume and mass with minimal manual input [22–25]. One of 
these limitations is the unreliable allocation of TPM to the 
myocardial mass or to the blood pool. TPM allocation was 
shown to substantially influence the accuracy of ventricu-
lar volume and mass assessment. In some recent automatic 
softwares, there is the possibility to exclude TPM from the 
blood pool [26–28]. However, in particular conditions such 
as FUH, the delineation of hypertrabeculations remains 
difficult.
A BT technique such as the Mass-K Mode algorithm can 
serve as a time-saving and accurate solution to this clinical 
issue. In this technique, after the reader has manually traced 
only the epicardial contours on the end-systolic and end-
diastolic phases of the cine images, the software calculates 
a blood percentage for each pixel inside the contoured area, 
considering the different signal intensity of the blood and 
myocardium. After visual inspection, the reader can freely 
alter, in any slice and phase, the default BT value of signal 
intensity discrimination. Moreover, semi-automated detec-
tion of the epicardial margin can be used, requiring only 
small manual adjustments on good quality images, further 
curtailing the time required for the post-processing stage 
[29].
Fig. 1  Bland–Altman plot for 
intra-reader reproducibility of 
stroke volume measurement (a); 
Bland–Altman plot for aortic 
forward flow measurement (b)
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The Mass-K Mode algorithm has been validated for clini-
cal routine application, showing both accurate and reproduc-
ible evaluation of ventricular mass and volume and reduced 
time of analysis, by Jaspers et al. [29] on phantoms and on 
12 patients with normal cardiac anatomy and function and 
more recently by Varga-Szemes et al. [25] on 137 patients 
with a broad range of cardiac diseases not including CHD.
The results of our study validate the use of this BT tech-
nique in patients with an abnormal cardiac anatomy, such 
as the one that is found in patients with FC. In the absence 
of other reference tools to validate ventricular volume 
assessments, we choose to use aortic flow measurements 
as an independent benchmark for SV, since previous studies 
showed it to be a solid and reproducible standard. Of note, 
we found no significant difference and a significant correla-
tion between the two values [30–32].
In addition, a greater level of automation and a lesser 
need of manual adjustments granted by the use of the BT 
technique and the semi-automated recognition of epicardial 
contours and aortic walls account for the excellent inter- 
and intra-reader reproducibility of both SV and aortic flow 
volume (85 and 96%, respectively).
Our study has limitations. First, it is a retrospective 
study on a relatively small number of subjects and it is 
Fig. 2  Bland–Altman plot for 
inter-reader reproducibility of 
stroke volume measurement (a); 
Bland–Altman plot for aortic 
forward flow measurement (b)
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based on a single-center historical series of FC patients; 
however, FUV patients are a very small population and 
usually referred to a single center. Second, it is possible 
that, due to the retrospective design of our study, even 
small differences in the acquisition parameters, reasonably 
likely to happen in the absence of a standardized CMR 
acquisition protocol, may have negatively influenced the 
quality of cine images and therefore the performance of 
the BT technique. Third, the study lacks of an independent 
reference standard, though the aortic flow analysis may 
be considered substantially independent of the cardiac 
cine study. Fourth, both readers were equally experienced 
(about 4 years); further studies are required to investigate 
reproducibility between readers with different levels of 
experience. Finally, we should consider the possibility of 
obtaining the same volume analysis with different soft-
wares; this new function could be integrated in future soft-
wares to be used in FUH patients.
To summarize, we successfully validated the use of 
a BT technique for the segmentation of cine images in 
patients with FC. We observed a high intra- and inter-
reader reproducibility for the assessment of ventricular 
SV and excellent agreement with aortic flow values used 
as a benchmark.
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A B S T R A C T
Objectives: To evaluate ascending aortic strain (AAS) with cardiac magnetic resonance (CMR) in a large con-
secutive series of patients with diﬀerent types of cardiovascular disease (CVD).
Methods: Two-dimensional phase-contrast gradient-echo sequences of the ascending aorta were retrospectively
reviewed in 1027 patients (726 males, 301 females). Aortic lumen area was segmented using a semi-automatic
approach to calculate AAS values. Subgroup analysis was performed for patients with normal CMR, tetralogy of
Fallot (ToF), and ischemic heart disease (IHD). Multivariate and post-hoc analyses were performed to evaluate
the eﬀect of age, gender, and CVD on AAS values. Shapiro-Wilk, three- and two-way ANOVA, Mann-Whitney U,
and Spearman correlation statistics were used.
Results: Multivariate analysis showed signiﬁcant diﬀerences in AAS among decades of age (p < 0.001), genders
(p = 0.006) and CVD subgroups (p < 0.001) without interaction among these factors. A gender-related dif-
ference (higher AAS in females) was signiﬁcant in ToF (p = 0.008), while an AAS reduction during aging was
observed in all CVD subgroups. Post-hoc analysis showed a signiﬁcantly lower AAS in ToF and IHD patients
compared to subjects with normal CMR (p < 0.001).
Conclusion: Diﬀerences in age, gender, and CVD independently aﬀect AAS. The lower AAS observed in ToF
fosters its assessment during follow-up in adulthood. Future studies on causes and clinical implications of a
higher AAS in females aﬀected by ToF are warranted.
1. Introduction
Arterial stiﬀness is one of the earliest manifestations of adverse
structural and functional changes within the vessel wall. When the
aorta is considered, stiﬀness is a main determinant of age-related sys-
tolic and pulse pressure increase, a major predictor of stroke and
myocardial infarction, and has been associated with heart failure [1–3].
Pulse wave velocity measured by applanation tonometry is a well-
known functional method to non-invasively quantify aortic stiﬀness
providing an average measure of stiﬀness over a certain vessel length.
Conversely, strain, compliance, and distensibility are local markers of
arterial elasticity, which can be measured using magnetic resonance
(MR) imaging, allowing the detection of more subtle changes in re-
gional stiﬀness [4].
The use of MR imaging has several advantages over ultrasound
imaging including three-dimensional visualization that allows to place
the imaging plane perpendicular to the vessel with a high reproduci-
bility. Thus, aortic distensibility can be measured as a change in two-
dimensional vessel perimeter or area instead of one-dimensional vessel
diameter [4]. Previous authors showed that ascending aortic strain
(AAS) measured with cardiac MR (CMR) is markedly decreased before
the ﬁfth decade of life and that can be considered as an early mani-
festation of vascular aging [5]; AAS was also shown to be independently
correlated with coronary atherosclerosis and coronary calcium content
[6] as well as to be an independent predictor of progression toward
hypertension in non-hypertensive subjects [7].
Our aim was to evaluate the AAS in a large consecutive series of
patients who underwent CMR, comparing age classes, gender, and
diﬀerent types of cardiovascular diseases (CVD), also including subjects
with normal CMR examinations.
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2. Materials and methods
2.1. Study design and population
The local Ethics Committee approved this retrospective study
(Ethics Committee of the University Hospital San Raﬀaele; protocol
code AS01; approved on April 7th, 2016) and informed consent was
waived. Patients were selected from a database of CMR studies per-
formed between September 2008 and August 2014 at the Radiology
unit of the IRCCS Policlinico San Donato, San Donato Milanese, Italy.
CMR examinations with an image quality that impairs AAS evaluation
were excluded from analysis. Moreover, in the case of multiple CMR
examinations in the same patient, only the ﬁrst one was included.
2.2. Image acquisition
We retrospectively selected images acquired with two diﬀerent
1.5 T machines. Magnetom Sonata Maestro Class (Siemens, Erlangen,
Germany), was used to perform the studies from September 2008 to
March 2014 (n = 1294); subsequent studies (n = 69) were performed
using Magnetom Aera (Siemens, Erlangen, Germany). Retrospectively
electrocardiographically (ECG)-gated breath-hold two-dimensional
phase-contrast gradient recalled echo sequences with a through-plane
velocity encoding gradient ranging from 150 to 350 cm/s were per-
formed on a transverse plane above the aortic bulb. Sequence para-
meters were as follows: repetition time 49.75 ms, echo time 3.1 ms, ﬂip
angle 30° for Magnetom Sonata; 37.12 ms, 2.47 ms, 20° for Magnetom
Aera. Parallel imaging with acceleration factor 2 and retrospective
ECG-gating with 30 phases per cycle (with repetition time dependent on
the R-R interval) were set on both machines.
2.3. Image analysis
Image post-processing was performed using Argus Flow software
(Syngo Argus Flow, version 4.02, Siemens, Erlangen, Germany).
Magnitude images were used to semi-automatically segment aortic
contours in each cardiac phase. During the segmentation process, an
expert cardiac radiologist with 2–7 years of experience in CMR selected
the frame with the optimal contrast between aortic lumen and aortic
wall. Then, the operator traced in the same frame the aortic contour,
which was automatically propagated in all frames of the cardiac cycle
and manually corrected when necessary.
The AAS was calculated as deﬁned by Redheuil et al. [5], namely:
=
−AAS A A
A
max min
min
where Amax and Amin represent respectively the maximum and
minimum aortic cross-sectional area measured during a single cardiac
cycle.
2.4. Statistical analysis
The Shapiro-Wilk test was employed to assess normality of data
distribution. Due to non-normal data distribution, descriptive statistics
are provided as median and corresponding inter quartile range (IQR)
values. To evaluate the inﬂuence of age, gender, and CVD on the AAS
values, we performed a three-way ANOVA test. The log-transformation
of the data was obtained to reach the condition of normal distribution
needed to perform the tree-way ANOVA. Age was categorized into 7 age
bins (0–9, 10–19, 20–29, 30–39, 40–49, 50–59 and≥60 years).
Moreover, post-hoc tests for CVD and age bin factors were performed.
After this global analysis, the statistical diﬀerences in AAS values
were analysed in the larger subgroups, namely: subjects with normal
CMR (i.e. unremarkable examination in subjects examined to exclude
cardiac abnormalities), patients with Tetralogy of Fallot (ToF), and
patients with ischemic heart disease (IHD). Taking into account only
these types of CVD, the evaluation of AAS changes over all the selected
age bins was not possible, due to the diﬀerent age distribution of sub-
jects aﬀected by congenital (ToF) and age-related (IHD) CVD.
Therefore, statistical inference on AAS trends over age was evaluated
comparing ToF and IHD subjects only with normal CMR subjects. To
this aim, the Mann-Whitney U tests was used for each age bin. On the
other hand, to evaluate the inﬂuence of gender and CVD on AAS values,
a two-way ANOVA was performed. Also in this case, log-transformation
of the data was obtained to perform multivariate analysis. Finally, age
was considered as a continuous variable and correlation between age
and AAS values was estimated using Spearman correlation coeﬃcient.
Statistical signiﬁcance level was set to p < 0.050 and the analysis was
performed using SPSS (IBM Corporation, New York, NY, United States).
3. Results
A total of 1363 CMRs were retrieved; among them, 42 examinations
were excluded due to an insuﬃcient image quality. Moreover, in order
to create homogenous CVD categories, we excluded disease subgroups
composed of less than 10 subjects. For this reason, other 294 cases were
excluded from the analysed sample.
The ﬁnal number of analysed patients was 1027. Among them, 726
were men (median age 37 years, IQR18–60) and 301 were women
(median age 34 years, IQR 16–54), with borderline signiﬁcance be-
tween genders (p = 0.051). Fig. 1 shows age distribution between
genders.
Taking into account all the analysed subjects, the median AAS value
was 0.25 (IQR 0.17–0.38). Shapiro Wilks test showed that AAS data
were not normally distributed (p < 0.001) The AAS resulted inversely
correlated with age (ρ =−0.51, p < 0.001). Moreover, women
showed a signiﬁcantly (p = 0.006) higher AAS (median 0.28, IQR
0.20–0.41) compared to men (median 0.24, IQR 0.16–0.36). The results
of the three-way ANOVA are shown in Table 1. Post-hoc analysis
showed signiﬁcant diﬀerences in AAS among all the age bins except for
those between 30 and 49 years of age. Fig. 2 shows the AAS trend over
decades of age, while results of post-hoc test for diﬀerent CVD types and
their corresponding descriptive statistics are presented in Table 2.
Of the total of 1027 cases, the major subgroups were represented by
192 subjects with normal CMR (128 men, 64 women; median age
36 years, IQR 18–51), 166 patients aﬀected with IHD (132 men, 34
women, median age 64 years, IQR 58–71), and 92 patients aﬀected
with ToF (57 men, 35 women; median age 25 years, IQR 14–40). In all
the three subgroups, there was no signiﬁcant diﬀerence in terms of age
between men and women (normal CMR, p = 0.997; IHD, p = 0.658,
ToF: p = 0.361).
Multivariate analysis performed on the subsample composed by
these three major subgroups showed signiﬁcant diﬀerences in AAS
values between genders (p = 0.002) and among CVD subgroups
(p < 0.001), without interaction between CVD subgroups and genders
(p = 0.119). In general, median AAS values were higher in women than
in men, as can be seen in the boxplot represented in Fig. 3. However,
post-hoc analysis showed a signiﬁcant diﬀerence in AAS between men
and women only for ToF patients (p = 0.008). Moreover, men with ToF
showed a signiﬁcantly lower AAS when compared with men with
normal CMR (p = 0.005). In the other two subgroups, this diﬀerence
appeared to be not signiﬁcant within the analysed sample. No sig-
niﬁcant diﬀerence was found between genders in subjects with normal
CMR (p = 0.728). In IHD patients, AAS was signiﬁcantly lower com-
pared to that of normal CMR subjects (men: p < 0.001, women:
p=0.016), without signiﬁcant diﬀerence between genders (p = 0.732).
In subjects with normal CMR, the analysis of AAS trend over age
showed an inverse correlation with age both in men (ρ=−0.53,
p < 0.001) and women (ρ=−0.54, p < 0.001); AAS decreased with
age also in IHD patients (ρ=−0.16, p = 0.039), this correlation re-
maining signiﬁcant in women (ρ =−0.40, p = 0.021) but not in men
(ρ=−0.11, p = 0.224). Evaluating AAS over decades of age, men
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with IHD had an AAS signiﬁcantly lower than that of normal CMR
subjects only between 50 and 59 years of age (p = 0.019). No sig-
niﬁcant diﬀerences were found between women aﬀected with IHD and
women with normal CMR for all age bins.
Also in ToF patients the AAS decreased with age, signiﬁcantly in
men (ρ =−0.66, p < 0.001), not signiﬁcantly in women (ρ=−0.28,
p = 0.106). Moreover, men aﬀected with ToF belonging to the 20–49
age range had AAS values signiﬁcantly lower than men with normal
CMR (20–29 years, p = 0.002; 30–39 years, p = 0.011; 40–49 years,
p < 0.001); after 50 years of age, this diﬀerence was not signiﬁcant.
On the other hand, women aﬀected by ToF did not show signiﬁcantly
lower AAS values for all the age bins when compared to normal CMR
women. Fig. 4 shows the age-related changes of AAS over decades of
age for all the above-mentioned subgroups.
4. Discussion
In this study, AAS values were analysed in a large consecutive series
of patients with diﬀerent types of CVD and in subjects with normal
(unremarkable) CMR. This study proved that diﬀerence in age, gender,
and CVD independently aﬀect the AAS.
Age distribution of the analysed sample was characterized by two
peaks, the ﬁrst at age 15 and the second at age 60, as visible in Fig. 1,
reﬂecting the high number of patients with congenital and age-related
heart diseases in our series. This was conﬁrmed by the fact that, among
the analysed CVDs, the most frequent were IHD and ToF, which re-
present two diﬀerent pathophysiological processes both aﬀecting AAS:
age-related factors and congenital/developmental factors, respectively.
Gender diﬀerence in AAS in the whole patient dataset was likely due
to a diﬀerent proportion between males and females in some CVD
subgroups, since subjects with normal (unremarkable) CMR showed no
signiﬁcant gender diﬀerence in term of AAS. Gender-related diﬀerences
appeared not to be inﬂuenced by age or CVD, although in patients with
ToF there was a gender-related diﬀerence in AAS, in line with a pre-
vious study where diﬀerences in functional cardiovascular parameters
between male and female patients with ToF was found [8]. Further-
more, other studies demonstrated a gender-related diﬀerence in arterial
aging and stiﬀening process, suggesting that hormonal and other
gender-speciﬁc factors can modulate the aging process [9].
Vascular changes with age are well-known. The progressive de-
crease in AAS during life reﬂects physiological and pathological
Fig. 1. Age distribution in the analysed sample.
Histograms representing age distribution among diﬀerent genders in the 1027 analysed patients.
Table 1
Output of the three-way ANOVA analysis that takes into account the eﬀect of age, gender
and cardiovascular disease on ascending aortic strain values. Data shows that all the three
variables (age, gender and CVD) are independently associated to AAS. Statistically sig-
niﬁcant p-values are highlighted in bold.
Source Type III Sum of
Squares
df Mean
Square
F p-value
Age bin 19.170 6 3.195 14.295 0.000
Gender 1.670 1 1.670 7.470 0.006
CVD 16.400 18 0.911 4.076 0.000
CVD * Age bin 20.899 89 0.235 1.051 0.360
CVD * Gender 4.011 18 0.223 0.997 0.460
Gender * Age bin 0.463 6 0.077 0.346 0.913
CVD * Gender * Age
bin
10.075 51 0.198 0.884 0.703
Error 187.071 837 0.224
Total 2272.154 1027
Corrected Total 348.130 1026
CVD: cardiovascular disease; df: degrees of freedom.
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modiﬁcations of mechanical, histological, and functional properties of
the aortic wall. Moreover, diﬀerences in cardiac function and pulse
wave reﬂection by medium and small arteries contribute to AAS.
Animal studies indicated that age-related changes in aortic stiﬀness and
strain may not entirely due to pathologic causes such as atherosclerosis
and diabetes but also to physiological aging [9]. However, we found
that patients with IHD have a signiﬁcantly lower AAS compared to
normal (unremarkable) CMR subjects between 50 and 59 years of age,
highlighting the association between coronary artery disease and re-
duction in aortic elasticity.
Multivariate analysis showed the presence of signiﬁcant diﬀerences
in AAS among patient with diﬀerent age, genders, and cardiovascular
conditions. Moreover, these results show that the interaction among
these parameters does not impact on AAS. In patients with certain
diseases such as IHD, a decrease or increase in AAS is more easily ex-
plainable on the basis of diﬀerent age, morpho-functional or patho-
physiologic characteristics. On the other hand, in patients with other
diseases such as ToF, the results are less obvious.
Patients with IHD showed a reduced AAS compared to normal CMR
subjects between 50 and 59 years of age; this diﬀerence is reduced for
subjects over 60 years of age, being not signiﬁcant. This result may be
due to a combination of factors: increased aortic stiﬀness determined by
atherosclerosis (more pronounced in patients with IHD) and reduced
cardiac output, implying a decreased stretching of the ascending aorta.
Fig. 2. Ascending Aortic strain over age.
Ascending aortic strain (AAS) values over decades of age in the analysed
sample of 1027 consecutive subjects. For each age subgroup the number of
included subjects is reported between brackets.
Table 2
Post hoc tests performed on diﬀerent cardiovascular disease subgroups. In this table are
shown only post hoc tests performed between subjects with normal cardiac magnetic
resonance and patients with diﬀerent diseases. Statistically signiﬁcant p-values are
highlighted in bold.
CVD (number of subjects) Median Q1 Q3 p-value
Normal CMR (192) 0.30 0.22 0.41
Tetralogy of Fallot (92) 0.30 0.16 0.39 <0.001
Transposition of the great arteries (61) 0.25 0.18 0.36 0.006
Post Melody valve implantation (39) 0.20 0.13 0.31 <0.001
Fontan procedure (23) 0.23 0.16 0.34 0.007
Bicuspid aortic valve (45) 0.36 0.23 0.61 0.047
Pulmonary insuﬃciency (70) 0.30 0.18 0.57 0.334
Aortic insuﬃciency (33) 0.30 0.18 0.42 0.487
Aortic valve stenosis (15) 0.64 0.32 0.90 <0.001
Pulmonary valve stenosis (22) 0.26 0.15 0.39 0.088
Ross procedure (10) 0.13 0.09 0.22 <0.001
Ascending aortic dilatation (58) 0.18 0.13 0.26 <0.001
Ascending aortic aneurysm (19) 0.14 0.10 0.20 <0.001
Aortic coarctation (66) 0.41 0.32 0.57 <0.001
Ischemic heart disease (166) 0.18 0.14 0.26 <0.001
Dilated cardiomyopathy (34) 0.22 0.19 0.30 0.001
Hypertrophic cardiomyopathy (31) 0.25 0.19 0.34 0.058
Surgical ventricular restoration (32) 0.22 0.16 0.26 <0.001
Left ventricular hypertrophy (19) 0.28 0.18 0.32 0.060
CMR: cardiac magnetic resonance; CVD: cardiovascular disease.
Fig. 3. Subgroup analysis.
Three boxplots that represents ascending aortic strain values in normal cardiac magnetic resonance (CMR) subjects, patients with tetralogy of Fallot (ToF) and ischemic heart disease
(IHD), subdivided by gender.
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This values may however underestimate the real diﬀerence because
subjects with normal CMR were not really healthy controls but patients
with unremarkable CMR who may have had one or more CVD risk
factors that could have contributed to a decrease in AAS.
AAS was signiﬁcantly lower in patients with ToF than in patients
with normal CMR, especially in males in the 3rd and 4th decade of life.
This result is probably due at least in part to an intrinsic morpho-
functional defect in ToF, described by other authors as a fragmentation
of elastic ﬁbres in aortic medial wall [10–15]. A similar study by
Christensen et al. [15] highlighted the relationship between age at re-
pair of ToF and AAS. One of the most though-provoking results was the
poor correlation between AAS and PWV, highlighting the need for a
local assessment of the aortic elastic properties. Our results were
slightly diﬀerent, the AAS being higher in the present study, probably
due to the age diﬀerence in the study population or the timing of the
ToF repair, with comparable correlations between AAS and ascending
aortic cross sectional area. The gender diﬀerence could reﬂect diﬀer-
ences in biventricular volumes and function, as well as diﬀerences in
timing and type of ToF treatment. Nonetheless, we could hypothesize
that there is also a gender-related factor that aﬀects AAS in ToF pa-
tients. AAS was also lower in patients aﬀected by TGA and in those
patients that underwent Fontan and Ross procedures, in accordance
with previously reported ﬁndings [14,16–18]. These results reaﬃrm
the importance of including aortic morphological and functional eva-
luation in the follow-up of patients with congenital heart diseases.
Aortic strain reﬂects vascular compliance in large vessels and is
lower in older patients. We did not ﬁnd a signiﬁcant diﬀerence in
subjects over 60 regardless of the pre-existing diseases, probably be-
cause of the prevailing aging process [19]. Another possible explana-
tion is that older subjects with a normal (unremarkable) CMR could
have been exposed to the same risk factors and have ongoing patho-
physiological processes similar to those aﬀecting patients with IHD,
making them less suitable for a direct comparison. On the other hand,
diﬀerences in AAS in young patients with congenital heart disease could
reﬂect a precocious arterial stiﬀening [5].
This study also showed that aortic strain can be easily and rapidly
obtained using phase-contrast sequences usually performed for ﬂow
analysis; its evaluation and monitoring could be beneﬁcial in detecting
aortic stiﬀening. Moreover, it may be used for non-invasive follow-up
evaluations of aortic condition in CVD patients.
This study is aﬀected by several limitations mainly due to its ret-
rospective design. Firstly, we should consider that prospective studies
included blood pressure data measured after the sequence [14] since it
is somewhat diﬃcult to measure blood pressure during the acquisition
of a CMR sequence. We could not include this parameter in our ana-
lysis. However, brachial blood pressure measurements could lead to an
overestimation of central blood pressure and biased aortic dis-
tensibility. Secondly, we did not use a standardized plane placement on
the ascending aorta. The sequences were not purposely acquired to
measure aortic cross sectional area but they were placed by the same
operator above the aortic root to evaluate ascending aortic ﬂow. For
this reason the systolic motion of the ascending aorta due to myocardial
contraction was not accounted for, similarly to another study [15]. Our
technique, being simple and not relying on peak ﬂow to choose the
timing for plane placement in order to assess minimum and maximum
area, is surely less accurate than the one used by Grotenhuis et al. [20].
Finally, we lack really healthy control subjects. Since the diﬀerences in
terms of AAS were signiﬁcant when comparing age matched subgroups
of patients with normal (unremarkable) CMR and with CVD, we are
conﬁdent that there was a signiﬁcant reduction in AAS in at least two of
the major subgroups of patients compared to what we expect in normal
subjects of similar age.
In conclusion, we found that AAS is independently aﬀected by dif-
ferences in age, gender, and cardiovascular condition. In particular, this
Fig. 4. Ascending aortic strain over age in subgroup analysis.
Ascending aortic strain (AAS) values over decades of age in subjects with normal cardiac magnetic resonance (CMR), patients with tetralogy of Fallot (ToF) and ischemic heart disease
(IHD), divided by gender. Statistically signiﬁcant comparisons are marked with a star (*).
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tendency was evident in patients with ToF and IHD, where the aging
process seems to prevail on pre-existent diﬀerences in terms of AAS in
subjects over 60. Our results highlight the possibility to use AAS for a
non-invasive assessment of the aortic status in CVD patients.
Nevertheless, further investigations on elderly patients and, in parti-
cular, in adults with congenital heart disease are advised.
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through-plane phase-contrast sequences). Two independent 
readers (R1, trained radiology resident; R2, lower-trained 
technician student) obtained segmented images twice (>10-
day interval), using a semi-automated method of segmen-
tation. Peak velocity, forward and backward flows were 
obtained. Bland–Altman analysis was used and reproduc-
ibility was reported as complement to 100% of the ratio 
between the coefficient of repeatability and the mean. R1 
intra-reader reproducibility for the aorta was 99% (peak 
velocity), 95% (forward flow) and 49% (backward flow); 
for the pulmonary artery, 99%, 91% and 90%, respectively. 
R2 intra-reader reproducibility was 92%, 91% and 38%; 
98%, 86% and 87%, respectively. Inter-reader reproducibil-
ity for the aorta was 91%, 85% and 20%; for the pulmo-
nary artery 96%, 75%, and 82%, respectively. Our results 
showed a good to excellent reproducibility of blood flow 
measurements of CMR together with a semiautomated 
method of segmentation, for all variables except the back-
ward flow of the ascending aorta, with a limited impact of 
operator’s training.
Keywords Cardiac magnetic resonance · Reproducibility · 
Heart valve · Phase-contrast sequences · Blood flow
Introduction
In the past years, cardiovascular magnetic resonance 
(CMR) has emerged as an alternative non-invasive imaging 
technique for the evaluation of patients with cardiovascu-
lar disease, providing an accurate anatomic and functional 
characterization of the heart and great vessels as well as 
the possibility to investigate nearly the whole spectrum of 
cardiac disease [1]. Especially for patients affected with 
congenital heart disease, CMR plays an important role in 
Abstract The aim of our study was to estimate the intra- 
and inter-reader reproducibility of blood flow measure-
ments in the ascending aorta and main pulmonary artery 
using cardiac magnetic resonance (CMR) and a semi-
automated segmentation method. The ethics committee 
approved this retrospective study. A total of 50 consecu-
tive patients (35 males and 15 females; mean age±standard 
deviation 27±13 years) affected by congenital heart disease 
were reviewed. They underwent CMR for flow analysis 
of the ascending aorta and main pulmonary artery (1.5 T, 
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the quantification of blood flow and evaluation of valve 
stenosis/insufficiency using phase-contrast (PC) through-
plane sequences [2–11]. The PC sequences were validated 
in phantom and in vivo studies and have proven to be a 
reliable tool for the quantitative and qualitative analysis of 
blood flow and tissue motion [12].
Despite its importance for the assessment of disease pro-
gression, few data are available about the reproducibility 
of CMR in the measurement of blood flow in patients with 
valve stenosis and/or insufficiency [2, 13–15]. Moreover, 
segmentation methods were validated indirectly, through 
the ability to provide accurate flow measurement [13, 16] 
or pulse wave velocity [16, 17] or directly in terms of oper-
ator variability [13, 14] or agreement with manual tracing 
[17].
Blood flow measurements are based on the segmenta-
tion of a vessel contour that may be performed manually 
or, more typically, semi-automatically, with the use of com-
puter software likely impacting on measurement reproduc-
ibility. Reader experience may play a role as well.
Thus, the aim of our study was to estimate the intra- and 
inter-reader reproducibility of blood flow CMR measure-
ments through the ascending aorta and main pulmonary 
artery in patients affected with congenital heart disease or 
with aortic and/or pulmonary valve disease. The impact on 
reproducibility of the reader’s experience with CMR was 
also investigated.
Materials and methods
The ethics committee approval was obtained for this retro-
spective study. A total of 50 consecutive patients affected 
with a congenital heart disease or with aortic and/or pul-
monary valve disease were reviewed. They all underwent 
CMR at our institution between November 2012 and May 
2013. Of 50 patients, 35 were males and 15 females, with 
a mean age of 27 ± 13 years (mean ± standard deviation). 
The disease spectrum is shown in Table 1. The majority of 
patients (n = 28, 56%) had a Tetralogy of Fallot.
All CMR examinations were performed with a 1.5-T unit 
with 40-mT/m gradient power (Magnetom Sonata Maestro 
Class, Siemens Medical Solution, Erlangen, Germany), 
using a four-channel surface phased-array coil placed over 
the thorax and with the patient in supine position.
A CMR study included a complete set of short-axis 
(from base to apex) and long-axis (2-, 3- and 4-chamber 
views) cine images, using an ECG-triggered breath-hold 
steady-state free precession sequence acquired with the fol-
lowing technical parameters: TR/TE 4.0/1.5 ms; flip angle 
80°; slice thickness 7 mm; time resolution 45 ms; mean 
acquisition time 14 ± 4 s.
The PC through-plane sequences were used for blood 
flow quantification. Images perpendicular to the vessel of 
interest were obtained. A breath-hold turbo spoiled gradi-
ent echo sequence (fast low-angle shot) was performed 
for phase-velocity mapping with the following techni-
cal parameters: TR/TE 4.0/3.2 ms; slice thickness 5 mm; 
velocity encoding (VENC) from 150 cm/s to 350 cm/s; 
time resolution 41 ms; mean acquisition time 15 ± 4 s. 
For each patient, we initially acquired the PC sequence 
with a VENC of 150 cm/s: in the presence of aliasing, 
we increased the VENC adding 50 cm/s for each new 
sequence, step-by-step up to the complete disappearance of 
the aliasing artifact.
Flow measurements were performed right above the aor-
tic or pulmonary valve in patients with surgical or percuta-
neous valve replacement. In patients without valve replace-
ment, measurements were performed below, at the level 
and above the native valve. The PC sequences produced 
two sets of images: the gradient echo image and the phase 
velocity map (Fig. 1). The magnitude image depicts the 
anatomy and allows to identify the vessel boundaries, while 
the phase velocity map corresponds to blood velocity [2].
Two independent readers (R1 and R2) performed meas-
urements twice, with at least a 10-day interval between the 
two sessions, for a total of four sessions. These readers 
had different educational background and different level of 
training in CMR segmentation. While R1 was a radiology 
resident with 4 months of full-immersion training (under 
the supervision of a radiologist with a 5-year experience 
in CMR), R2 was a technician student with 2 weeks of 
training (under the supervision of the same experienced 
radiologist).
Both readers used the Argus software on a remote work-
station (Leonardo, Siemens Medical Solution, Erlangen, 
Table 1  Disease spectrum in 50 studied patients
ToF tetralogy of fallot, VSD ventricular septal defect
Category Detail n %
Aortic disease Aortic insufficiency 1 2%
Pulmonary artery disease Pulmonary insufficiency in 
ToF
28 56%
Pulmonary insufficiency 7 14%
Stenosis of pulmonary artery 
conduit
6 12%
Pulmonary stenosis 3 6%
Pulmonary steno-insuffi-
ciency
2 4%
Other VSD 2 4%
Truncus arteriosus 1 2%
Total 50 100%
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Germany). For each patient, the reader positioned a region 
of interest on the vessel boundary of a selected slice and 
propagated the segmentation through the remaining slices. 
Then, the software proposed an automated adjustment and 
the reader was allowed to manually correct the adjusted 
contours (hence semi-automated method). Blood peak 
velocity, forward and backward flows were obtained. An 
example of flow analysis is shown in Fig. 1.
Intra- and inter-reader reproducibility was estimated 
using the Bland–Altman method; for the inter-reader repro-
ducibility the first measurement of both readers was used. 
The coefficient of repeatability (CoR) was calculated as 
1.96 × standard deviation of differences of the two com-
pared datasets. Reproducibility was reported as comple-
ment to 100% of the ratio between the CoR and the mean. 
Bland–Altman graphs were plotted as well, showing bias 
(mean of the differences of the two compared datasets), and 
95% limits of agreement (bias ± CoR).
Results
Of 50 analyzed patients, 46 (92%) had a pulmonary dis-
ease, two (4%) ventricular septal defect, one (2%) aortic 
insufficiency, and one (2%) truncus arteriosus. Further 
details are reported in Table 1.
Image analysis was feasible in all patients and no mal-
formations or artifacts prevented from a correct segmenta-
tion. The PC sequence showed no artifacts in patients with 
a surgical or percutaneous valve replacement. The time 
needed for measurement was about 5 min per patient, with-
out substantial difference between the two readers.
The mean blood peak velocity of the aortic flow meas-
ured by R1 was 103 cm/s, accompanied by a CoR of 1 cm/s, 
corresponding to an intra-reader reproducibility of 99%; 
the same data for R2 were 103 cm/s, 9 cm/s, and 92%. The 
mean blood peak velocity of the pulmonary flow measured 
by R1 was 180 cm/s, accompanied by a CoR of 1 cm/s, 
Fig. 1  Example of the segmentation of the pulmonary artery, showing the gradient echo image, with a region of interest right after the valve, 
and the phase velocity map with the same ROI
Author's personal copy
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corresponding to an intra-reader reproducibility of 99%; the 
same data for R2 were 181 cm/s, 3 cm/s, and 98%. Further 
details are reported in Table 2 for R1 and in Table 3 for R2, 
while Bland–Altman plots for R1 only are shown in Fig. 2.  
The inter-reader reproducibility analysis of the aortic 
flow peak velocity showed a CoR of 10 cm/s, over a mean 
of 103 cm/s, corresponding to an inter-reader reproduc-
ibility of 91%; the same data for the pulmonary flow were 
7 cm/s, 180 cm/s, and 96%. Further details regarding the 
inter-reader reproducibility are reported in Table 4, while 
Bland–Altman plots are shown in Fig. 3.
Discussion
Cardiac magnetic resonance has emerged as a reliable imag-
ing technique for assessing heart valve disease, quantify its 
severity, and to evaluate its effect on the heart morphology 
and function [1–3, 7]. It is used for evaluating cardiomyopa-
thy-related valve dysfunction since more than two decades 
[18]. Patient management using CMR includes follow-up for 
treatment effect monitoring or disease progression [19, 20].
Reproducibility means the ability of a reader to provide 
the same values when repeating the measurement a number 
of times. If two or more readers are involved in the patient 
management, they need to provide as similar as possible 
results when analyzing a given CMR examination. When a 
follow-up measurement is performed on a patient, the clini-
cian needs to identify a true change that can be ascribed to 
treatment effect or worsening of disease, rather than to meas-
urement errors [21]. In this scenario, the readers’ experience 
may play a role and skilled operators may be necessary.
In this study, we obtained a good-to-excellent intra-
reader reproducibility of CMR in flow measurement for all 
variables under consideration, except for the backward flow 
of the ascending aorta. Indeed, intra-reader reproducibility 
was higher than 90% for the trained reader (R1) and higher 
than 86% for the lower trained reader (R2). Such a good 
result may be due thanks to the semi-automated method 
used for segmentation that is not difficult to be used also 
by less experienced readers [9]. This means that a reader’s 
learning curve should be short and that the segmentation 
of vessel boundaries through a semi-automated method 
may also be performed by not highly specialized person-
nel. Probably, if we had used a manual method of segmen-
tation we could have found a lower reproducibility for the 
untrained reader. However, although of a small magnitude, 
data suggest an additional reproducibility of R1 over R2, 
likely due to the different educational background and the 
different level of training [9].
Inter-reader reproducibility, even if reaching a maximum 
of 96% for the blood peak velocity of the pulmonary artery, 
decreased to 75 and 82% for the forward and backward 
flow of the pulmonary artery, respectively, being lower than 
Table 2  Intra-reader 
reproducibility of the first 
reader
The first reader was a radiology resident (see text)
CoR coefficient of repeatability
Aortic flow Pulmonary flow
Peak 
velocity
(cm/s)
Forward
(ml/beat)
Backward
(ml/beat)
Peak 
velocity
(cm/s)
Forward
(ml/beat)
Backward
(ml/beat)
Mean 103 69 3 180 91 23
Bias −0.1 −0.1 −0.1 0.1 0.1 0.3
CoR 1 3 1 1 8 2
Reproducibility 99% 95% 49% 99% 91% 90%
Table 3  Intra-reader 
reproducibility of the second 
reader
The second reader was a technician student (see text)
CoR coefficient of repeatability
Aortic flow Pulmonary flow
Peak 
velocity
(cm/s)
Forward
(ml/beat)
Backward
(ml/beat)
Peak 
velocity
(cm/s)
Forward
(ml/beat)
Backward
(ml/beat)
Mean 103 69 3 181 89 23
Bias −0.6 0.7 −0.2 −0.3 1.5 0.1
CoR 9 6 2 3 12 3
Reproducibility 92% 91% 38% 98% 86% 87%
Author's personal copy
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Fig. 2  Bland–Altman plots for intra-reader reproducibility analysis of the first reader: a and b peak velocity, c and d forward flow and e and f 
backward flow of the aorta (left column) and pulmonary artery (right column)
Table 4  Inter-reader 
reproducibility analysis
CoR coefficient of repeatability
Aortic flow Pulmonary flow
Peak 
velocity
(cm/s)
Forward
(ml/beat)
Backward
(ml/beat)
Peak 
velocity
(cm/s)
Forward
(ml/beat)
Backward
(ml/beat)
Mean 103 70 3 180 89 24
Bias 0.1 2.3 0.2 −1.0 0.1 0.6
CoR 10 11 2 7 22 4
Reproducibility 91% 85% 20% 96% 75% 82%
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that observed in previous studies. Van Der Geest et al. com-
pared an automated contour detection algorithm for anal-
ysis of the ascending aorta flow with a fully manual seg-
mentation, showing intra- and inter-reader variability lower 
than 2% for both manual and automated methods [13]. 
Conversely, Herment et al. demonstrated a higher inter-
reader variability for manual tracing than for automated 
segmentation using PC CMR images in healthy volunteers 
and in patients with a dilated aorta [14].
The backward flow of the ascending aorta deserves some 
considerations. In fact, a low to very low reproducibility 
for this variable was obtained, being lower than 50% for 
the intra-reader analysis and equal to 20% for the inter-
reader analysis. This is only an apparently negative result 
being mainly related to the low magnitude of the ascend-
ing aorta backward flow, even in patients with aortic insuf-
ficiency. Reproducibility being given as percentage of the 
mean, even subtle measurement variations due to small 
Fig. 3  Bland–Altman plots for inter-reader reproducibility analysis: a and b peak velocity, c and d forward flow and e and f backward flow of 
the aorta (left column) and pulmonary artery (right column)
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differences in segmentation may have a strong negative 
impact on reproducibility.
The major limitation of this study is that results are 
related to the particular 1.5-T unit used for imaging patients 
and to the sequences and technical parameters used, also 
including the use of breath-hold or respiratory gating for 
avoiding artifacts from respiratory movements. However, 
1.5-T magnets are mostly used for cardiac imaging and 
our imaging protocol is quite generally accepted. Thus, our 
results should be generalizable. Another limitation may be 
the study population that included patients affected with 
different cardiovascular diseases (even if the majority of 
patients had a Tetralogy of Fallot) who had a pathology of 
the aortic and/or pulmonary valve. However, we wanted to 
estimate the intra- and inter-reader reproducibility in a het-
erogeneous population for a higher generalizability. Prob-
ably, limiting to a more homogeneous population could 
demonstrate an even higher reproducibility.
In conclusion, this study showed a good-to-excellent 
intra- and inter-reader reproducibility of blood flow meas-
urements in patients with congenital heart disease using 
CMR and a semi-automated method of segmentation, with 
a limited impact of the operator’s training.
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Abstract
The aims of this paper are to illustrate the trend towards data
sharing, i.e. the regulated availability of the original patient-
level data obtained during a study, and to discuss the expected
advantages (pros) and disadvantages (cons) of data sharing in
radiological research. Expected pros include the potential for
verification of original results with alternative or supplemen-
tary analyses (including estimation of reproducibility), ad-
vancement of knowledge by providing new results by testing
new hypotheses (not explored by the original authors) on pre-
existing databases, larger scale analyses based on individual-
patient data, enhanced multidisciplinary cooperation, reduced
publication of false studies, improved clinical practice, and
reduced cost and time for clinical research. Expected cons
are outlined as the risk that the original authors could not
exploit the entire potential of the data they obtained, possible
failures in patients’ privacy protection, technical barriers such
as the lack of standard formats, and possible data misinterpre-
tation. Finally, open issues regarding data ownership, the role
of individual patients, advocacy groups and funding institu-
tions in decision making about sharing of data and images are
discussed.
Key Points
• Regulated availability of patient-level data of published clin-
ical studies (data-sharing) is expected.
• Expected benefits include verification/advancement of
knowledge, reduced cost/time of research, clinical
improvement.
• Potential drawbacks include faults in patients’ identity pro-
tection and data misinterpretation.
Keywords Confidentiality . Database . Data sharing .
Information dissemination . Radiology
Introduction
In clinical research, spontaneous data sharing is not yet as
common as it is in other fields such as genetics, astronomy
or physics [1]. However, the concept of data sharing has been
suggested for many reasons, including the patient-centred na-
ture of medical research and healthcare and the expectation
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that knowledge from existing data should be maximized to
benefit all stakeholders.
Although a transition to data sharing is a process that will
take time and planning, those who adopt the principles and
practices of open science will likely benefit from it [2, 3]. In
addition, the emergence of data sharing as a potential require-
ment by some agencies and journals warrants attention by the
imaging community. Indeed, from July 1st, 2018 the
International Committee of Medical Journal Editors
(ICMJE) will require a data sharing statement as a condition
of consideration for publication of clinical trials [4].
In this article, we discuss potential advantages and disad-
vantages of data sharing.
From open-access to data sharing
A trend towards larger accessibility to scientific medical
knowledge is already visible in the progressive tendency of
medical journals in ensuring the open-access option, in which
the authors or their institutions pay an article-level fee to guar-
antee the immediate free availability of their papers [5].
In Table 1 we report the policies of all the 18 general im-
aging journals on access and data sharing [6–17]. This was
derived from the current Thomson Reuters list – Radiology,
Nuclear Medicine, and Medical Imaging. For comparison, the
17 most-impacted general medicine journals were selected
from the current Thomson Reuters list – Medicine, General
and Internal [18–35]. Among the 18 imaging journals, four are
open access, 12 offer open access as an option (Radiology
provides free access 12 months after publication), and two
do not offer an open-access option. Among the 17 medical
journals, six are open access (The Medical Journal of
Australia only for research articles and case reports), eight
offer open access as an option (Journal of the American
Medical Association [JAMA] provides free access 6 months
after publication), two do not offer an open access option, and
one (The New England Journal of Medicine [NEJM]) pro-
vides free access to research articles 6 months after publica-
tion. Thus, the open access option is currently widely adopted
by both general imaging journals (11/18) and general medi-
cine journals (8/17).
The practice of data sharing entails much more than open
access. It is the regulated availability of the original
participant-by-participant data obtained during a study, which
may include data not yet analysed. Among the 18 general
imaging journals, data sharing is not even mentioned by 12
journals, encouraged by three, mandatory only upon request
in two, and requested by one. Among the 17 general medicine
journals, it is not mentioned by seven journals, encouraged by
six, requested by three (NEJM only for data obtained by mi-
croarray), and considered mandatory only upon request by one
(Table 1). In practice, data repository or sharing is currently not
mentioned in the instructions for authors of the majority of
general imaging journals (14/18) and major general medicine
journals (10/17). Despite individual journals do not mention
any policy on data sharing, some publishers such as Elsevier
have their own general suggestions, which refer to Open
Access [8], even though not immediately visible to the authors
when they submit a manuscript. When data sharing is encour-
aged, authors are informed they should be prepared to provide
original study data if requested by the editors.
In recent years, several funding bodies declared the neces-
sity for data sharing. In 2015, the U.S. National Institutes of
Health (NIH) expressed its intention to request making the
digital data from NIH-funded studies publicly available [36].
Regulatory agencies, specifically the European Medicines
Agency, have requested greater data sharing by companies
manufacturing drugs and clinical devices. Influential organi-
zations such as the World Health Organization and the U.S.
National Academy of Medicine published reports asking for
responsible sharing of data from clinical trials [37]. Also, sev-
eral foundations, for instance the Alfred P. Sloan Foundation
[38], the Bill and Melinda Gates Foundation [39], the Ford
Foundation [40], the Gordon and Betty Moore Foundation
[41], and the National Science Foundation [42], require data
sharing and data management plans for all research grant
proposals.
The pharmaceutical industry also plays a role in promoting
data sharing. The Yale University Open Data Access (YODA)
project [43] performs independent scientific review of inves-
tigators’ requests for pharmaceutical and medical data from
clinical trials on devices marketed by Johnson & Johnson,
including both full clinical study reports and participant-
level data. Notably, the YODA project has obtained permis-
sion to make independent decisions about the release of
Johnson & Johnson’s clinical trial data. This project estab-
lishes a process in which requests are judged fairly and deci-
sions are made by an independent academic partner, a model
that could be applied to other fields of medicine [44].
Another example is the Academic Research Organization
Consortium for Continuing Evaluation of Scientific Studies –
Cardiovascular (ACCESS CV) [45]. They propose a secure
method for sharing patient-sensitive data that combines the
protection of patients’ identity with the legitimate desire of
the scientific community for data access and the viewpoint
of the researchers who created the database. This approach
consists of the following steps: (1) After publication of the
primary results of a trial, researchers interested in the study
data may send a request to the trial's publication committee;
(2) Twenty-four months after the publication of the primary
study, requests should be considered by a review group com-
posed of members of ACCESS CV not involved in the trial,
the trial principal investigator, a trial statistician, and a mem-
ber of the data and safety monitoring board. This committee
evaluates all proposals to approve those that are feasible,
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Table 1 Policies on access and data repository or sharing by major general imaging journals and major general medicine journals
Journal Access1 Data repository or sharing2
General imaging journals
Acad Radiol Open access option Not mentioned
Acta Radiol Open access option Requested
Am J Roentgenol No open access option Not mentioned
BMC Med Imaging Open access Encouraged
Br J Radiol Open access option. Articles freely available
more than 12 months after publication
Encouraged
Clin Radiol Open access option Not mentioned
Eur J Radiol Open access option Not mentioned
Eur Radiol Open access option Not mentioned
Invest Radiol Open access option Not mentioned
Iran J Radiol Open access Not mentioned
J Am Coll Radiol Open access option Not mentioned
JBR-BTR Open access Not mentioned
Jpn J Radiol No open access option Upon request
Korean J Radiol Open access Not mentioned
Radiol Med Open access option Encouraged
Radiologe Open access option Not mentioned
Radiology Open access option. Articles freely available
12 months after publication
Upon request
Rofo Open access option Not mentioned
General medicine journals
Am J Med Open access option Not mentioned
Ann Intern Med No open access option Encouraged
BMC Medicine Open access Encouraged
Br J Gen Pract Open access option Not mentioned
Br Med Bull Open access option Not mentioned
BMJ Open access option Encouraged
BMJ Open Open access Encouraged
CMAJ Open access option Requested only for clinical trials of drugs
and medical devices
Dtsch Arztebl Int Open access Not mentioned
Eur J Clin Invest Open access option Encouraged
Int J Med Sci Open access Not mentioned
Lancet Open access option Encouraged
JAMA Open access option. Research articles freely
available 6 months after publication
Upon request
Med Clin North Am3 No open access option Not mentioned
Med J Aust Open access for research articles and case reports Not mentioned
New England J Med Original articles and special articles freely available
6 months after publication.
Requested for data obtained by microarray
PLoS Med Open access Requested
Note: Imaging journals were selected for being general (not subspecialty) journals from the Thomson Reuters list – Radiology, Nuclear Medicine, and
Medical Imaging (n=18). For comparison, the general medicine journals from the first quartile were selected from the Thomson Reuters list –Medicine,
General and Internal (n=17)
1Most journals offer free accessibility for selected articles
2 Despite individual journals do not mention any policy on data sharing, some publishers (e.g. Elsevier) have their own general rules to which refer to.
Moreover, when data sharing is encouraged, authors are informed to be prepared to provide original study data if requested by the editors
3 Publishes only invited reviews
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hypothesis-based, non-duplicative, and guided by investiga-
tors with technical capability and a plan for publication. The
period of 24 months is chosen to secure the database and to
allow the original investigators to perform their own pre-
planned secondary analyses; (3) All requests and subsequent
decisions will be posted on an ACCESS CV Web portal, ide-
ally within 60 days [45].
In the field of radiology, data sharing also means ac-
cessibility to medical images. Indeed, “Images are more
than pictures, they are data” [46]. This implies access to
the images produced in a given study for additional read-
ing, interpretation, and extraction. To this end, several
image repositories were created. An example is the
XNAT Central [47, 48], a publicly accessible data repos-
itory based on the XNAT open-source platform which
hosts a wide variety of research imaging datasets, espe-
cially from neuroimaging, but also from oncology, ortho-
paedics and cardiology. Other examples are The Cancer
Imaging Archive [49] and the Lung Image Database
Consortium [50].
Such repositories may be very helpful in several fields,
especially for image biomarker development, radiomics and
machine learning, each field demanding different approaches.
Moreover, the integration, standardization and analysis of
these data poses a big challenge, the solution to which may
be addressed using cognitive computing. An example of cog-
nitive computing is the system developed by IBM named
Watson (IBM Watson Health Imaging, Armonk, NY, USA).
It strives to organize available information and present it in a
contextually relevant, probability-driven manner to assist
healthcare professionals in an objective manner, whether at a
reading workstation or at the point-of-care [51]. An important
change is underway. To make datasets from medical research
publicly available in a timely fashion requires regulations that
maximize the benefits and minimize the risks [52, 53]. Indeed,
data sharing provides a potential for stimulating new ideas,
avoiding duplication of trials, and enhance transparency [36,
54–57] as well as increasing collaboration and interdisciplin-
ary research [1, 58, 59]. However, at the same time, sharing
clinical data presents some risks, burdens and challenges such
as the need to preserve the privacy of patients, to defend the
legitimate economic interests of the sponsors, and to guard
against invalid secondary analyses potentially undermining
trust in clinical trials or otherwise harming public health [36,
37, 53, 60].
Potential benefits of data sharing
These can be subdivided into: (i) verification and advance-
ment in knowledge; (ii) reduced cost and time for clinical
research; and (iii) clinical improvement (Fig. 1).
Verification and advancement in knowledge
The first potential implication of data-sharing is the verifica-
tion by independent authors of the results presented in a given
publication. When data are shared, they may be used by other
researchers to perform alternative or supplementary analyses.
This ‘second-hand’ analysis may show results in support of
the initial findings or could reveal errors or inconsistencies in
the original research, or could identify issues needing extend-
ed analysis.
In other cases, data sharing can allow elucidation of new
results. New findings can be disclosed starting from hypothe-
ses not considered by the original study team. New insights
can be presented from existing data but not yet analysed in the
original publication(s). Also, investigators may be interested
in performing the analysis of datasets coming from various
sources to enhance precision, i.e. to perform reproducibility
analyses across different databases, regarding established the-
ories or new hypotheses. In fact, reproducibility analysis is
crucial for emergent topics in radiology such as standardiza-
tion of imaging biomarkers, especially from magnetic reso-
nance imaging [61]. The availability of databases from differ-
ent studies could allow for this gap to be filled and could help
in translating new imaging biomarkers into clinical practice
[62]. In this regard, reproducibility analysis could become one
of the main advantages of data sharing.
The introduction of registries of patients affected with a
defined disease could be considered a primitive form of data
sharing [63, 64], important not only for widespread diseases,
such as cancers, but especially for rare diseases.
Another approach of spontaneous data sharing is that un-
derlying individual patient data meta-analyses [65]. Authors
of an individual patient data meta-analysis typically contact
the authors of each eligible study asking to share their data,
with the aim of creating a new unique individual-patient da-
tabase. Of note, the power of the individual-patient data ap-
proach is higher than that of conventional (study-level) meta-
analyses, which rely on complex statistical methods [66]. For
instance, in a study published byMarinovich et al. [67] on the
agreement between MRI and pathological breast tumour size
after treatment, a total of 24 studies (1,228 patients) were
eligible for inclusion, but only eight of these contributed to
the individual-patient data analysis for a total of 300 patients.
Had regulated data sharing been in place, that individual-
patient data meta-analysis would have included a much richer
dataset. Moreover, data sharing could boost a wider adoption
of health technology assessment. Indeed, in the context of a
new product evaluation, data sharing may be useful in the
validation level, requiring a high number of data/images, rath-
er than at the initial development level.
Another potential advantage of data sharing is to reduce the
publication of false studies, especially when the data are in-
tentionally falsified. Recently, 64 articles were retracted from
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ten Springer journals after editorial checks found fake email
addresses, and subsequent internal investigations uncovered
fabricated peer-review reports [68]. This retraction came only
a few months after BioMed Central had retracted 43 articles
for the same reason; however, this phenomenon involvedmost
major publishers such as also SAGE, Elsevier, Informa, and
Lippincott Williams & Wilkins [69]. Data sharing might dis-
courage data creation and manipulation, potentially more de-
tectable in a complete database than in reported results.
Reduced cost and time for clinical research
Data sharing could potentially lead to an optimization of time
and costs of clinical research by preventing the duplication of
trials [70, 71]. For example, costs for the stipulation of insur-
ances for patients’ coverage, the purchase of materials or the
salaries of the staff responsible for data collection can be
avoided. In addition, using an existing shared database, the
new results could be obtained many years prior to those de-
rived from a new clinical study.
Clinical improvement
An effect in terms of clearer evidence on the safety and effective-
ness of diagnostic procedures and therapies, improving public
healthcare [72–74], may be considered the final aim of data
sharing. To avoid the loss of findings contained in the original
dataset and not used for the primary publication(s) could play a
role in this direction [53]. Institutions sharing their data could
obtain a more comprehensive picture about the benefits and risks
of amedical decision.However, a real clinical improvement from
data sharing is a hypothesis that still needs to be demonstrated.
Potential drawbacks from data sharing
The sharing of clinical databases raises several concerns
(see Fig. 1). One of the reasons not to share data is that
researchers are evaluated competitively, based on the qual-
ity and number of articles published during their career, so
they may worry that other people will use their data and
efforts to produce new publications. The potential for sec-
ondary analyses contradicting initially reported results may
be a deterrent. Authors may not be willing to share data that
had cost them great effort and resources. However, recipro-
cally, they would also directly benefit from using someone
else’s data.
Bierer et al. [75] recently suggested formalizing ‘data au-
thorship’ as an incentive to data sharing: “as a matter of fair-
ness and as a matter of providing an incentive for data sharing,
the persons who initially gathered the data should receive
appropriate and standardized credit that can be used for aca-
demic advancement, for grant applications, and in broader
situations”.
Another concern is the potential for fault in the patient
identity protection caused by the transmission of sensitive
information. Data must be de-identified: de-identification,
not simply anonymization, consists of transforming a dataset
so that the back identification of individuals becomes impos-
sible or extremely difficult. Different regulations may require
different degrees of de-identification, particularly in the ab-
sence of informed consents specifying the possibility of data
sharing. De-identification can be achieved with different types
of data transformations that must ensure patient privacy with-
out affecting data quality [76]. However, the de-identified data
do not eliminate all risks of re-identification. Moreover, the
reduction of this risk to zero may destroy or significantly
impair the utility of the data for subsequent analysis or
Fig. 1 Expected pros and cons of
data sharing. IPD individual
patient data meta-analyses
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verification. For these reasons, the stipulation of Data Use
Agreements (DUAs) is considered a useful strategy and best
practice for increasing the benefits and mitigating the risks of
clinical data sharing [77]. Specifically, DUAs address impor-
tant issues such as limitations on date usage, obligations to
data safeguard, liability for harm arising from data usage and
publication, and privacy rights that are associated with transfer
of confidential or protected data. In contrast, the U.S. Office
for Human Research Protections stated that there is no need
for separate consent from trial participants for the sharing of
de-identified data [4].
A limitation to the adoption of data sharing can origi-
nate from technical barriers. The image conformity is in-
fluenced by vendor, modality, and acquisition parameters
on the one hand; and by image post-processing manufac-
turer, reconstruction parameters, and software versions, on
the other hand. An example is represented by the use in
magnetic resonance of arbitrary units that clearly depend
on the specific vendor and model, making a between-study
comparison impossible. A way to overcome this limitation
could be a drastic standardization, with manufacturers de-
fining new shared standards.
Another intrinsic barrier to data sharing could be the poor
documentation of datasets, especially if not documented in
English.Moreover, important information about methodology
might not be contained immediately in the database or imme-
diately retrievable. All these issues should be considered when
planning for potential data sharing of research.
To share or not to share?
In conclusion, in a world that moves towards greater transpar-
ency and privacy protection, data sharing stands between
these two competing interests. Not all concerns on data shar-
ing have already been solved and many questions remain to be
addressed: Who is the rightful owner of the data? What is the
role of individual patients and advocacy groups in decision
making about sharing of data and images? Should Ethics
Committees change their approach for study approval? And
how? What is the exact role of institutions, especially public
ones, that funded the original study? Should patient advocacy
groups and funding organizations be involved in decision
making about data sharing? These issues must be regulated.
Despite all the above-described issues relating to data shar-
ing, a transition to a more open medical science has begun. If
benefits of data sharing will be more and more perceived as
prevailing over harms therefrom, this option will win.
Researchers and institutions who first seize this opportunity
will be on the wave-front of an innovation likely to be in
favour of patients and public health. Radiologists should be
kept informed of this emerging issue. It is time to share!
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